[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, a synonym for Acrokeratosis paraneoplastica is Bazex syndrome.",
    "llama-2-13b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Bazex syndrome.",
    "llama-2-13b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Bazex syndrome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, Weaver syndrome and Sotos syndrome are similar in that they are both autosomal dominant overgrowth and intellectual disability (OGID) syndromes. However, they are distinct conditions with different causes and characteristics.\nWeaver syndrome is caused by pathogenic variants in the DNMT3B gene, while Sotos syndrome is caused by pathogenic variants in the NSD1 gene. Weaver syndrome is characterized by bone overgrowth, facial dysmorphism, and intellectual disability, while Sotos syndrome is characterized by macrocephaly, intellectual disability, and seizures.\nTatton–Brown–Rahman syndrome, also known as DNMT3A-related overgrowth syndrome, is a condition that is similar to Weaver syndrome and Sotos syndrome, and is caused by pathogenic variants in the DNMT3A gene. It is important to note that while these conditions share some similarities, they are distinct and have different causes and characteristics.\nIn summary, Weaver syndrome and Sotos syndrome are both OGID syndromes, but they have different causes and characteristics. Tatton–Brown–Rahman syndrome is a related condition that is caused by pathogenic variants in the DNMT3A gene.",
    "llama-2-13b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome are both autosomal dominant overgrowth and intellectual disability (OGID) syndromes.\n2. Weaver syndrome is caused by pathogenic variants in the DNMT3B gene.\n3. Sotos syndrome is caused by pathogenic variants in the NSD1 gene.\n4. Weaver syndrome is characterized by bone overgrowth, facial dysmorphism, and intellectual disability.\n5. Sotos syndrome is characterized by macrocephaly, intellectual disability, and seizures.",
    "llama-2-13b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome are both autosomal dominant overgrowth and intellectual disability (OGID) syndromes.",
      "Weaver syndrome is caused by pathogenic variants in the DNMT3B gene.",
      "Sotos syndrome is caused by pathogenic variants in the NSD1 gene.",
      "Weaver syndrome is characterized by bone overgrowth, facial dysmorphism, and intellectual disability.",
      "Sotos syndrome is characterized by macrocephaly, intellectual disability, and seizures."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Weaver syndrome is caused by pathogenic variants in the EZH2 gene, not the DNMT3B gene.\n3. TRUE\n4. TRUE\n5. TRUE (although seizures are not a defining characteristic of Sotos syndrome, they can occur in some individuals with the condition)",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, here are the releases of the JASPAR database:\n1. JASPAR 2016 (released on September 23, 2016)\n2. JASPAR 2018 (released on June 7, 2018)\n3. JASPAR 2020 (released on November 7, 2020)\n4. JASPAR 2022 (released on January 7, 2022)\nThese releases are based on the information provided in the two documents you provided, specifically Document 0 and Document 1. Document 0 provides general information about the JASPAR database, while Document 1 announces the release of JASPAR 2022.",
    "llama-2-13b-chat-hf_fact_raw": "1. JASPAR 2016 was released on September 23, 2016.\n2. JASPAR 2018 was released on June 7, 2018.\n3. JASPAR 2020 was released on November 7, 2020.\n4. JASPAR 2022 was released on January 7, 2022.",
    "llama-2-13b-chat-hf_fact": [
      "JASPAR 2016 was released on September 23, 2016.",
      "JASPAR 2018 was released on June 7, 2018.",
      "JASPAR 2020 was released on November 7, 2020.",
      "JASPAR 2022 was released on January 7, 2022."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe release dates for the JASPAR database versions are not common knowledge and would require specific reference to the JASPAR database release history or announcements. Without access to that information, the truthfulness of these statements cannot be determined.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the function of the viral KP4 protein is to kill sensitive Ustilago strains and inhibit Fusarium and plant root growth by inhibiting calcium uptake.",
    "llama-2-13b-chat-hf_fact_raw": "1. The viral KP4 protein functions to kill sensitive Ustilago strains.\n2. The KP4 protein inhibits Fusarium growth.\n3. The KP4 protein inhibits plant root growth.\n4. The KP4 protein functions by inhibiting calcium uptake.",
    "llama-2-13b-chat-hf_fact": [
      "The viral KP4 protein functions to kill sensitive Ustilago strains.",
      "The KP4 protein inhibits Fusarium growth.",
      "The KP4 protein inhibits plant root growth.",
      "The KP4 protein functions by inhibiting calcium uptake."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The KP4 protein does not inhibit plant root growth; it is a viral protein that targets fungal pathogens.\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-13b-chat-hf_response": "Based on the information provided, yes, DITPA is a thyroid hormone analog that has been utilized in experimental and clinical studies. Document 1 states that DITPA is a synthetic thyroid hormone analog with positive inotropic effects similar to thyroid hormone but with minimal systemic effects. Additionally, Document 0 mentions that DITPA had beneficial hemodynamic effects in animal studies and a pilot trial in patients with congestive heart failure. Therefore, it can be concluded that DITPA is a thyroid hormone analog that has been studied and used in experimental and clinical settings.",
    "llama-2-13b-chat-hf_fact_raw": "1. DITPA is a thyroid hormone analog.\n2. DITPA has been utilized in experimental and clinical studies.\n3. DITPA is a synthetic thyroid hormone analog with positive inotropic effects.\n4. DITPA has minimal systemic effects compared to thyroid hormone.\n5. DITPA had beneficial hemodynamic effects in animal studies and a pilot trial in patients with congestive heart failure.",
    "llama-2-13b-chat-hf_fact": [
      "DITPA is a thyroid hormone analog.",
      "DITPA has been utilized in experimental and clinical studies.",
      "DITPA is a synthetic thyroid hormone analog with positive inotropic effects.",
      "DITPA has minimal systemic effects compared to thyroid hormone.",
      "DITPA had beneficial hemodynamic effects in animal studies and a pilot trial in patients with congestive heart failure."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the COUGER tool is a tool used for course-level assessment.",
    "llama-2-13b-chat-hf_fact_raw": "1. The COUGER tool is used for course-level assessment.",
    "llama-2-13b-chat-hf_fact": [
      "The COUGER tool is used for course-level assessment."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there are no drugs available to treat tick-borne encephalitis (TBE). However, a vaccine is available to prevent infection, and it is recommended for certain individuals, as stated in Document 0. Additionally, supportive clinical management, such as rest, fluids, and over-the-counter pain medications, may help relieve some symptoms, as mentioned in Document 1. It is important to note that severe cases of TBE may require hospitalization and more intensive treatment.",
    "llama-2-13b-chat-hf_fact_raw": "1. There are no drugs available to treat tick-borne encephalitis (TBE).\n2. A vaccine is available to prevent tick-borne encephalitis infection.\n3. The vaccine for tick-borne encephalitis is recommended for certain individuals.\n4. Supportive clinical management for TBE may include rest, fluids, and over-the-counter pain medications.\n5. Severe cases of tick-borne encephalitis may require hospitalization and more intensive treatment.",
    "llama-2-13b-chat-hf_fact": [
      "There are no drugs available to treat tick-borne encephalitis (TBE).",
      "A vaccine is available to prevent tick-borne encephalitis infection.",
      "The vaccine for tick-borne encephalitis is recommended for certain individuals.",
      "Supportive clinical management for TBE may include rest, fluids, and over-the-counter pain medications.",
      "Severe cases of tick-borne encephalitis may require hospitalization and more intensive treatment."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: While there are no specific antiviral drugs to cure tick-borne encephalitis (TBE), there are treatments available to alleviate symptoms.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the genome browser database for DNA shape annotations available is GBshape. According to Document 1, GBshape provides DNA shape annotations of entire genomes for 94 organisms, including minor groove width (MGW), propeller twist (ProT), Roll, helix twist (HelT), and hydroxyl radical cleavage (ORChID2). Additionally, the database allows for easy addition of annotations for additional genomes within the provided framework.",
    "llama-2-13b-chat-hf_fact_raw": "1. GBshape is a genome browser database for DNA shape annotations.\n2. GBshape provides DNA shape annotations for entire genomes of 94 organisms.\n3. The DNA shape annotations in GBshape include minor groove width (MGW), propeller twist (ProT), Roll, helix twist (HelT), and hydroxyl radical cleavage (ORChID2).\n4. GBshape's framework allows for the addition of annotations for additional genomes.",
    "llama-2-13b-chat-hf_fact": [
      "GBshape is a genome browser database for DNA shape annotations.",
      "GBshape provides DNA shape annotations for entire genomes of 94 organisms.",
      "The DNA shape annotations in GBshape include minor groove width (MGW), propeller twist (ProT), Roll, helix twist (HelT), and hydroxyl radical cleavage (ORChID2).",
      "GBshape's framework allows for the addition of annotations for additional genomes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GBshape provides DNA shape annotations for entire genomes of 3 organisms, not 94.\n3. TRUE\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the following syndromes are associated with mutations in the EZH2 gene:\n1. Weaver Syndrome: The p.Glu745Lys mutation in the EZH2 gene has been previously associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.\n2. Inactivation of gene expression: Oncogenic gain-of-function EZH2 mutations alter gene-promoter interactions and lead to silencing of 1,034 genes within topologically associating domains, resulting in inactivation of gene expression.\nNote that the information provided is based on the two documents given, and there may be other syndromes or associations with EZH2 mutations that are not mentioned in the provided documents.",
    "llama-2-13b-chat-hf_fact_raw": "1. Weaver Syndrome is associated with mutations in the EZH2 gene.\n2. The p.Glu745Lys mutation in the EZH2 gene has been associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.\n3. Oncogenic gain-of-function EZH2 mutations can lead to the silencing of 1,034 genes within topologically associating domains.\n4. Mutations in the EZH2 gene can result in inactivation of gene expression.",
    "llama-2-13b-chat-hf_fact": [
      "Weaver Syndrome is associated with mutations in the EZH2 gene.",
      "The p.Glu745Lys mutation in the EZH2 gene has been associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.",
      "Oncogenic gain-of-function EZH2 mutations can lead to the silencing of 1,034 genes within topologically associating domains.",
      "Mutations in the EZH2 gene can result in inactivation of gene expression."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The p.Glu745Lys mutation in the EZH2 gene has been associated with Weaver Syndrome, but there is no specific evidence provided here that it is associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients. This mutation is more commonly associated with myeloid malignancies.\n3. UNKNOWN\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, the following human proteins are subject to a dimer-to-tetramer transition:\n1. Inositol-Requiring Enzyme 1α (IRE1)\n2. Protein Kinase R (PKR)-like ER Kinase (PERK)\n3. Activating Transcription Factor 6 (ATF6)\nThese proteins are activated by the accumulation of misfolded proteins in the endoplasmic reticulum (ER) and undergo a dimer-to-tetramer transition, which is a conformational change that allows them to perform their biological functions.\nAccording to Document 1, the dimer-to-tetramer transition of these proteins might represent an intermediate point during the evolution of the more stable haemoglobin tetramer found in higher vertebrates, where cooperative ligand binding is based on switching between quaternary states with different affinities for oxygen.\nTherefore, the answer to the user's question is:\nThe human proteins that are subject to a dimer-to-tetramer transition are Inositol-Requiring Enzyme 1α (IRE1), Protein Kinase R (PKR)-like ER Kinase (PERK), and Activating Transcription Factor 6 (ATF6).",
    "llama-2-13b-chat-hf_fact_raw": "1. Inositol-Requiring Enzyme 1α (IRE1) undergoes a dimer-to-tetramer transition.\n2. Protein Kinase R (PKR)-like ER Kinase (PERK) undergoes a dimer-to-tetramer transition.\n3. Activating Transcription Factor 6 (ATF6) undergoes a dimer-to-tetramer transition.\n4. The dimer-to-tetramer transition in these proteins is activated by the accumulation of misfolded proteins in the endoplasmic reticulum (ER).\n5. The dimer-to-tetramer transition might represent an intermediate point during the evolution of the haemoglobin tetramer in higher vertebrates.",
    "llama-2-13b-chat-hf_fact": [
      "Inositol-Requiring Enzyme 1α (IRE1) undergoes a dimer-to-tetramer transition.",
      "Protein Kinase R (PKR)-like ER Kinase (PERK) undergoes a dimer-to-tetramer transition.",
      "Activating Transcription Factor 6 (ATF6) undergoes a dimer-to-tetramer transition.",
      "The dimer-to-tetramer transition in these proteins is activated by the accumulation of misfolded proteins in the endoplasmic reticulum (ER).",
      "The dimer-to-tetramer transition might represent an intermediate point during the evolution of the haemoglobin tetramer in higher vertebrates."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: Inositol-Requiring Enzyme 1α (IRE1) is known to undergo oligomerization, which can include a dimer-to-tetramer transition as part of its activation mechanism in response to ER stress.\n2. FALSE [correction]: Protein Kinase R (PKR)-like ER Kinase (PERK) is known to undergo dimerization upon activation by ER stress, but it is not typically described as undergoing a dimer-to-tetramer transition.\n3. UNKNOWN: The activation mechanism of Activating Transcription Factor 6 (ATF6) involves translocation to the Golgi and subsequent proteolysis rather than a well-characterized dimer-to-tetramer transition.\n4. TRUE: The dimer-to-tetramer transition in proteins such as IRE1 is part of the unfolded protein response (UPR) activated by the accumulation of misfolded proteins in the endoplasmic reticulum (ER).\n5. UNKNOWN: The statement about the dimer-to-tetramer transition representing an intermediate point during the evolution of the haemoglobin tetramer in higher vertebrates is speculative and would require specific evolutionary evidence to confirm or refute.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is HAX-1. This information can be found in Document 1, where it is stated that HAX-1 interacts with PLN and has anti-apoptotic functions.",
    "llama-2-13b-chat-hf_fact_raw": "1. HAX-1 has been found to interact with phospholamban (PLN).\n2. HAX-1 is an anti-apoptotic protein.",
    "llama-2-13b-chat-hf_fact": [
      "HAX-1 has been found to interact with phospholamban (PLN).",
      "HAX-1 is an anti-apoptotic protein."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is evidence to suggest that vitamin D may reduce the incidence of falls in older people. Document 0 highlights the evidence for vitamin D's action on postural adaptations, which may explain the decreased fall and bone fracture rates. Additionally, Document 1 mentions that falls can be prevented through evidence-based interventions, which may include vitamin D supplementation. While the information does not provide a direct answer to the question, it suggests that vitamin D may be a useful tool in preventing falls in older adults.",
    "llama-2-13b-chat-hf_fact_raw": "1. Vitamin D may reduce the incidence of falls in older people.\n2. Vitamin D's action on postural adaptations could explain decreased fall and bone fracture rates.\n3. Evidence-based interventions to prevent falls in older adults may include vitamin D supplementation.",
    "llama-2-13b-chat-hf_fact": [
      "Vitamin D may reduce the incidence of falls in older people.",
      "Vitamin D's action on postural adaptations could explain decreased fall and bone fracture rates.",
      "Evidence-based interventions to prevent falls in older adults may include vitamin D supplementation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: There is evidence suggesting that Vitamin D may reduce the incidence of falls in older people by improving muscle function and bone health.\n2. TRUE: Vitamin D is known to play a role in bone health and muscle function, which could contribute to postural adaptations and thus potentially decrease fall and bone fracture rates.\n3. TRUE: Evidence-based interventions for preventing falls in older adults often include vitamin D supplementation, especially in those with low baseline levels or at high risk for falls.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is an association between Jarid2 and miR-155 in Th17 cells. Document 0 states that Jarid2 links posttranscriptional regulation by miR-155 to the transcriptional regulation of cytokine genes in Th17 cells, and Document 1 suggests that Jarid2 associates with the polycomb repressive complex 2 (PRC2) in a range of different cell types, including ESCs and thymocytes. This association between Jarid2 and PRC2 is likely to play a role in the regulation of cytokine gene expression in Th17 cells.",
    "llama-2-13b-chat-hf_fact_raw": "1. Jarid2 is associated with miR-155 in Th17 cells.\n2. Jarid2 is involved in linking posttranscriptional regulation by miR-155 to the transcriptional regulation of cytokine genes in Th17 cells.\n3. Jarid2 associates with the polycomb repressive complex 2 (PRC2) in various cell types, including ESCs and thymocytes.\n4. The association between Jarid2 and PRC2 is likely to influence the regulation of cytokine gene expression in Th17 cells.",
    "llama-2-13b-chat-hf_fact": [
      "Jarid2 is associated with miR-155 in Th17 cells.",
      "Jarid2 is involved in linking posttranscriptional regulation by miR-155 to the transcriptional regulation of cytokine genes in Th17 cells.",
      "Jarid2 associates with the polycomb repressive complex 2 (PRC2) in various cell types, including ESCs and thymocytes.",
      "The association between Jarid2 and PRC2 is likely to influence the regulation of cytokine gene expression in Th17 cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n\nThe statements regarding Jarid2's association with miR-155 in Th17 cells and its involvement in linking posttranscriptional regulation by miR-155 to the transcriptional regulation of cytokine genes in Th17 cells are specific and would require access to the relevant scientific literature to verify. Without the specific context or references, it is not possible to determine the truthfulness of these statements.\n\nHowever, it is well-established in scientific literature that Jarid2 associates with the polycomb repressive complex 2 (PRC2) in various cell types, including embryonic stem cells (ESCs) and thymocytes. This association is known to influence the regulation of gene expression, which could include cytokine genes in Th17 cells, making the third and fourth statements true.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the human hoxD cluster contains 39 genes.",
    "llama-2-13b-chat-hf_fact_raw": "1. The human hoxD cluster contains 39 genes.",
    "llama-2-13b-chat-hf_fact": [
      "The human hoxD cluster contains 39 genes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The human HOXD cluster contains 9 genes.",
    "llama-2-13b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, here are some phosphorylation consensus motifs for Casein Kinase 1 (CK1):\n1. Ser-X-X-Ser/Thr: CK1 has been shown to preferentially phosphorylate serine residues that are flanked by acidic amino acids, such as glutamic acid or aspartic acid. This motif is commonly found in the N-terminal region of substrate proteins.\n2. Ser-X-X-Ser/Thr-X-X-Ser/Thr: CK1 has been shown to phosphorylate clusters of consecutive serine residues, with the first serine residue being followed by a threonine residue. This motif is often found in the internal regions of substrate proteins.\n3. Ser-X-X-Ser/Thr-X-X-Ser/Thr-X-X-Ser/Thr: This motif is a variation of the previous one, with an additional serine or threonine residue present in the cluster.\nThese phosphorylation consensus motifs are based on the information provided in Document 1, which describes the phosphorylation of β-catenin by CK1. The motifs are consistent with the idea that CK1 preferentially phosphorylates serine residues that are flanked by acidic amino acids, and that it can phosphorylate clusters of consecutive serine residues.",
    "llama-2-13b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) preferentially phosphorylates serine residues flanked by acidic amino acids.\n2. The phosphorylation consensus motif \"Ser-X-X-Ser/Thr\" is commonly found in the N-terminal region of substrate proteins for CK1.\n3. CK1 has been shown to phosphorylate clusters of consecutive serine residues, as indicated by the motif \"Ser-X-X-Ser/Thr-X-X-Ser/Thr\".\n4. An extended motif \"Ser-X-X-Ser/Thr-X-X-Ser/Thr-X-X-Ser/Thr\" includes an additional serine or threonine residue in the cluster for CK1 phosphorylation.\n5. The phosphorylation of β-catenin by CK1 is described in Document 1, which provides information on the phosphorylation consensus motifs.",
    "llama-2-13b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) preferentially phosphorylates serine residues flanked by acidic amino acids.",
      "The phosphorylation consensus motif \"Ser-X-X-Ser/Thr\" is commonly found in the N-terminal region of substrate proteins for CK1.",
      "CK1 has been shown to phosphorylate clusters of consecutive serine residues, as indicated by the motif \"Ser-X-X-Ser/Thr-X-X-Ser/Thr\".",
      "An extended motif \"Ser-X-X-Ser/Thr-X-X-Ser/Thr-X-X-Ser/Thr\" includes an additional serine or threonine residue in the cluster for CK1 phosphorylation.",
      "The phosphorylation of β-catenin by CK1 is described in Document 1, which provides information on the phosphorylation consensus motifs."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The phosphorylation consensus motif for CK1 is \"Ser/Thr-X-X-Ser/Thr,\" where X can be any amino acid, and it is not necessarily found in the N-terminal region of substrate proteins.\n3. TRUE\n4. UNKNOWN: Without specific information on CK1 substrate recognition or extended motifs, it is not possible to confirm the accuracy of this statement.\n5. UNKNOWN: Without access to Document 1, it is not possible to confirm whether the phosphorylation of β-catenin by CK1 is described or what information is provided about phosphorylation consensus motifs.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, the different proteins/isoforms encoded by the ASPH (aspartate beta-hydroxylase) gene in humans are:\n1. Protein C: This protein is a vitamin K-dependent protein that plays a role in the regulation of blood coagulation. It contains EGF-like domains that are hydroxylated by AspH.\n2. Coagulation factors VII, IX, and X: These proteins are also involved in blood coagulation and contain EGF-like domains that are hydroxylated by AspH.\n3. Complement factors C1R and C1S: These proteins are involved in the complement system, which is a part of the immune system. They contain EGF-like domains that are hydroxylated by AspH.\nIn addition to these proteins, AspH may also hydroxylate other proteins containing EGF-like domains that have not been specifically identified.\nIt is important to note that the hydroxylation of Asp/Asn residues by AspH is essential for the proper functioning of these proteins, as it affects their stability, localization, and interactions with other proteins.",
    "llama-2-13b-chat-hf_fact_raw": "1. The ASPH gene encodes for a protein involved in the regulation of blood coagulation known as Protein C.\n2. The ASPH gene is responsible for encoding coagulation factors VII, IX, and X, which are involved in blood coagulation.\n3. The ASPH gene encodes complement factors C1R and C1S, which are part of the immune system.\n4. The proteins encoded by the ASPH gene contain EGF-like domains that are hydroxylated by AspH.\n5. The hydroxylation of Asp/Asn residues by AspH affects the stability, localization, and interactions of the proteins it modifies.",
    "llama-2-13b-chat-hf_fact": [
      "The ASPH gene encodes for a protein involved in the regulation of blood coagulation known as Protein C.",
      "The ASPH gene is responsible for encoding coagulation factors VII, IX, and X, which are involved in blood coagulation.",
      "The ASPH gene encodes complement factors C1R and C1S, which are part of the immune system.",
      "The proteins encoded by the ASPH gene contain EGF-like domains that are hydroxylated by AspH.",
      "The hydroxylation of Asp/Asn residues by AspH affects the stability, localization, and interactions of the proteins it modifies."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The PROC gene encodes for a protein involved in the regulation of blood coagulation known as Protein C, not the ASPH gene.\n2. FALSE [correction]: The ASPH gene does not encode coagulation factors VII, IX, and X. These factors are encoded by different genes: F7, F9, and F10 respectively.\n3. FALSE [correction]: The ASPH gene does not encode complement factors C1R and C1S. These are encoded by the C1R and C1S genes, respectively.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, empagliflozin was FDA approved on August 1, 2014.",
    "llama-2-13b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on August 1, 2014.",
    "llama-2-13b-chat-hf_fact": [
      "Empagliflozin was FDA approved on August 1, 2014."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Empagliflozin was FDA approved on August 1, 2014, is incorrect. The correct approval date is August 1, 2014.",
    "llama-2-13b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the results of loss of the protein Lon1 in the plant Arabidopsis are:\n1. Altered metabolite profiles: The loss of Lon1 in Arabidopsis leads to changes in the mitochondrial proteome, which in turn affects the plant's metabolic profile.\n2. Growth retardation: The alterations in the mitochondrial proteome and metabolite profiles result in growth retardation of the plant.\n3. No accumulation of oxidative damage: Despite the changes in the mitochondrial proteome and metabolite profiles, there is no accumulation of oxidative damage in the plant.\nThese results suggest that Lon1 plays a critical role in regulating mitochondrial function and metabolism in Arabidopsis, and that its loss can have significant effects on plant growth and metabolism.",
    "llama-2-13b-chat-hf_fact_raw": "1. Loss of the protein Lon1 in Arabidopsis leads to changes in the mitochondrial proteome.\n2. Changes in the mitochondrial proteome affect the plant's metabolic profile.\n3. Growth retardation occurs as a result of alterations in the mitochondrial proteome and metabolite profiles.\n4. There is no accumulation of oxidative damage in Arabidopsis despite the loss of Lon1.\n5. Lon1 is implicated in regulating mitochondrial function and metabolism in Arabidopsis.",
    "llama-2-13b-chat-hf_fact": [
      "Loss of the protein Lon1 in Arabidopsis leads to changes in the mitochondrial proteome.",
      "Changes in the mitochondrial proteome affect the plant's metabolic profile.",
      "Growth retardation occurs as a result of alterations in the mitochondrial proteome and metabolite profiles.",
      "There is no accumulation of oxidative damage in Arabidopsis despite the loss of Lon1.",
      "Lon1 is implicated in regulating mitochondrial function and metabolism in Arabidopsis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The loss of Lon1 in Arabidopsis can lead to the accumulation of oxidative damage due to impaired mitochondrial function.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is no linker histone in the yeast genome. The documents state that Hho1, a protein with great sequence similarity to histone H1, is present in Saccharomyces cerevisiae, but it is not involved in chromatin assembly. Instead, Hmo1 is involved in chromatin assembly, but only in nucleoplasmic extracts. Therefore, there is no linker histone in the yeast genome.",
    "llama-2-13b-chat-hf_fact_raw": "1. There is no linker histone in the yeast genome.\n2. Hho1 is a protein present in Saccharomyces cerevisiae with great sequence similarity to histone H1.\n3. Hho1 is not involved in chromatin assembly in Saccharomyces cerevisiae.\n4. Hmo1 is involved in chromatin assembly in Saccharomyces cerevisiae, but only in nucleoplasmic extracts.",
    "llama-2-13b-chat-hf_fact": [
      "There is no linker histone in the yeast genome.",
      "Hho1 is a protein present in Saccharomyces cerevisiae with great sequence similarity to histone H1.",
      "Hho1 is not involved in chromatin assembly in Saccharomyces cerevisiae.",
      "Hmo1 is involved in chromatin assembly in Saccharomyces cerevisiae, but only in nucleoplasmic extracts."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Yeast, specifically Saccharomyces cerevisiae, does have a linker histone, which is known as Hho1.\n2. TRUE\n3. TRUE: While Hho1 is similar to histone H1, it is generally considered not to be involved in chromatin assembly in Saccharomyces cerevisiae.\n4. UNKNOWN: The specific role of Hmo1 in chromatin assembly in Saccharomyces cerevisiae and whether it is limited to nucleoplasmic extracts is not clearly stated and would require more specific information to determine the truth of the statement.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is evidence that tomato juice may lower cholesterol levels. Document 0 states that a high dietary intake of tomato products had atheroprotective effects, including significantly reducing LDL cholesterol levels, and increasing LDL resistance to oxidation in healthy normocholesterolaemic adults. Additionally, Document 1 mentions a 2014 study that investigated the effects of dietary tomato juice intake on inflammation, insulin resistance, and high cholesterol, all of which are implicated in metabolic syndrome. This study suggests that tomato juice may have a positive impact on cholesterol levels.",
    "llama-2-13b-chat-hf_fact_raw": "1. Tomato products have been found to have atheroprotective effects.\n2. A high dietary intake of tomato products can significantly reduce LDL cholesterol levels.\n3. A high dietary intake of tomato products can increase LDL resistance to oxidation in healthy normocholesterolaemic adults.\n4. A 2014 study investigated the effects of dietary tomato juice intake on inflammation, insulin resistance, and high cholesterol.\n5. The 2014 study suggests that tomato juice may have a positive impact on cholesterol levels.",
    "llama-2-13b-chat-hf_fact": [
      "Tomato products have been found to have atheroprotective effects.",
      "A high dietary intake of tomato products can significantly reduce LDL cholesterol levels.",
      "A high dietary intake of tomato products can increase LDL resistance to oxidation in healthy normocholesterolaemic adults.",
      "A 2014 study investigated the effects of dietary tomato juice intake on inflammation, insulin resistance, and high cholesterol.",
      "The 2014 study suggests that tomato juice may have a positive impact on cholesterol levels."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: Tomato products contain lycopene and other compounds that have been found to have atheroprotective effects.\n2. TRUE: Some studies have shown that a high dietary intake of tomato products can significantly reduce LDL cholesterol levels.\n3. TRUE: Research indicates that a high dietary intake of tomato products can increase LDL resistance to oxidation, which is beneficial for heart health.\n4. TRUE: There have been studies in 2014 and other years that investigated the effects of dietary tomato juice intake on various health parameters, including inflammation and insulin resistance.\n5. TRUE: The 2014 study, along with other research, suggests that tomato juice may have a positive impact on cholesterol levels, although individual study results can vary and more research may be needed for a definitive conclusion.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, Hsp70 and Hsp110 affect mRNA stability by binding to AU-rich RNA motifs. Hsp70 is known to bind U-rich RNA, including AREs, which regulate the decay kinetics of select mRNAs. Hsp110 also preferentially binds AU-rich RNA in vitro. The binding of these proteins to AREs can stabilize some ARE-containing transcripts, suggesting that Hsp70 and Hsp110 may play a role in regulating mRNA stability.",
    "llama-2-13b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 can bind to AU-rich RNA motifs.\n2. Hsp70 is known to bind U-rich RNA, including AU-rich elements (AREs).\n3. The binding of Hsp70 to AREs regulates the decay kinetics of select mRNAs.\n4. Hsp110 preferentially binds AU-rich RNA in vitro.\n5. The binding of Hsp70 and Hsp110 to AREs can stabilize some ARE-containing transcripts.",
    "llama-2-13b-chat-hf_fact": [
      "Hsp70 and Hsp110 can bind to AU-rich RNA motifs.",
      "Hsp70 is known to bind U-rich RNA, including AU-rich elements (AREs).",
      "The binding of Hsp70 to AREs regulates the decay kinetics of select mRNAs.",
      "Hsp110 preferentially binds AU-rich RNA in vitro.",
      "The binding of Hsp70 and Hsp110 to AREs can stabilize some ARE-containing transcripts."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: The statement is specific, but without the context of a specific study or source, it's difficult to confirm the accuracy of the claim that Hsp70 and Hsp110 can bind to AU-rich RNA motifs.\n2. UNKNOWN: Similar to statement 1, this statement is specific, but without additional context or a source, the accuracy of the claim that Hsp70 is known to bind U-rich RNA, including AU-rich elements (AREs), cannot be confirmed.\n3. UNKNOWN: The statement about the binding of Hsp70 to AREs regulating the decay kinetics of select mRNAs is specific and plausible, but without context or a source, its accuracy cannot be confirmed.\n4. UNKNOWN: The statement that Hsp110 preferentially binds AU-rich RNA in vitro is specific, but without context or a source, its accuracy cannot be confirmed.\n5. UNKNOWN: The statement that the binding of Hsp70 and Hsp110 to AREs can stabilize some ARE-containing transcripts is specific and plausible, but without context or a source, its accuracy cannot be confirmed.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the answer to the user's question is:\nThe deiodinases present in skeletal muscle are type 2 (DIO2) and type 3 (DIO3).",
    "llama-2-13b-chat-hf_fact_raw": "1. Type 2 deiodinase (DIO2) is present in skeletal muscle.\n2. Type 3 deiodinase (DIO3) is present in skeletal muscle.",
    "llama-2-13b-chat-hf_fact": [
      "Type 2 deiodinase (DIO2) is present in skeletal muscle.",
      "Type 3 deiodinase (DIO3) is present in skeletal muscle."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n\nType 2 deiodinase (DIO2) is indeed present in skeletal muscle, where it plays a role in local thyroid hormone activation by converting the prohormone thyroxine (T4) into the active hormone triiodothyronine (T3). Type 3 deiodinase (DIO3) is also present in skeletal muscle and other tissues, where it inactivates thyroid hormones by converting T4 into reverse T3 (rT3) and T3 into diiodothyronine (T2), which are biologically inactive.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, here is a list of inflammatory caspase proteins:\n1. Caspase-1\n2. Caspase-4\n3. Caspase-5\n4. Caspase-11 (in humans and mice)\nThese proteins are grouped as inflammatory caspases and share a CARD-domain at the N-terminal end. They are involved in the regulation of inflammation and are distinct from the apoptotic caspases, which can be further sub-categorized into initiator and executioner caspases.",
    "llama-2-13b-chat-hf_fact_raw": "1. Caspase-1 is classified as an inflammatory caspase protein.\n2. Caspase-4 is classified as an inflammatory caspase protein.\n3. Caspase-5 is classified as an inflammatory caspase protein.\n4. Caspase-11 is classified as an inflammatory caspase protein in humans and mice.\n5. Inflammatory caspases share a CARD-domain at the N-terminal end.",
    "llama-2-13b-chat-hf_fact": [
      "Caspase-1 is classified as an inflammatory caspase protein.",
      "Caspase-4 is classified as an inflammatory caspase protein.",
      "Caspase-5 is classified as an inflammatory caspase protein.",
      "Caspase-11 is classified as an inflammatory caspase protein in humans and mice.",
      "Inflammatory caspases share a CARD-domain at the N-terminal end."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Caspase-11 is classified as an inflammatory caspase protein in mice, but in humans, the equivalent protein is known as caspase-4.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there is a link between the Aurora B kinase and the polycomb protein Ring1B. The documents suggest that both proteins play essential roles in regulating transcriptionally active genes in quiescent lymphocytes. Specifically, Ring1B and Aurora B bind to a wide range of active promoters in resting B and T cells, indicating that they are involved in the regulation of gene expression. Additionally, the documents suggest that the Aurora B kinase and the polycomb protein Ring1B are important for maintaining cellular quiescence, a state characterized by reduced cell size and transcriptional activity.",
    "llama-2-13b-chat-hf_fact_raw": "1. Aurora B kinase and the polycomb protein Ring1B are linked.\n2. Both proteins play roles in regulating transcriptionally active genes in quiescent lymphocytes.\n3. Ring1B and Aurora B bind to a wide range of active promoters in resting B and T cells.\n4. They are involved in the regulation of gene expression.\n5. Aurora B kinase and the polycomb protein Ring1B are important for maintaining cellular quiescence.",
    "llama-2-13b-chat-hf_fact": [
      "Aurora B kinase and the polycomb protein Ring1B are linked.",
      "Both proteins play roles in regulating transcriptionally active genes in quiescent lymphocytes.",
      "Ring1B and Aurora B bind to a wide range of active promoters in resting B and T cells.",
      "They are involved in the regulation of gene expression.",
      "Aurora B kinase and the polycomb protein Ring1B are important for maintaining cellular quiescence."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: Aurora B kinase and the polycomb protein Ring1B are indeed linked in the context of chromatin modification and regulation.\n2. FALSE [correction]: Both proteins are typically associated with transcriptionally repressed, not active, genes in quiescent lymphocytes. Ring1B is a polycomb protein involved in gene silencing, while Aurora B kinase is involved in chromosome segregation and can also play a role in chromatin structure and gene expression regulation.\n3. FALSE [correction]: Ring1B and Aurora B are not known to bind to a wide range of active promoters in resting B and T cells. Instead, they are generally associated with repressed chromatin regions.\n4. TRUE: Both Aurora B kinase and the polycomb protein Ring1B are involved in the regulation of gene expression, although often associated with gene repression.\n5. TRUE: Aurora B kinase and the polycomb protein Ring1B are important for maintaining cellular quiescence by regulating gene expression and ensuring proper chromatin organization and stability.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are not well established and are still an area of active research. However, recent studies have identified additional \"non-canonical\" motifs for some transcription factors (TFs) that recognize related nucleotide sequences at their DNA binding sites. These non-canonical motifs are not as well characterized as the canonical motifs, but they are thought to play important roles in regulating gene expression.\nDocument 0 mentions that sequence-specific TFs recognize motifs of related nucleotide sequences at their DNA binding sites, and that recent studies have identified additional non-canonical motifs for some TFs. However, it does not provide specific information on the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates.\nDocument 1 mentions that the development of new methods for preparing and sequencing RNA sequencing libraries, as well as new alignment algorithms, have revealed many thousands of previously unknown exons and splice sites in vertebrates. However, it does not provide specific information on the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates.\nTherefore, based on the information provided, I cannot provide a definitive answer to the user's question. However, I can suggest that the user consult recent studies on the topic, such as those published in scientific journals, to gain a more comprehensive understanding of the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the event that results in the acetylation of S6K1 is autophagy. Document 1 states that autophagy is a process by which macromolecules and organelles are degraded, and that the target molecules or organelles are delivered along acetylated microtubules to the lysosome. Since S6K1 is involved in directing cell apoptosis, metabolism, and feedback, it is likely that it is also involved in the regulation of autophagy. Therefore, the acetylation of S6K1 is likely to be a result of autophagy.",
    "llama-2-13b-chat-hf_fact_raw": "1. Autophagy is a process by which macromolecules and organelles are degraded.\n2. During autophagy, target molecules or organelles are delivered to the lysosome along acetylated microtubules.\n3. S6K1 is involved in directing cell apoptosis, metabolism, and feedback.\n4. The acetylation of S6K1 is likely a result of autophagy.",
    "llama-2-13b-chat-hf_fact": [
      "Autophagy is a process by which macromolecules and organelles are degraded.",
      "During autophagy, target molecules or organelles are delivered to the lysosome along acetylated microtubules.",
      "S6K1 is involved in directing cell apoptosis, metabolism, and feedback.",
      "The acetylation of S6K1 is likely a result of autophagy."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: During autophagy, target molecules or organelles are delivered to the lysosome along microtubules, but the statement about acetylation is not universally accepted as a characteristic of autophagy. Microtubules can be acetylated, but this modification is not specifically linked to the process of autophagy.\n3. TRUE\n4. FALSE [correction]: The acetylation of S6K1 is not directly linked to autophagy. S6K1 is a protein involved in cell growth and metabolism, primarily regulated by the mTOR pathway, and its acetylation status is not typically associated with autophagy.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the cause of episodic ataxia type 6 is not specifically mentioned. However, according to the information in Document 1, episodic ataxia is caused by mutations in the SCA6 gene. This gene provides instructions for making a protein called alpha-1 sodium-dependent high-affinity glutamate transporter 1 (GLT1). The GLT1 protein is involved in the transport of glutamate, a neurotransmitter that plays a critical role in nerve signaling. Mutations in the SCA6 gene can lead to a deficiency of functional GLT1 protein, which can cause the symptoms of episodic ataxia.",
    "llama-2-13b-chat-hf_fact_raw": "1. Episodic ataxia type 6 is caused by mutations in the SCA6 gene.\n2. The SCA6 gene provides instructions for making the alpha-1 sodium-dependent high-affinity glutamate transporter 1 (GLT1) protein.\n3. The GLT1 protein is involved in the transport of glutamate.\n4. Glutamate is a neurotransmitter that plays a critical role in nerve signaling.\n5. Mutations in the SCA6 gene can lead to a deficiency of functional GLT1 protein.",
    "llama-2-13b-chat-hf_fact": [
      "Episodic ataxia type 6 is caused by mutations in the SCA6 gene.",
      "The SCA6 gene provides instructions for making the alpha-1 sodium-dependent high-affinity glutamate transporter 1 (GLT1) protein.",
      "The GLT1 protein is involved in the transport of glutamate.",
      "Glutamate is a neurotransmitter that plays a critical role in nerve signaling.",
      "Mutations in the SCA6 gene can lead to a deficiency of functional GLT1 protein."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Episodic ataxia type 6 is not caused by mutations in the SCA6 gene. It is caused by mutations in the CACNA1A gene.\n2. FALSE [correction]: The SCA6 gene is not associated with the alpha-1 sodium-dependent high-affinity glutamate transporter 1 (GLT1) protein. The SLC1A3 gene provides instructions for making the GLT1 protein.\n3. TRUE: The GLT1 protein is involved in the transport of glutamate across cell membranes.\n4. TRUE: Glutamate is a neurotransmitter that plays a critical role in nerve signaling in the brain and throughout the nervous system.\n5. FALSE [correction]: Since the SCA6 gene is not associated with the GLT1 protein, mutations in the SCA6 gene would not lead to a deficiency of functional GLT1 protein. Instead, mutations in the SCA6 gene (CACNA1A) can affect the function of a calcium channel protein.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, chromomethylases are not present in animal genomes. The information states that chromomethylases are plant-specific enzymes and are characterized by the presence of a CHROMO domain between the catalytic motifs. There is no mention of chromomethylases in animal genomes. Additionally, Document 1 states that cytosine methylation is a common modification in the bodies of active genes in animals and vascular plants, but it does not mention chromomethylases specifically. Therefore, the answer to the question is \"no\" chromomethylases are not present in animal genomes.",
    "llama-2-13b-chat-hf_fact_raw": "1. Chromomethylases are plant-specific enzymes.\n2. Chromomethylases are characterized by the presence of a CHROMO domain between the catalytic motifs.\n3. There is no mention of chromomethylases in animal genomes according to the provided information.\n4. Cytosine methylation is a common modification in the bodies of active genes in animals and vascular plants.",
    "llama-2-13b-chat-hf_fact": [
      "Chromomethylases are plant-specific enzymes.",
      "Chromomethylases are characterized by the presence of a CHROMO domain between the catalytic motifs.",
      "There is no mention of chromomethylases in animal genomes according to the provided information.",
      "Cytosine methylation is a common modification in the bodies of active genes in animals and vascular plants."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN (The statement implies that chromomethylases are not found in animal genomes, but without explicit information from the provided context, we cannot confirm or deny this.)\n4. FALSE [correction]: Cytosine methylation is commonly found in the DNA of plants and animals, but it is typically associated with gene repression rather than being a modification in the bodies of active genes.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-13b-chat-hf_response": "Based on the information provided, here are some packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis:\n1. TFBSTools: As mentioned in the information, TFBSTools is a package specifically designed for TFBS analysis and manipulation. It provides a range of tools for handling TFBS profile matrices, scanning sequences and alignments, and querying the JASPAR database.\n2. GenomicRanges: This package provides functions for working with genomic intervals and performing operations such as intersection, union, and difference on them. It can be used in conjunction with TFBSTools to perform operations on TFBSs.\n3. Matrix: This package provides a set of functions for working with matrices, including matrix multiplication, inversion, and determinant calculation. It can be used to perform matrix operations on TFBS profile matrices.\n4. BiocGenerics: This package provides a set of generic functions for working with biological data in R, including functions for sequence manipulation, alignment, and analysis. It can be used to perform a range of tasks related to TFBS analysis, such as sequence alignment and motif discovery.\n5. HISAT2: This package provides functions for spliced aligning RNA-seq reads to a reference genome, and can be used to identify TFBSs in RNA-seq data.\n6. STAR: This package provides functions for spliced aligning RNA-seq reads to a reference genome, and can be used to identify TFBSs in RNA-seq data.\n7. DeepTools: This package provides functions for working with deep-sequencing data, including functions for read alignment, motif discovery, and transcription factor binding site analysis.\n8. RSAT: This package provides functions for working with transcription factor binding sites, including functions for identifying TFBSs in genomic sequences, and for predicting the activity of transcription factors.\nThese packages can be used to perform a range of tasks related to TFBS analysis, including identifying TFBSs in genomic sequences, predicting the activity of transcription factors, and analyzing the functional impact of TFBSs.",
    "llama-2-13b-chat-hf_fact_raw": "1. TFBSTools is a package in R/Bioconductor designed for transcription factor binding site (TFBS) analysis.\n2. GenomicRanges is a package in R/Bioconductor that provides functions for working with genomic intervals.\n3. Matrix is a package in R/Bioconductor that includes functions for matrix operations such as multiplication and inversion.\n4. HISAT2 is a package in R/Bioconductor for spliced aligning RNA-seq reads to a reference genome.\n5. STAR is a package in R/Bioconductor that also provides functions for spliced aligning RNA-seq reads to a reference genome.",
    "llama-2-13b-chat-hf_fact": [
      "TFBSTools is a package in R/Bioconductor designed for transcription factor binding site (TFBS) analysis.",
      "GenomicRanges is a package in R/Bioconductor that provides functions for working with genomic intervals.",
      "Matrix is a package in R/Bioconductor that includes functions for matrix operations such as multiplication and inversion.",
      "HISAT2 is a package in R/Bioconductor for spliced aligning RNA-seq reads to a reference genome.",
      "STAR is a package in R/Bioconductor that also provides functions for spliced aligning RNA-seq reads to a reference genome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Matrix is a package in R, but it is not part of Bioconductor. It is a base R package that includes functions for dense and sparse matrix operations.\n4. FALSE [correction]: HISAT2 is not a package in R/Bioconductor. It is a standalone, fast and sensitive alignment program for mapping next-generation sequencing reads (both DNA and RNA) to a population of genomes or to a reference genome.\n5. FALSE [correction]: STAR (Spliced Transcripts Alignment to a Reference) is not a package in R/Bioconductor. It is a standalone software tool for aligning RNA sequencing reads to a reference genome.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there are no clinical trials for the prevention of sarcopenia. Document 0 states that exercise is the only effective strategy shown to alleviate sarcopenia, and Document 1 reiterates this finding. Therefore, there is no need for clinical trials on prevention of sarcopenia, as exercise is the established effective intervention.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the database of molecular recognition features in membrane proteins is called \"mpMoRFsDB\". This information can be found in Document 0, which is a bioinformatics article titled \"mpMoRFsDB: a database of molecular recognition features in membrane proteins\" published in 2013. The authors of the article are Foivos Gypas, Georgios N Tsaousis, and Stavros J Hamodrakas.",
    "llama-2-13b-chat-hf_fact_raw": "1. The database of molecular recognition features in membrane proteins is called \"mpMoRFsDB\".\n2. The information about \"mpMoRFsDB\" can be found in a bioinformatics article.\n3. The article is titled \"mpMoRFsDB: a database of molecular recognition features in membrane proteins\".\n4. The article was published in 2013.\n5. The authors of the article are Foivos Gypas, Georgios N Tsaousis, and Stavros J Hamodrakas.",
    "llama-2-13b-chat-hf_fact": [
      "The database of molecular recognition features in membrane proteins is called \"mpMoRFsDB\".",
      "The information about \"mpMoRFsDB\" can be found in a bioinformatics article.",
      "The article is titled \"mpMoRFsDB: a database of molecular recognition features in membrane proteins\".",
      "The article was published in 2013.",
      "The authors of the article are Foivos Gypas, Georgios N Tsaousis, and Stavros J Hamodrakas."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Without specific information on the publication date, it is not possible to confirm whether the article was published in 2013.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, rivaroxaban is not metabolized in the kidneys. The document states that rivaroxaban is a selective, reversible, direct Factor Xa inhibitor, which means it directly inhibits the activity of Factor Xa in the coagulation cascade, without requiring cofactors. This suggests that the drug is metabolized primarily in the liver, where Factor Xa is present, rather than in the kidneys.",
    "llama-2-13b-chat-hf_fact_raw": "1. Rivaroxaban is not metabolized in the kidneys.\n2. Rivaroxaban is a selective, reversible, direct Factor Xa inhibitor.\n3. Rivaroxaban directly inhibits the activity of Factor Xa in the coagulation cascade without requiring cofactors.\n4. Rivaroxaban is metabolized primarily in the liver.",
    "llama-2-13b-chat-hf_fact": [
      "Rivaroxaban is not metabolized in the kidneys.",
      "Rivaroxaban is a selective, reversible, direct Factor Xa inhibitor.",
      "Rivaroxaban directly inhibits the activity of Factor Xa in the coagulation cascade without requiring cofactors.",
      "Rivaroxaban is metabolized primarily in the liver."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the genes regulated by TRalpha2 in the heart are:\n1. Genes involved in the regulation of heart rate (GO:0002027)\n2. Potassium channels\n3. TTN isoforms (as regulated by RBM20 and PTBP1)\nThese genes are regulated by TRalpha2 in the heart, as revealed by the documents provided.",
    "llama-2-13b-chat-hf_fact_raw": "1. TRalpha2 regulates genes involved in the regulation of heart rate.\n2. TRalpha2 regulates potassium channels in the heart.\n3. TRalpha2 regulates TTN isoforms in the heart.\n4. RBM20 and PTBP1 are involved in the regulation of TTN isoforms by TRalpha2.",
    "llama-2-13b-chat-hf_fact": [
      "TRalpha2 regulates genes involved in the regulation of heart rate.",
      "TRalpha2 regulates potassium channels in the heart.",
      "TRalpha2 regulates TTN isoforms in the heart.",
      "RBM20 and PTBP1 are involved in the regulation of TTN isoforms by TRalpha2."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe statements provided seem to be specific assertions about the role of TRalpha2 and its involvement in the regulation of heart function and specific proteins. Given the specificity of these statements, they are likely based on scientific research findings. However, without the specific context or source material to verify these claims, it is difficult to provide definitive corrections if any of these statements were false. Therefore, I have assumed that the statements are accurate based on the context in which they were likely made, such as a scientific study or review article. If any of these statements were incorrect according to the latest scientific research as of my knowledge cutoff date, then the response would need to be updated accordingly.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-13b-chat-hf_response": "Based on the information provided, here are some available biomedical question answering systems:\n1. BioASQ 3 (Biomedical Semantic Indexing and Question Answering): This system pushes research towards highly precise biomedical information access systems through a series of evaluation campaigns.\n2. PubMed Question Answering (PQA): A system that answers questions about biomedical literature using PubMed, a database of biomedical articles.\n3. Biomedical Question Answering Challenge (BQAC): A challenge that aims to evaluate the performance of biomedical question answering systems on a variety of questions.\n4. Medical Information Extraction and Question Answering (MEDLINE): A system that extracts information from biomedical articles and answers questions based on that information.\n5. Biomedical Natural Language Processing (NLP) Systems: These systems use machine learning and natural language processing techniques to answer biomedical questions based on text data.\n6. Biomedical Informatics Research and Development (BIRD): A system that provides a platform for researchers to develop and evaluate biomedical question answering systems.\n7. Biomedical Question Answering with Deep Learning (BQA-DL): A system that uses deep learning techniques to answer biomedical questions based on text data.\n8. Biomedical Question Answering using Knowledge Graph Embeddings (BQA-KGE): A system that uses knowledge graph embeddings to answer biomedical questions based on the relationships between entities in a knowledge graph.\nThese systems are just a few examples of the many available biomedical question answering systems. The field is constantly evolving, and new systems are being developed all the time to meet the growing need for accurate and efficient biomedical question answering.",
    "llama-2-13b-chat-hf_fact_raw": "1. BioASQ 3 is a biomedical question answering system that aims to improve biomedical information access.\n2. PubMed Question Answering (PQA) is a system designed to answer questions using the PubMed database.\n3. The Biomedical Question Answering Challenge (BQAC) evaluates the performance of biomedical question answering systems.\n4. Medical Information Extraction and Question Answering (MEDLINE) extracts information from biomedical articles to answer questions.\n5. Biomedical Natural Language Processing (NLP) Systems apply machine learning and NLP techniques to answer biomedical questions.",
    "llama-2-13b-chat-hf_fact": [
      "BioASQ 3 is a biomedical question answering system that aims to improve biomedical information access.",
      "PubMed Question Answering (PQA) is a system designed to answer questions using the PubMed database.",
      "The Biomedical Question Answering Challenge (BQAC) evaluates the performance of biomedical question answering systems.",
      "Medical Information Extraction and Question Answering (MEDLINE) extracts information from biomedical articles to answer questions.",
      "Biomedical Natural Language Processing (NLP) Systems apply machine learning and NLP techniques to answer biomedical questions."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context, it's unclear whether \"BioASQ 3\" refers to a specific version of a system or something else. BioASQ is known as a challenge in biomedical question answering, but without more information, the statement's accuracy cannot be determined.\n2. TRUE: PubMed Question Answering (PQA) could refer to systems designed to answer questions using the PubMed database, which is a repository of biomedical literature.\n3. TRUE: The Biomedical Question Answering Challenge (BQAC) sounds like a plausible initiative that could evaluate the performance of biomedical question answering systems, similar to challenges like BioASQ.\n4. FALSE [correction]: MEDLINE is a bibliographic database of life sciences and biomedical information, not a system for medical information extraction and question answering. However, systems may use MEDLINE to extract information for answering biomedical questions.\n5. TRUE: Biomedical Natural Language Processing (NLP) Systems indeed apply machine learning and NLP techniques to process and answer questions related to biomedical information.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the trancription factor that activates the betalain pathway is:\n1. PhyA (phytochrome A)\nAccording to Document 0, light cues control betalain production in plants, and PhyA is a key regulator of light signaling in plants. It is a photoreceptor that mediates light-dependent regulation of gene expression and is involved in the control of betalain biosynthesis.\nTherefore, PhyA is the trancription factor that activates the betalain pathway in plants.",
    "llama-2-13b-chat-hf_fact_raw": "1. Phytochrome A (PhyA) is a key regulator of light signaling in plants.\n2. PhyA mediates light-dependent regulation of gene expression.\n3. PhyA is involved in the control of betalain biosynthesis.\n4. Light cues control betalain production in plants.",
    "llama-2-13b-chat-hf_fact": [
      "Phytochrome A (PhyA) is a key regulator of light signaling in plants.",
      "PhyA mediates light-dependent regulation of gene expression.",
      "PhyA is involved in the control of betalain biosynthesis.",
      "Light cues control betalain production in plants."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Phytochrome B (PhyB), not PhyA, is primarily associated with the control of betalain biosynthesis.\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the preferred technologies for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses are:\n1. TiO2-based phosphopeptide enrichment: This method uses titanium dioxide (TiO2) to bind phosphorylated peptides, which are then isolated and analyzed by mass spectrometry.\n2. IMAC (Immuno-precipitation of phosphorylated peptides): This method uses antibodies specific to phosphorylated serine, threonine, or tyrosine residues to immunoprecipitate phosphorylated peptides, which are then analyzed by mass spectrometry.\n3. Fe3O4-based phosphopeptide enrichment: This method uses iron oxide (Fe3O4) to bind phosphorylated peptides, which are then isolated and analyzed by mass spectrometry.\n4. Phospho-specific antibody enrichment: This method uses antibodies specific to phosphorylated residues to immunoprecipitate phosphorylated peptides, which are then analyzed by mass spectrometry.\n5. Phosphopeptide enrichment using metal-ion affinity tags (MIT): This method uses metal-ion affinity tags (MIT) to selectively isolate phosphorylated peptides, which are then analyzed by mass spectrometry.\nThese technologies have been widely used in global quantitative phosphoproteomic analyses to enrich for phosphorylated peptides and identify changes in protein phosphorylation patterns. The choice of technology may depend on the specific research question and experimental design.",
    "llama-2-13b-chat-hf_fact_raw": "1. Titanium dioxide (TiO2) is used in TiO2-based phosphopeptide enrichment to bind phosphorylated peptides for mass spectrometry analysis.\n2. Immuno-precipitation of phosphorylated peptides (IMAC) involves using antibodies specific to phosphorylated serine, threonine, or tyrosine residues.\n3. Iron oxide (Fe3O4) is used in Fe3O4-based phosphopeptide enrichment to bind phosphorylated peptides for mass spectrometry analysis.\n4. Phospho-specific antibody enrichment uses antibodies specific to phosphorylated residues to immunoprecipitate phosphorylated peptides for mass spectrometry analysis.\n5. Metal-ion affinity tags (MIT) are used in phosphopeptide enrichment to selectively isolate phosphorylated peptides for mass spectrometry analysis.",
    "llama-2-13b-chat-hf_fact": [
      "Titanium dioxide (TiO2) is used in TiO2-based phosphopeptide enrichment to bind phosphorylated peptides for mass spectrometry analysis.",
      "Immuno-precipitation of phosphorylated peptides (IMAC) involves using antibodies specific to phosphorylated serine, threonine, or tyrosine residues.",
      "Iron oxide (Fe3O4) is used in Fe3O4-based phosphopeptide enrichment to bind phosphorylated peptides for mass spectrometry analysis.",
      "Phospho-specific antibody enrichment uses antibodies specific to phosphorylated residues to immunoprecipitate phosphorylated peptides for mass spectrometry analysis.",
      "Metal-ion affinity tags (MIT) are used in phosphopeptide enrichment to selectively isolate phosphorylated peptides for mass spectrometry analysis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Immunoaffinity precipitation (IAP) of phosphorylated peptides involves using antibodies specific to phosphorylated serine, threonine, or tyrosine residues, not Immuno-precipitation (IMAC), which stands for immobilized metal affinity chromatography and uses metal ions to bind phosphorylated peptides.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Metal-ion affinity chromatography (IMAC) is used in phosphopeptide enrichment to selectively isolate phosphorylated peptides for mass spectrometry analysis, not metal-ion affinity tags (MIT), which is not a standard term in this context.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the disorder that is rated by Palmini classification is Focal Cortical Dysplasia (FCD). The Palmini classification divides FCD into three groups:\n1. Mild Malformation of Cortical Development (mild MCD)\n2. Type I\n3. Type II\nThe classification is based on the presence and location of ectopically placed neurons in or adjacent to layer I, and the presence of microscopic neuronal heterotopia outside layer I.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Palmini classification is used to rate Focal Cortical Dysplasia (FCD).\n2. The Palmini classification divides FCD into three groups: mild Malformation of Cortical Development (mild MCD), Type I, and Type II.\n3. The Palmini classification considers the presence and location of ectopically placed neurons in or adjacent to layer I.\n4. The Palmini classification considers the presence of microscopic neuronal heterotopia outside layer I.",
    "llama-2-13b-chat-hf_fact": [
      "The Palmini classification is used to rate Focal Cortical Dysplasia (FCD).",
      "The Palmini classification divides FCD into three groups: mild Malformation of Cortical Development (mild MCD), Type I, and Type II.",
      "The Palmini classification considers the presence and location of ectopically placed neurons in or adjacent to layer I.",
      "The Palmini classification considers the presence of microscopic neuronal heterotopia outside layer I."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe Palmini classification is indeed used to categorize different types of Focal Cortical Dysplasia, which is a common cause of epilepsy. It does divide FCD into the specified groups, and it takes into account the presence and location of ectopically placed neurons, including those in layer I and those that may be found as microscopic neuronal heterotopia outside layer I.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is evidence to suggest that viruses may be involved in the etiology of human subacute thyroiditis. Document 0 states that viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases, and Document 1 lists viral infection as one of the major environmental factors related to common thyroid disorders, including subacute thyroiditis. Therefore, it is likely that viruses play a role in the development of subacute thyroiditis.",
    "llama-2-13b-chat-hf_fact_raw": "1. Viruses are frequently cited as a major environmental factor involved in subacute thyroiditis.\n2. Viral infections are related to common thyroid disorders, including subacute thyroiditis.",
    "llama-2-13b-chat-hf_fact": [
      "Viruses are frequently cited as a major environmental factor involved in subacute thyroiditis.",
      "Viral infections are related to common thyroid disorders, including subacute thyroiditis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 1, it appears that STAT3 is involved in the suppression of autophagy. According to the document, cytoplasmic STAT3 inhibits autophagy by sequestering EIF2AK2, as well as interacting with other autophagy-related signaling molecules such as FOXO1 and FOXO3. Therefore, it is likely that STAT3 plays a role in the EIF2AK2-dependent suppression of autophagy.",
    "llama-2-13b-chat-hf_fact_raw": "1. STAT3 is involved in the suppression of autophagy.\n2. Cytoplasmic STAT3 inhibits autophagy by sequestering EIF2AK2.\n3. STAT3 interacts with autophagy-related signaling molecules such as FOXO1 and FOXO3.\n4. STAT3 likely plays a role in the EIF2AK2-dependent suppression of autophagy.",
    "llama-2-13b-chat-hf_fact": [
      "STAT3 is involved in the suppression of autophagy.",
      "Cytoplasmic STAT3 inhibits autophagy by sequestering EIF2AK2.",
      "STAT3 interacts with autophagy-related signaling molecules such as FOXO1 and FOXO3.",
      "STAT3 likely plays a role in the EIF2AK2-dependent suppression of autophagy."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe statements provided are consistent with known roles of STAT3 (Signal Transducer and Activator of Transcription 3) in cellular processes. STAT3 has been implicated in the suppression of autophagy, and it can interact with various signaling molecules, including those related to autophagy. It is known to inhibit autophagy through mechanisms involving sequestration of EIF2AK2 (also known as PKR) and interactions with FOXO transcription factors. However, it is important to note that the specifics of these interactions can be complex and context-dependent, and ongoing research may further elucidate these pathways.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-13b-chat-hf_response": "Based on the information provided, Theatre is a software tool used for genomic analysis, specifically for the comparative analysis of genomic sequences. It is designed to determine or predict the positions of coding regions, repetitive sequences, and transcription factor binding sites in families of DNA sequences. Theatre is a web-based computing system that allows users to analyze and compare the genomic sequences of different organisms, including mammals and fish species.\nTheatre provides a user-friendly interface to access a variety of sequence analysis tools and biological sequence databases, making it easier for researchers to perform comprehensive genomic analysis. It can be used to identify motifs likely to be involved in the regulation of gene expression, and to compare the differences in the p53 promoter region of different species.\nSome of the key features of Theatre include:\n1. Multiple sequence alignment: Theatre allows users to align multiple DNA sequences to identify conserved regions and variations.\n2. Motif discovery: Theatre can identify motifs, which are short sequences that are conserved across different species and are often involved in gene regulation.\n3. Transcription factor binding site prediction: Theatre can predict the binding sites of transcription factors, which are proteins that regulate gene expression by binding to specific DNA sequences.\n4. Gene prediction: Theatre can predict the locations of coding regions and non-coding regions in DNA sequences.\n5. Repeat analysis: Theatre can identify repetitive sequences in DNA sequences, which can be useful for identifying functional elements such as transposons and pseudogenes.\nOverall, Theatre is a powerful tool for genomic analysis that can be used to understand the evolution and function of genomes, and to identify potential regulatory elements and functional regions.",
    "llama-2-13b-chat-hf_fact_raw": "1. Theatre is a software tool used for the comparative analysis of genomic sequences.\n2. Theatre is designed to predict the positions of coding regions, repetitive sequences, and transcription factor binding sites in families of DNA sequences.\n3. Theatre is a web-based computing system that allows the analysis and comparison of genomic sequences of different organisms.\n4. Theatre provides a user-friendly interface to access sequence analysis tools and biological sequence databases.\n5. Theatre can be used to identify motifs and predict transcription factor binding sites involved in the regulation of gene expression.",
    "llama-2-13b-chat-hf_fact": [
      "Theatre is a software tool used for the comparative analysis of genomic sequences.",
      "Theatre is designed to predict the positions of coding regions, repetitive sequences, and transcription factor binding sites in families of DNA sequences.",
      "Theatre is a web-based computing system that allows the analysis and comparison of genomic sequences of different organisms.",
      "Theatre provides a user-friendly interface to access sequence analysis tools and biological sequence databases.",
      "Theatre can be used to identify motifs and predict transcription factor binding sites involved in the regulation of gene expression."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Theatre is not a software tool; the correct term for a software tool used for the comparative analysis of genomic sequences is likely \"Genome browser\" or \"Bioinformatics software.\"\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe term \"Theatre\" does not correspond to any known bioinformatics software tool for genomic sequence analysis. The statements seem to describe functions that would be typical of a bioinformatics platform, but without the correct name of the software, it is not possible to verify the accuracy of the statements. If \"Theatre\" is a hypothetical or fictional software tool, then the statements could be true within that context, but based on real-world knowledge, they are not accurate.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2), where n is the length of the sequences.\nThe Smith-Waterman algorithm is a dynamic programming algorithm that finds the highest-scoring local alignment between two sequences. It is a time-consuming algorithm, and its complexity is directly proportional to the length of the sequences. In particular, the algorithm's time complexity is O(n^2), which means that the time required to align two sequences of length n increases quadratically with the length of the sequences.\nThis is because the algorithm needs to compare each element of one sequence with every element of the other sequence, which results in a quadratic number of comparisons. Moreover, the algorithm uses a two-dimensional matrix to store the scores of the alignments, which also contributes to the quadratic time complexity.\nTherefore, the Smith-Waterman algorithm is not suitable for very large sequences, and other algorithms such as the Needleman-Wunsch algorithm or the Longest Common Subsequence (LCS) algorithm may be more appropriate for such cases.",
    "llama-2-13b-chat-hf_fact_raw": "1. The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2).\n2. The Smith-Waterman algorithm is a dynamic programming algorithm.\n3. The Smith-Waterman algorithm finds the highest-scoring local alignment between two sequences.\n4. The time required to align two sequences of length n increases quadratically with the length of the sequences.\n5. The Smith-Waterman algorithm uses a two-dimensional matrix to store the scores of the alignments.",
    "llama-2-13b-chat-hf_fact": [
      "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2).",
      "The Smith-Waterman algorithm is a dynamic programming algorithm.",
      "The Smith-Waterman algorithm finds the highest-scoring local alignment between two sequences.",
      "The time required to align two sequences of length n increases quadratically with the length of the sequences.",
      "The Smith-Waterman algorithm uses a two-dimensional matrix to store the scores of the alignments."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, FLVCR1 is a member of the SLC49 family of genes.",
    "llama-2-13b-chat-hf_fact_raw": "1. FLVCR1 is a member of the SLC49 family of genes.",
    "llama-2-13b-chat-hf_fact": [
      "FLVCR1 is a member of the SLC49 family of genes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-13b-chat-hf_response": "Based on the information provided, here are some of the interacting partners of GATA-1 that have been discovered using the biotinylation tagging approach:\n1. HES6: The novel GATA1-interacting protein HES6 is an essential transcriptional cofactor for human erythropoiesis.\n2. Other transcription factors: GATA-1 has been shown to interact with other transcription factors, such as NF-E2, NF-E4, and PU.1, to regulate erythropoiesis.\n3. Chromatin-modifying enzymes: GATA-1 has been found to interact with chromatin-modifying enzymes, such as histone-modifying enzymes and chromatin remodelers, to regulate gene expression during erythropoiesis.\n4. Coactivators and corepressors: GATA-1 has been shown to interact with coactivators, such as p300 and CBP, and corepressors, such as NCOR1 and NCOR2, to modulate transcriptional activity.\n5. Other proteins: GATA-1 has been found to interact with other proteins, such as the erythropoietin receptor (EPOR), to regulate erythropoiesis.\nThese interactions are thought to play a crucial role in regulating gene expression during erythropoiesis and maintaining the balance of erythroid cell development. Deregulation of these interactions has been implicated in erythroid disorders, such as anemia and leukemia.",
    "llama-2-13b-chat-hf_fact_raw": "1. HES6 is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.\n2. GATA-1 interacts with the transcription factors NF-E2, NF-E4, and PU.1.\n3. GATA-1 interacts with chromatin-modifying enzymes to regulate gene expression during erythropoiesis.\n4. GATA-1 interacts with coactivators such as p300 and CBP, as well as corepressors like NCOR1 and NCOR2.\n5. The erythropoietin receptor (EPOR) is an interacting partner of GATA-1.",
    "llama-2-13b-chat-hf_fact": [
      "HES6 is an interacting partner of GATA-1 discovered using the biotinylation tagging approach.",
      "GATA-1 interacts with the transcription factors NF-E2, NF-E4, and PU.1.",
      "GATA-1 interacts with chromatin-modifying enzymes to regulate gene expression during erythropoiesis.",
      "GATA-1 interacts with coactivators such as p300 and CBP, as well as corepressors like NCOR1 and NCOR2.",
      "The erythropoietin receptor (EPOR) is an interacting partner of GATA-1."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The erythropoietin receptor (EPOR) is not an interacting partner of GATA-1; it is a receptor for erythropoietin, which is involved in erythropoiesis, but it does not directly interact with the transcription factor GATA-1.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0, the outcome of TAF10 interacting with the GATA1 transcription factor is that TAF10 is enriched on the GATA1 locus in human fetal erythroid cells. This suggests that TAF10 and GATA1 interact directly and that this interaction plays a role in the regulation of transcription during erythroid cell differentiation and development.",
    "llama-2-13b-chat-hf_fact_raw": "1. TAF10 is enriched on the GATA1 locus in human fetal erythroid cells.\n2. TAF10 and GATA1 are suggested to interact directly.\n3. The interaction between TAF10 and GATA1 plays a role in the regulation of transcription.\n4. The regulation of transcription by TAF10 and GATA1 interaction is related to erythroid cell differentiation and development.",
    "llama-2-13b-chat-hf_fact": [
      "TAF10 is enriched on the GATA1 locus in human fetal erythroid cells.",
      "TAF10 and GATA1 are suggested to interact directly.",
      "The interaction between TAF10 and GATA1 plays a role in the regulation of transcription.",
      "The regulation of transcription by TAF10 and GATA1 interaction is related to erythroid cell differentiation and development."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe statements provided are specific to molecular biology and the interactions between proteins and genes. Without the specific context or scientific study to reference, it is not possible to determine the truthfulness of these statements. They would require specialized knowledge or a specific source to verify.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there are decision support systems for chronic pain management. Document 1 highlights the potential of computerized decision-support systems (CDSSs) in improving chronic pain management, particularly in primary care settings where physicians may lack sufficient pain-specific clinical expertise and communication skills.\nCDSSs can provide clinicians with real-time, evidence-based recommendations for diagnosis, treatment, and management of chronic pain. These systems can help clinicians make more informed decisions, improve patient outcomes, and reduce the risk of adverse events.\nSome examples of decision support systems for chronic pain management include:\n1. The Pain Management Decision Support System (PMDSS), which provides clinicians with evidence-based recommendations for assessing and managing chronic pain.\n2. The Chronic Pain Management System (CPMS), which offers a comprehensive set of tools and resources for managing chronic pain, including clinical decision support, patient education, and communication tools.\n3. The Pain Care Coordination System (PCCS), which is designed to improve the coordination of care for patients with chronic pain, including communication between healthcare providers, patient education, and clinical decision support.\nIt is important to note that while decision support systems can be helpful in managing chronic pain, they should not be relied upon as the sole source of clinical decision-making. Clinicians should always use their professional judgment and expertise when making decisions about patient care.",
    "llama-2-13b-chat-hf_fact_raw": "1. Computerized decision-support systems (CDSSs) can improve chronic pain management in primary care settings.\n2. CDSSs provide real-time, evidence-based recommendations for the diagnosis, treatment, and management of chronic pain.\n3. The Pain Management Decision Support System (PMDSS) offers evidence-based recommendations for assessing and managing chronic pain.\n4. The Chronic Pain Management System (CPMS) includes clinical decision support, patient education, and communication tools for managing chronic pain.\n5. The Pain Care Coordination System (PCCS) is designed to improve care coordination for patients with chronic pain, including communication between healthcare providers.",
    "llama-2-13b-chat-hf_fact": [
      "Computerized decision-support systems (CDSSs) can improve chronic pain management in primary care settings.",
      "CDSSs provide real-time, evidence-based recommendations for the diagnosis, treatment, and management of chronic pain.",
      "The Pain Management Decision Support System (PMDSS) offers evidence-based recommendations for assessing and managing chronic pain.",
      "The Chronic Pain Management System (CPMS) includes clinical decision support, patient education, and communication tools for managing chronic pain.",
      "The Pain Care Coordination System (PCCS) is designed to improve care coordination for patients with chronic pain, including communication between healthcare providers."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: Computerized decision-support systems (CDSSs) are designed to improve various aspects of healthcare, including chronic pain management in primary care settings, by providing clinicians with integrated, patient-specific information.\n2. TRUE: CDSSs typically provide real-time, evidence-based recommendations to support healthcare professionals in the diagnosis, treatment, and management of various conditions, including chronic pain.\n3. UNKNOWN: Without specific information about a system named the Pain Management Decision Support System (PMDSS), it is not possible to confirm the accuracy of this statement.\n4. UNKNOWN: Similar to statement 3, without specific information about a system named the Chronic Pain Management System (CPMS), the accuracy of this statement cannot be confirmed.\n5. UNKNOWN: As with statements 3 and 4, without specific information about a system named the Pain Care Coordination System (PCCS), the accuracy of this statement cannot be confirmed.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, the subcellular localization of the protein angiogenin is extracellular. Angiogenin is a secreted ribonuclease that is involved in regulating cell proliferation, survival, migration, and invasion, and it has been recognized to play important roles in various physiological and pathological processes. As it is secreted from cells, it is not present within the cell itself, but rather in the extracellular space.",
    "llama-2-13b-chat-hf_fact_raw": "1. The protein angiogenin is localized in the extracellular space.\n2. Angiogenin is a secreted ribonuclease.\n3. Angiogenin is involved in regulating cell proliferation, survival, migration, and invasion.\n4. Angiogenin plays important roles in various physiological and pathological processes.",
    "llama-2-13b-chat-hf_fact": [
      "The protein angiogenin is localized in the extracellular space.",
      "Angiogenin is a secreted ribonuclease.",
      "Angiogenin is involved in regulating cell proliferation, survival, migration, and invasion.",
      "Angiogenin plays important roles in various physiological and pathological processes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, ranolazine has been shown to inhibit the late phase of the inward sodium current in ventricular myocardial cells, which reduces intracellular calcium overload and associated diastolic contractile dysfunction. However, there is a novel effect of ranolazine on heart rate and rate pressure product in humans that requires further evaluation.\nAs a helpful assistant, I would like to add that ranolazine's effect on kinase signaling activation in the heart is not explicitly mentioned in the provided information. However, it is known that kinase signaling pathways play a crucial role in regulating cardiac function and contraction, and dysregulation of these pathways can contribute to the development and progression of heart failure. Therefore, it is possible that ranolazine may have an impact on kinase signaling activation in the heart, although further research is needed to confirm this.\nAdditionally, it is worth noting that heart failure is a complex and multifactorial condition, and its pathophysiology involves a range of cellular and molecular mechanisms. Therefore, any potential therapeutic intervention, including ranolazine, would need to be carefully evaluated in the context of the underlying disease mechanisms and the patient population being treated.",
    "llama-2-13b-chat-hf_fact_raw": "1. Ranolazine inhibits the late phase of the inward sodium current in ventricular myocardial cells.\n2. Ranolazine reduces intracellular calcium overload in ventricular myocardial cells.\n3. Ranolazine is associated with a reduction in diastolic contractile dysfunction.\n4. Ranolazine has a novel effect on heart rate and rate pressure product in humans.\n5. Further evaluation is required to understand the novel effect of ranolazine on heart rate and rate pressure product in humans.",
    "llama-2-13b-chat-hf_fact": [
      "Ranolazine inhibits the late phase of the inward sodium current in ventricular myocardial cells.",
      "Ranolazine reduces intracellular calcium overload in ventricular myocardial cells.",
      "Ranolazine is associated with a reduction in diastolic contractile dysfunction.",
      "Ranolazine has a novel effect on heart rate and rate pressure product in humans.",
      "Further evaluation is required to understand the novel effect of ranolazine on heart rate and rate pressure product in humans."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Ranolazine does not have a significant effect on heart rate and rate pressure product in humans.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Documents 0 and 1, it appears that the regulation of Vsr endonuclease is growth phase dependent, as the levels of Vsr relative to Dcm cytosine methylase change during cell growth. Specifically, the levels of Vsr are decreased during the log phase compared to Dcm, which may contribute to the mutability of 5-methylcytosine.",
    "llama-2-13b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is growth phase dependent.\n2. The levels of Vsr relative to Dcm cytosine methylase change during cell growth.\n3. Vsr levels are decreased during the log phase compared to Dcm.\n4. The mutability of 5-methylcytosine may be affected by the levels of Vsr during the log phase.",
    "llama-2-13b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is growth phase dependent.",
      "The levels of Vsr relative to Dcm cytosine methylase change during cell growth.",
      "Vsr levels are decreased during the log phase compared to Dcm.",
      "The mutability of 5-methylcytosine may be affected by the levels of Vsr during the log phase."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific information from the passage or a reliable source, it is not possible to determine the accuracy of these statements regarding the regulation of Vsr endonuclease, its levels relative to Dcm cytosine methylase, or the mutability of 5-methylcytosine. These are specialized topics in molecular biology that require expert knowledge or reference to specific scientific studies.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there are two computational tools for the prediction of beta-barrel transmembrane proteins:\n1. TMBHMM (Transmembrane beta-helix hidden Markov model): This is a hidden Markov model-based method that predicts the exposure status of residues predicted to be in the membrane. The method has been compared with two other methods from the literature and has been implemented as a web server.\n2. BetAware-Deep: This is a deep learning-based method that outperforms two recently released state-of-the-art methods for topology prediction, predicting correct topologies of 10 out of 15 proteins.\nBoth of these tools can be used to predict the presence of beta-barrel transmembrane proteins in a given protein sequence.",
    "llama-2-13b-chat-hf_fact_raw": "1. TMBHMM is a computational tool that predicts the exposure status of residues in beta-barrel transmembrane proteins.\n2. TMBHMM is based on a hidden Markov model.\n3. BetAware-Deep is a computational tool that uses deep learning for the prediction of beta-barrel transmembrane proteins.\n4. BetAware-Deep has been shown to predict correct topologies of 10 out of 15 proteins.\n5. Both TMBHMM and BetAware-Deep are designed to predict beta-barrel transmembrane proteins.",
    "llama-2-13b-chat-hf_fact": [
      "TMBHMM is a computational tool that predicts the exposure status of residues in beta-barrel transmembrane proteins.",
      "TMBHMM is based on a hidden Markov model.",
      "BetAware-Deep is a computational tool that uses deep learning for the prediction of beta-barrel transmembrane proteins.",
      "BetAware-Deep has been shown to predict correct topologies of 10 out of 15 proteins.",
      "Both TMBHMM and BetAware-Deep are designed to predict beta-barrel transmembrane proteins."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The correct name of the computational tool is BetAware, not BetAware-Deep, and it uses a combination of machine learning techniques, not specifically deep learning.\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, Galassi classification is used to classify arachnoid cysts in the middle cranial fossa.",
    "llama-2-13b-chat-hf_fact_raw": "1. Galassi classification is used to classify arachnoid cysts.\n2. Galassi classification is specifically for arachnoid cysts located in the middle cranial fossa.",
    "llama-2-13b-chat-hf_fact": [
      "Galassi classification is used to classify arachnoid cysts.",
      "Galassi classification is specifically for arachnoid cysts located in the middle cranial fossa."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-13b-chat-hf_response": "Based on the information provided in the two documents, here are some common features of Shapiro syndrome:\n1. Spontaneous periodic hypothermia: This is the primary characteristic of Shapiro syndrome, where patients experience sudden and unexplained episodes of hypothermia, regardless of their age or sex.\n2. Limited number of cases: According to the documents, there have been less than 60 reported cases of Shapiro syndrome worldwide, making it a rare condition.\n3. Controversial pathogenesis and etiology: The exact cause of Shapiro syndrome is still not well understood, and there is ongoing debate among medical professionals about its origins.\n4. Limited knowledge: Due to the rarity of the condition and the limited number of reported cases, there is a lack of comprehensive understanding of Shapiro syndrome, and more research is needed to fully characterize its clinical features and potential causes.\nBased on these common features, it is important to note that Shapiro syndrome is a rare and poorly understood condition that requires careful monitoring and management by medical professionals.",
    "llama-2-13b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by spontaneous periodic hypothermia.\n2. There have been less than 60 reported cases of Shapiro syndrome worldwide.\n3. The exact cause of Shapiro syndrome is not well understood.\n4. There is ongoing debate among medical professionals about the origins of Shapiro syndrome.\n5. More research is needed to fully characterize the clinical features and potential causes of Shapiro syndrome.",
    "llama-2-13b-chat-hf_fact": [
      "Shapiro syndrome is characterized by spontaneous periodic hypothermia.",
      "There have been less than 60 reported cases of Shapiro syndrome worldwide.",
      "The exact cause of Shapiro syndrome is not well understood.",
      "There is ongoing debate among medical professionals about the origins of Shapiro syndrome.",
      "More research is needed to fully characterize the clinical features and potential causes of Shapiro syndrome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE (As of my knowledge cutoff in 2023, there have been around 50 reported cases of Shapiro syndrome, so this statement is true based on the information available up to that time.)\n3. TRUE\n4. UNKNOWN (Without specific information on the current state of debate among medical professionals regarding the origins of Shapiro syndrome, it is not possible to confirm or deny this statement.)\n5. TRUE (Given the rarity and complexity of the condition, it is reasonable to assume that more research would be beneficial to fully understand Shapiro syndrome.)",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the disease linked to mutations within the BRAG1 gene is nonsyndromic X-chromosome-linked intellectual disability (XLID).",
    "llama-2-13b-chat-hf_fact_raw": "1. Mutations within the BRAG1 gene are linked to nonsyndromic X-chromosome-linked intellectual disability (XLID).",
    "llama-2-13b-chat-hf_fact": [
      "Mutations within the BRAG1 gene are linked to nonsyndromic X-chromosome-linked intellectual disability (XLID)."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n\n[Note: The statement provided is very specific and would require access to current and accurate genetic research data to confirm. The gene mentioned, BRAG1, may be a typographical error or a less commonly used name for a gene. In scientific literature, the gene associated with X-linked intellectual disability is often referred to as ARX (Aristaless Related Homeobox) or other gene names depending on the specific type of mutation or syndrome. Without the correct gene name or additional context, it is not possible to verify the accuracy of the statement.]",
    "llama-2-13b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0, the main inhibitor of protein phosphatase 1 (PP1) is Inhibitor-3. According to the document, Inhibitor-3 inhibits PP1 via a metal binding dynamic protein-protein interaction.",
    "llama-2-13b-chat-hf_fact_raw": "1. Inhibitor-3 is the main inhibitor of protein phosphatase 1 (PP1).\n2. Inhibitor-3 inhibits PP1 through a metal binding dynamic protein-protein interaction.",
    "llama-2-13b-chat-hf_fact": [
      "Inhibitor-3 is the main inhibitor of protein phosphatase 1 (PP1).",
      "Inhibitor-3 inhibits PP1 through a metal binding dynamic protein-protein interaction."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Inhibitor-1 (I-1) is the main inhibitor of protein phosphatase 1 (PP1), not Inhibitor-3.\n2. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 1, the mechanisms underlying adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis are the production of mutations that arise in nondividing or stationary-phase bacteria when the cells are subjected to nonlethal selective pressure, such as nutrient-limited environments.",
    "llama-2-13b-chat-hf_fact_raw": "1. Adaptive mutagenesis in Bacillus subtilis involves mutations that arise in nondividing or stationary-phase bacteria.\n2. These mutations occur when the cells are subjected to nonlethal selective pressure.\n3. Nutrient-limited environments are an example of nonlethal selective pressure that can lead to adaptive mutagenesis in Bacillus subtilis.",
    "llama-2-13b-chat-hf_fact": [
      "Adaptive mutagenesis in Bacillus subtilis involves mutations that arise in nondividing or stationary-phase bacteria.",
      "These mutations occur when the cells are subjected to nonlethal selective pressure.",
      "Nutrient-limited environments are an example of nonlethal selective pressure that can lead to adaptive mutagenesis in Bacillus subtilis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, erucism is caused by the toxins contained in the bristles of moth larvae. When these bristles penetrate the skin, they release toxins that contain thermolabile proteins, proteolytic enzymes, and histamine, which can cause inflammation and skin lesions.",
    "llama-2-13b-chat-hf_fact_raw": "1. Erucism is caused by toxins in the bristles of moth larvae.\n2. The bristles of moth larvae release toxins when they penetrate the skin.\n3. The toxins that cause erucism contain thermolabile proteins.\n4. The toxins that cause erucism contain proteolytic enzymes.\n5. The toxins that cause erucism contain histamine, which can cause inflammation and skin lesions.",
    "llama-2-13b-chat-hf_fact": [
      "Erucism is caused by toxins in the bristles of moth larvae.",
      "The bristles of moth larvae release toxins when they penetrate the skin.",
      "The toxins that cause erucism contain thermolabile proteins.",
      "The toxins that cause erucism contain proteolytic enzymes.",
      "The toxins that cause erucism contain histamine, which can cause inflammation and skin lesions."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the indications for hydrochlorothiazide are:\n1. Hypertension (high blood pressure)\n2. Fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, or kidney disorders\n3. Edema caused by taking steroids or estrogen.\nIt is important to note that hydrochlorothiazide is contraindicated in patients who are unable to urinate.",
    "llama-2-13b-chat-hf_fact_raw": "1. Hydrochlorothiazide is indicated for the treatment of hypertension (high blood pressure).\n2. Hydrochlorothiazide is used to treat fluid retention (edema) in people with congestive heart failure.\n3. Hydrochlorothiazide is used to treat fluid retention (edema) in people with cirrhosis of the liver.\n4. Hydrochlorothiazide is used to treat fluid retention (edema) in people with kidney disorders.\n5. Hydrochlorothiazide is contraindicated in patients who are unable to urinate.",
    "llama-2-13b-chat-hf_fact": [
      "Hydrochlorothiazide is indicated for the treatment of hypertension (high blood pressure).",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with congestive heart failure.",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with cirrhosis of the liver.",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with kidney disorders.",
      "Hydrochlorothiazide is contraindicated in patients who are unable to urinate."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-13b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. According to Document 0, periurethral or transurethral injection of bulking agents is a minimally invasive surgical procedure used to treat stress urinary incontinence (SUI) in adult women. These bulking agents, which can be made of silicone, are injected into the urethra or periurethral tissue to support the bladder neck and urethral sphincter, thereby improving urinary control.\nAdditionally, Document 1 mentions that vaginal pessaries, which can also be made of silicone, are a commonly used conservative treatment for incontinence in women. These pessaries are inserted into the vagina and can help support the pelvic floor, reducing the symptoms of incontinence.\nIn summary, silicon has been used in the treatment of incontinence in the form of bulking agents and vaginal pessaries, and has been shown to be effective in improving urinary control and reducing symptoms of incontinence in women.",
    "llama-2-13b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of incontinence.\n2. Periurethral or transurethral injection of bulking agents is a procedure used to treat stress urinary incontinence in adult women.\n3. Bulking agents used in the treatment of incontinence can be made of silicone.\n4. Silicone bulking agents are injected into the urethra or periurethral tissue to support the bladder neck and urethral sphincter.\n5. Vaginal pessaries made of silicone are used as a conservative treatment for incontinence in women.",
    "llama-2-13b-chat-hf_fact": [
      "Silicon has been used in the treatment of incontinence.",
      "Periurethral or transurethral injection of bulking agents is a procedure used to treat stress urinary incontinence in adult women.",
      "Bulking agents used in the treatment of incontinence can be made of silicone.",
      "Silicone bulking agents are injected into the urethra or periurethral tissue to support the bladder neck and urethral sphincter.",
      "Vaginal pessaries made of silicone are used as a conservative treatment for incontinence in women."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Silicon is a chemical element and is not used in medical treatments. However, silicone, which is a polymer, has been used in the treatment of incontinence.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is no established association between moon cycle and rupture risk of intracranial aneurysms. Document 0 states that moon phases are not associated with the incidence of intracranial aneurysm rupture, and Document 1, a research article, also found no association between lunar phase and intracranial aneurysm rupture. Therefore, there is no conclusive evidence to support a link between the two.",
    "llama-2-13b-chat-hf_fact_raw": "1. There is no established association between moon cycle and rupture risk of intracranial aneurysms.\n2. Document 0 states that moon phases are not associated with the incidence of intracranial aneurysm rupture.\n3. Document 1, a research article, found no association between lunar phase and intracranial aneurysm rupture.",
    "llama-2-13b-chat-hf_fact": [
      "There is no established association between moon cycle and rupture risk of intracranial aneurysms.",
      "Document 0 states that moon phases are not associated with the incidence of intracranial aneurysm rupture.",
      "Document 1, a research article, found no association between lunar phase and intracranial aneurysm rupture."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, it appears that HuR protein does regulate the splicing process. Document 0 states that HuR regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle, and modulates a gene signature associated with cell cycle progression. Document 1 provides in vivo splicing experiments in HeLa cells that show that HuR alone or in combination with TIA-1 or TIAR can regulate the splicing of Fas minigenes. These findings suggest that HuR plays a role in regulating the splicing of specific mRNAs, including those involved in cell cycle progression.",
    "llama-2-13b-chat-hf_fact_raw": "1. HuR protein regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle.\n2. HuR modulates a gene signature associated with cell cycle progression.\n3. In vivo splicing experiments in HeLa cells show that HuR can regulate the splicing of Fas minigenes.\n4. HuR alone or in combination with TIA-1 or TIAR can regulate splicing processes.",
    "llama-2-13b-chat-hf_fact": [
      "HuR protein regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle.",
      "HuR modulates a gene signature associated with cell cycle progression.",
      "In vivo splicing experiments in HeLa cells show that HuR can regulate the splicing of Fas minigenes.",
      "HuR alone or in combination with TIA-1 or TIAR can regulate splicing processes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe statements provided are consistent with the known functions of the HuR protein (also known as ELAVL1), which is involved in the regulation of mRNA stability and splicing, and it is known to interact with other proteins such as TIA-1 and TIAR to modulate these processes. However, without specific references to experimental results or literature, the statements are assumed to be true based on general knowledge of the protein's functions.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the known functions of the prothymosin alpha c-terminal peptide are:\n1. Interaction with the Keap1 Kelch domain: Prothymosin alpha has a Kelch-binding domain that is similar to that of Neh2, and has been investigated by crystallographic and NMR methods.\n2. Proteolytic modifications: Prothymosin alpha undergoes two types of protease-mediated modifications, which are useful in understanding its interactions with other molecules.\n3. Cellular localization and cell type-specific functions: The function of prothymosin alpha seems to be determined by its cellular localization and the specific cell type in which it is present.\nIt is worth noting that the information provided is based on two documents, and the specific functions of the prothymosin alpha c-terminal peptide may be further elucidated by additional research.",
    "llama-2-13b-chat-hf_fact_raw": "1. Prothymosin alpha interacts with the Keap1 Kelch domain.\n2. Prothymosin alpha undergoes proteolytic modifications.\n3. The function of prothymosin alpha is influenced by its cellular localization and the specific cell type in which it is present.",
    "llama-2-13b-chat-hf_fact": [
      "Prothymosin alpha interacts with the Keap1 Kelch domain.",
      "Prothymosin alpha undergoes proteolytic modifications.",
      "The function of prothymosin alpha is influenced by its cellular localization and the specific cell type in which it is present."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the peptide that plays a pivotal role in human cystatin C fibrillization is LQVVR. This information is stated in Document 0, which is a scientific article published in FEBS Letters. The article states that the pentapeptide LQVVR plays a pivotal role in human cystatin C fibrillization.",
    "llama-2-13b-chat-hf_fact_raw": "1. The peptide LQVVR plays a pivotal role in human cystatin C fibrillization.\n2. The information about LQVVR's role in cystatin C fibrillization is published in FEBS Letters.",
    "llama-2-13b-chat-hf_fact": [
      "The peptide LQVVR plays a pivotal role in human cystatin C fibrillization.",
      "The information about LQVVR's role in cystatin C fibrillization is published in FEBS Letters."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nWithout access to the specific publication in FEBS Letters or detailed knowledge about the peptide LQVVR and its role in human cystatin C fibrillization, it is not possible to verify the accuracy of these statements.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0, it appears that the concentration of HIF-1α protein does increase during the G1 phase of the cell cycle in an AMPK-dependent manner. However, there is no direct information provided in Document 0 or Document 1 about the effect of amifostine (ethyol) on HIF-1α protein levels. Therefore, I cannot provide a definitive answer to the user's question without additional information.\nHowever, I can provide some context and background information on the HIF-1α pathway and its potential relationship to amifostine. HIF-1α is a transcription factor that plays a crucial role in response to hypoxia and is involved in various cellular processes, including angiogenesis, glucose metabolism, and cell survival. Amifostine, also known as ethyol, is a cytoprotective prodrug that has been used to protect normal tissues from the toxic effects of radiation and chemotherapy. It has been shown to inhibit the activity of various enzymes involved in DNA replication and repair, leading to cell cycle arrest and apoptosis.\nGiven the role of HIF-1α in cell survival and the potential of amifostine to inhibit cell proliferation, it is possible that amifostine may affect HIF-1α protein levels. However, without direct evidence from the provided documents, I cannot confirm whether amifostine increases or decreases HIF-1α protein levels. Further research or additional information would be needed to answer the user's question definitively.",
    "llama-2-13b-chat-hf_fact_raw": "1. HIF-1α protein concentration increases during the G1 phase of the cell cycle in an AMPK-dependent manner.\n2. HIF-1α is a transcription factor that is involved in the cellular response to hypoxia.\n3. HIF-1α is involved in various cellular processes, including angiogenesis, glucose metabolism, and cell survival.\n4. Amifostine, also known as ethyol, is a cytoprotective prodrug used to protect normal tissues from the toxic effects of radiation and chemotherapy.\n5. Amifostine has been shown to inhibit the activity of various enzymes involved in DNA replication and repair.",
    "llama-2-13b-chat-hf_fact": [
      "HIF-1α protein concentration increases during the G1 phase of the cell cycle in an AMPK-dependent manner.",
      "HIF-1α is a transcription factor that is involved in the cellular response to hypoxia.",
      "HIF-1α is involved in various cellular processes, including angiogenesis, glucose metabolism, and cell survival.",
      "Amifostine, also known as ethyol, is a cytoprotective prodrug used to protect normal tissues from the toxic effects of radiation and chemotherapy.",
      "Amifostine has been shown to inhibit the activity of various enzymes involved in DNA replication and repair."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Amifostine is used to protect normal tissues during cancer treatment and does not inhibit the activity of enzymes involved in DNA replication and repair; rather, it acts as a scavenger of free radicals and can provide protection against the harmful effects of radiation and chemotherapy.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0, Set7 is known to deposit H3K4 methylation.",
    "llama-2-13b-chat-hf_fact_raw": "1. Set7 deposits H3K4 methylation.",
    "llama-2-13b-chat-hf_fact": [
      "Set7 deposits H3K4 methylation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Set7 (also known as Set7/9 or SETD7) is a histone methyltransferase that specifically catalyzes the methylation of lysine 4 on histone H3 (H3K4). However, the term \"deposits\" is not typically used in this context; it is more accurate to say that Set7 catalyzes or mediates the methylation of H3K4.",
    "llama-2-13b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the protein hepcidin has four disulfide bridges.",
    "llama-2-13b-chat-hf_fact_raw": "1. The protein hepcidin has four disulfide bridges.",
    "llama-2-13b-chat-hf_fact": [
      "The protein hepcidin has four disulfide bridges."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the localization of the protein encoded by the gene DNAJC11 is in the nucleus.\nDocument 0 mentions that the protein folding problem is a major contributor to the pathology of Alzheimer's disease, and the neuronal aggregated tau observed in AD cells suggests that the protein folding problem is a major issue. This implies that the protein encoded by DNAJC11 is involved in protein folding, and since the nucleus is the site of protein synthesis and folding, it is likely that the protein is localized in the nucleus.\nDocument 1 provides a schematic model for nuclear protein import through the nuclear pore complex (NPC), which further supports the idea that the protein encoded by DNAJC11 is localized in the nucleus. The model illustrates how a complex biological function can be generated by a spatially and temporally organized cycle of interactions between cargoes, carriers, and Ran GTPase, which is involved in NLS-dependent protein trafficking from the cytoplasm into the nucleus. As the protein encoded by DNAJC11 is likely to be involved in protein folding, it is likely that it is localized in the nucleus and undergoes NLS-dependent trafficking.",
    "llama-2-13b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized in the nucleus.\n2. The protein folding problem is a major contributor to the pathology of Alzheimer's disease.\n3. Neuronal aggregated tau is observed in Alzheimer's disease (AD) cells.\n4. The nucleus is the site of protein synthesis and folding.\n5. Nuclear protein import involves the nuclear pore complex (NPC).",
    "llama-2-13b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is localized in the nucleus.",
      "The protein folding problem is a major contributor to the pathology of Alzheimer's disease.",
      "Neuronal aggregated tau is observed in Alzheimer's disease (AD) cells.",
      "The nucleus is the site of protein synthesis and folding.",
      "Nuclear protein import involves the nuclear pore complex (NPC)."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The protein encoded by the gene DNAJC11 is primarily localized in the mitochondria, not the nucleus.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The cytoplasm is the site of protein synthesis, and protein folding can occur both in the cytoplasm and the endoplasmic reticulum, not the nucleus.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, it appears that ultraconserved elements are depleted among copy number variants (CNVs). The documents state that mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants. This suggests that CNVs are associated with the loss of ultraconserved elements, which are regions of the genome that are highly conserved across species and are thought to be functionally important.",
    "llama-2-13b-chat-hf_fact_raw": "1. Ultraconserved elements are regions of the genome that are highly conserved across species.\n2. Ultraconserved elements are thought to be functionally important.\n3. Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants (CNVs).\n4. Copy number variants (CNVs) are associated with the loss of ultraconserved elements.",
    "llama-2-13b-chat-hf_fact": [
      "Ultraconserved elements are regions of the genome that are highly conserved across species.",
      "Ultraconserved elements are thought to be functionally important.",
      "Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants (CNVs).",
      "Copy number variants (CNVs) are associated with the loss of ultraconserved elements."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Copy number variants (CNVs) are typically associated with genomic instability and can lead to the duplication or deletion of various genomic elements, but saying they are associated with the \"loss\" of ultraconserved elements is misleading. Ultraconserved elements are generally resistant to such changes, which is why they are conserved across species.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the substrate of the haspin kinase during mitosis is histone H3 (H3T3). According to Document 1, haspin/Gsg2 specifically phosphorylates Thr-3 in histone H3, indicating that H3T3 is the substrate of the haspin kinase during mitosis.",
    "llama-2-13b-chat-hf_fact_raw": "1. The substrate of the haspin kinase during mitosis is histone H3 (H3T3).\n2. Haspin kinase specifically phosphorylates Thr-3 in histone H3 during mitosis.",
    "llama-2-13b-chat-hf_fact": [
      "The substrate of the haspin kinase during mitosis is histone H3 (H3T3).",
      "Haspin kinase specifically phosphorylates Thr-3 in histone H3 during mitosis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, the mechanism of viroid replication is a rolling-circle mechanism that involves the synthesis of longer-than-unit strands catalyzed by RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase. This process occurs in both polarity strands and results in the amplification of the viroid genome. The noncoding nature of viroids requires them to harness host machinery for infection, providing valuable opportunities for understanding fundamental principles of RNA structure and function.",
    "llama-2-13b-chat-hf_fact_raw": "1. Viroid replication involves a rolling-circle mechanism.\n2. The synthesis of longer-than-unit strands in viroid replication is catalyzed by RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase.\n3. Viroid replication occurs in both polarity strands.\n4. The replication process results in the amplification of the viroid genome.\n5. Viroids are noncoding and require host machinery for infection.",
    "llama-2-13b-chat-hf_fact": [
      "Viroid replication involves a rolling-circle mechanism.",
      "The synthesis of longer-than-unit strands in viroid replication is catalyzed by RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase.",
      "Viroid replication occurs in both polarity strands.",
      "The replication process results in the amplification of the viroid genome.",
      "Viroids are noncoding and require host machinery for infection."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, it appears that fibronectin may constitute a serum biomarker for Duchenne muscular dystrophy (DMD). Document 0 suggests that fibronectin was chosen for follow-up based on differences in peptide spectral counts and sequence coverage between the DMD and control groups, indicating that there may be differences in fibronectin levels between the two groups. Document 1 further supports this idea, suggesting that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients. However, it is important to note that more research is needed to confirm these findings and establish the specificity and sensitivity of fibronectin as a biomarker for DMD.",
    "llama-2-13b-chat-hf_fact_raw": "1. Fibronectin may be a serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Document 0 indicates differences in peptide spectral counts and sequence coverage between DMD and control groups.\n3. Document 1 suggests that serum fibronectin levels could be a promising biomarker to monitor disease progression in DMD patients.\n4. More research is needed to confirm the findings regarding fibronectin as a biomarker for DMD.\n5. The specificity and sensitivity of fibronectin as a biomarker for DMD have not been fully established.",
    "llama-2-13b-chat-hf_fact": [
      "Fibronectin may be a serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Document 0 indicates differences in peptide spectral counts and sequence coverage between DMD and control groups.",
      "Document 1 suggests that serum fibronectin levels could be a promising biomarker to monitor disease progression in DMD patients.",
      "More research is needed to confirm the findings regarding fibronectin as a biomarker for DMD.",
      "The specificity and sensitivity of fibronectin as a biomarker for DMD have not been fully established."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the data from the following major epigenome projects are contained in the DeepBlue epigenomic data server:\n1. ENCODE (Encyclopedia of DNA Elements)\n2. ROADMAP (Roadmap Epigenomics Mapping and Analysis Platform)\n3. BLUEPRINT (Blueprint of the Human Epigenome)\n4. DEEP (Dynamic Epigenetic Epigenomics Project)\nThe DeepBlue epigenomic data server provides access to these data through a well-documented application programming interface (API) via the XML-RPC protocol, which is supported by many programming languages.",
    "llama-2-13b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project.\n2. The DeepBlue epigenomic data server contains data from the ROADMAP project.\n3. The DeepBlue epigenomic data server contains data from the BLUEPRINT project.\n4. The DeepBlue epigenomic data server contains data from the DEEP project.\n5. The DeepBlue epigenomic data server provides access to data through an API via the XML-RPC protocol.",
    "llama-2-13b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project.",
      "The DeepBlue epigenomic data server contains data from the ROADMAP project.",
      "The DeepBlue epigenomic data server contains data from the BLUEPRINT project.",
      "The DeepBlue epigenomic data server contains data from the DEEP project.",
      "The DeepBlue epigenomic data server provides access to data through an API via the XML-RPC protocol."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The DeepBlue epigenomic data server provides access to data through an API via the JSON-RPC protocol, not the XML-RPC protocol.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the tool that employs self-organizing maps for analyzing synonymous codon usage is CUBAP (Codon Usage Biases Analyzer). CUBAP is an interactive web portal for analyzing codon usage biases across populations, as mentioned in Document 1: CUBAP: an interactive web portal for analyzing codon usage biases across populations | Nucleic Acids Research | Oxford Academic Abstract.\nCUBAP uses self-organizing maps (SOMs) to visualize codon usage data and identify patterns and trends in synonymous codon usage. SOMs are a type of artificial neural network that can be used for data visualization and clustering. They consist of a two-dimensional grid of neurons, where each neuron represents a point in the high-dimensional data space. The neurons are connected to their neighboring neurons in a hierarchical manner, allowing the SOM to learn the underlying structure of the data.\nIn the context of codon usage analysis, SOMs can be used to visualize the distribution of codons in a dataset and identify clusters of codons that are used together more frequently than expected by chance. This can help researchers identify patterns and trends in synonymous codon usage that may be related to specific biological processes or functional elements in the genome.\nTherefore, based on the information provided, the answer to the user's question is CUBAP.",
    "llama-2-13b-chat-hf_fact_raw": "1. CUBAP (Codon Usage Biases Analyzer) is a tool that employs self-organizing maps for analyzing synonymous codon usage.\n2. CUBAP is an interactive web portal for analyzing codon usage biases across populations.\n3. Self-organizing maps (SOMs) are a type of artificial neural network used for data visualization and clustering.\n4. SOMs consist of a two-dimensional grid of neurons that represent points in high-dimensional data space.\n5. In codon usage analysis, SOMs can visualize the distribution of codons and identify clusters of codons that are used together more frequently than expected by chance.",
    "llama-2-13b-chat-hf_fact": [
      "CUBAP (Codon Usage Biases Analyzer) is a tool that employs self-organizing maps for analyzing synonymous codon usage.",
      "CUBAP is an interactive web portal for analyzing codon usage biases across populations.",
      "Self-organizing maps (SOMs) are a type of artificial neural network used for data visualization and clustering.",
      "SOMs consist of a two-dimensional grid of neurons that represent points in high-dimensional data space.",
      "In codon usage analysis, SOMs can visualize the distribution of codons and identify clusters of codons that are used together more frequently than expected by chance."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: CUBAP is not specifically described as an interactive web portal for analyzing codon usage biases across populations. It is a tool for analyzing synonymous codon usage, but the statement about it being an interactive web portal for analyzing codon usage biases across populations is too specific and not supported by the given context.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, MINDY-1 is a member of a new family of deubiquitinating enzymes, as stated in Document 0.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the software package available for the analysis of conserved genomic loci is PHYLUCE. This information is provided in both Document 0 and Document 1. PHYLUCE is a software package specifically designed for the analysis of conserved genomic loci, and it was published in the journal Bioinformatics in 2016.",
    "llama-2-13b-chat-hf_fact_raw": "1. PHYLUCE is a software package designed for the analysis of conserved genomic loci.\n2. PHYLUCE was published in the journal Bioinformatics in 2016.",
    "llama-2-13b-chat-hf_fact": [
      "PHYLUCE is a software package designed for the analysis of conserved genomic loci.",
      "PHYLUCE was published in the journal Bioinformatics in 2016."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: PHYLUCE was published in the journal Bioinformatics in 2014.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, here are three diseases associated with the PIEZO2 gene:\n1. Autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis: This is a disease caused by loss-of-function mutations in the PIEZO2 gene.\n2. Distal arthrogryposis: This is a group of diseases caused by gain-of-function mutations in the PIEZO2 gene, which can lead to muscle weakness and joint contractures.\n3. Congenital lymphatic dysplasia: This is a disease caused by loss-of-function mutations in the PIEZO1 gene, which can lead to impaired lymphatic vessel development and function.\nI hope this information is helpful! Let me know if you have any further questions.",
    "llama-2-13b-chat-hf_fact_raw": "1. Autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis is associated with loss-of-function mutations in the PIEZO2 gene.\n2. Distal arthrogryposis is associated with gain-of-function mutations in the PIEZO2 gene.\n3. Congenital lymphatic dysplasia is associated with loss-of-function mutations in the PIEZO1 gene.",
    "llama-2-13b-chat-hf_fact": [
      "Autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis is associated with loss-of-function mutations in the PIEZO2 gene.",
      "Distal arthrogryposis is associated with gain-of-function mutations in the PIEZO2 gene.",
      "Congenital lymphatic dysplasia is associated with loss-of-function mutations in the PIEZO1 gene."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Distal arthrogryposis is associated with mutations in genes other than PIEZO2, such as MYH3, TNNI2, TNNT3, and TPM2.\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, ERAP1-ERAP2 dimerization promotes the modulation of ERAP1/2 activity, which is a novel immunological strategy for cancer immunotherapy. The dimerization of ERAP1 and ERAP2 allows access to the active site of both enzymes, and this structure is consistent with a previously reported construct in which ERAP1 and ERAP2 were linked by Fos/Jun zipper tags. This suggests that the dimerization of ERAP1 and ERAP2 is a key aspect of their physiological role and significance in immune responses, and may have important implications for the development of new cancer therapies.",
    "llama-2-13b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the modulation of ERAP1/2 activity.\n2. The dimerization of ERAP1 and ERAP2 allows access to the active site of both enzymes.\n3. ERAP1 and ERAP2 were previously reported to be linked by Fos/Jun zipper tags.\n4. The dimerization of ERAP1 and ERAP2 is considered a key aspect of their physiological role in immune responses.\n5. ERAP1-ERAP2 dimerization has implications for the development of new cancer therapies.",
    "llama-2-13b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the modulation of ERAP1/2 activity.",
      "The dimerization of ERAP1 and ERAP2 allows access to the active site of both enzymes.",
      "ERAP1 and ERAP2 were previously reported to be linked by Fos/Jun zipper tags.",
      "The dimerization of ERAP1 and ERAP2 is considered a key aspect of their physiological role in immune responses.",
      "ERAP1-ERAP2 dimerization has implications for the development of new cancer therapies."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: ERAP1-ERAP2 dimerization is known to modulate the activity of these aminopeptidases, which can affect the processing of antigenic peptides.\n2. TRUE: The dimerization of ERAP1 and ERAP2 can indeed affect access to the active sites of the enzymes, influencing their function.\n3. FALSE [correction]: ERAP1 and ERAP2 are not reported to be linked by Fos/Jun zipper tags. Fos and Jun are components of the AP-1 transcription factor, not tags for protein dimerization.\n4. TRUE: The dimerization of ERAP1 and ERAP2 is considered important for their physiological role in immune responses, as it can influence the generation of peptides that bind to MHC class I molecules.\n5. TRUE: The modulation of ERAP1 and ERAP2 activity through dimerization has potential implications for the development of new therapeutic approaches, including cancer therapies, due to their role in immune surveillance.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, R-spondin 1 and noggin play a role in the growth and differentiation of gallbladder-derived organoids. In non-damaged gallbladders, these growth factors stimulate the growth of organoids and prevent partial differentiation towards the hepatocyte fate. This suggests that R-spondin 1 and noggin are important for the maintenance of the progenitor cell pool in the gallbladder and may play a role in the regulation of gallbladder function.\nAdditionally, the fact that subsets of hepatocellular carcinoma have been found to have amplifications of the RSPO2 gene or increased expression of RSPO2 mRNA, which is associated with Wnt/β-catenin activation, suggests that R-spondin 1 and noggin may also play a role in the development of certain types of liver cancer. However, further research is needed to fully understand the mechanisms by which R-spondin 1 and noggin contribute to gallbladder function and the development of liver cancer.",
    "llama-2-13b-chat-hf_fact_raw": "1. R-spondin 1 and noggin stimulate the growth of gallbladder-derived organoids.\n2. In non-damaged gallbladders, R-spondin 1 and noggin prevent partial differentiation towards the hepatocyte fate.\n3. R-spondin 1 and noggin are important for the maintenance of the progenitor cell pool in the gallbladder.\n4. Subsets of hepatocellular carcinoma have been found to have amplifications of the RSPO2 gene or increased expression of RSPO2 mRNA.\n5. Amplifications of the RSPO2 gene or increased expression of RSPO2 mRNA are associated with Wnt/β-catenin activation.",
    "llama-2-13b-chat-hf_fact": [
      "R-spondin 1 and noggin stimulate the growth of gallbladder-derived organoids.",
      "In non-damaged gallbladders, R-spondin 1 and noggin prevent partial differentiation towards the hepatocyte fate.",
      "R-spondin 1 and noggin are important for the maintenance of the progenitor cell pool in the gallbladder.",
      "Subsets of hepatocellular carcinoma have been found to have amplifications of the RSPO2 gene or increased expression of RSPO2 mRNA.",
      "Amplifications of the RSPO2 gene or increased expression of RSPO2 mRNA are associated with Wnt/β-catenin activation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: R-spondin 1 and noggin are known to be involved in the growth and development of various types of organoids, including those derived from the gallbladder. They are part of a cocktail of growth factors that can stimulate organoid growth.\n\n2. UNKNOWN: The specific effect of R-spondin 1 and noggin on non-damaged gallbladders and their role in preventing partial differentiation towards the hepatocyte fate is not clearly stated. This would require specific biological context or experimental results to confirm.\n\n3. UNKNOWN: While R-spondin 1 is involved in the maintenance of various stem cell populations, the statement about its role in maintaining the progenitor cell pool specifically in the gallbladder is not verifiable without specific scientific evidence or context.\n\n4. TRUE: Amplifications of the RSPO2 gene or increased expression of RSPO2 mRNA have been observed in subsets of hepatocellular carcinoma, which is a type of liver cancer. RSPO2 is one of the R-spondin family members that can be involved in cancer development.\n\n5. TRUE: Amplifications of the RSPO2 gene or increased expression of RSPO2 mRNA are indeed associated with the activation of the Wnt/β-catenin signaling pathway, which is a key pathway in cell proliferation, differentiation, and development. Aberrant activation of this pathway is a common feature in various cancers, including hepatocellular carcinoma.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, it appears that NADPH oxidase 5 (NOX5) does require subunits for its function. Document 1 states that NOX is a multisubunit enzyme complex composed of five essential subunits, two of which are localized in the membrane, while three are localized in the cytosol. This suggests that NOX5, as a member of the NOX family, requires the presence of multiple subunits to function properly. Additionally, Document 0 mentions that NOX5 contains four Ca2+ binding domains at the N-terminus, which suggests that the enzyme's activity may be regulated by the intracellular concentration of Ca2+. Therefore, it is likely that the proper functioning of NOX5 requires the presence of multiple subunits and the regulation of Ca2+ levels within the cell.",
    "llama-2-13b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) requires subunits for its function.\n2. NOX is a multisubunit enzyme complex composed of five essential subunits.\n3. Two of the essential subunits of NOX are localized in the membrane.\n4. Three of the essential subunits of NOX are localized in the cytosol.\n5. NOX5 contains four Ca2+ binding domains at the N-terminus.",
    "llama-2-13b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) requires subunits for its function.",
      "NOX is a multisubunit enzyme complex composed of five essential subunits.",
      "Two of the essential subunits of NOX are localized in the membrane.",
      "Three of the essential subunits of NOX are localized in the cytosol.",
      "NOX5 contains four Ca2+ binding domains at the N-terminus."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) does not require additional subunits for its function; it is a calcium-dependent enzyme that functions independently.\n2. FALSE [correction]: NOX is a family of enzymes, and not all members are multisubunit complexes. For example, NOX1-4 require subunits for their function, but NOX5 does not.\n3. TRUE: For NOX1-4, which are multisubunit complexes, two of the essential subunits (p22phox and gp91phox/NOX2 or its homologues) are indeed localized in the membrane.\n4. TRUE: For NOX1-4, the remaining essential subunits (p40phox, p47phox, and p67phox or their homologues) are localized in the cytosol.\n5. TRUE: NOX5 contains four EF-hand motifs at the N-terminus, which are calcium-binding domains.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is a connection between furin and hepcidin. Furin is an endoplasmic reticulum (ER) resident protein that is involved in the processing and maturation of other proteins, including hepcidin. Hepcidin is a hormone that regulates iron metabolism by binding to the iron-exporting protein ferroportin and inducing its internalization and degradation.\nDocument 0 mentions that hepcidin binds to the only known iron export protein, ferroportin, and induces its internalization and degradation, which limits the amount of iron released into the blood. This suggests that hepcidin plays a key role in regulating iron metabolism by controlling the amount of iron available for use in the body.\nDocument 1 further supports this connection by stating that hepcidin is thought to be the key regulator of iron metabolism in humans through its inhibition of the iron-exporting protein ferroportin. This suggests that hepcidin regulates iron metabolism by inhibiting the activity of ferroportin, which is essential for the export of iron from cells.\nTherefore, based on the information provided, there is a connection between furin and hepcidin, as furin is involved in the processing and maturation of hepcidin, and hepcidin regulates iron metabolism by inhibiting the activity of ferroportin.",
    "llama-2-13b-chat-hf_fact_raw": "1. Furin is an endoplasmic reticulum resident protein involved in the processing and maturation of other proteins, including hepcidin.\n2. Hepcidin is a hormone that regulates iron metabolism.\n3. Hepcidin binds to the iron-exporting protein ferroportin and induces its internalization and degradation.\n4. The internalization and degradation of ferroportin by hepcidin limits the amount of iron released into the blood.\n5. Hepcidin is considered the key regulator of iron metabolism in humans through its inhibition of ferroportin.",
    "llama-2-13b-chat-hf_fact": [
      "Furin is an endoplasmic reticulum resident protein involved in the processing and maturation of other proteins, including hepcidin.",
      "Hepcidin is a hormone that regulates iron metabolism.",
      "Hepcidin binds to the iron-exporting protein ferroportin and induces its internalization and degradation.",
      "The internalization and degradation of ferroportin by hepcidin limits the amount of iron released into the blood.",
      "Hepcidin is considered the key regulator of iron metabolism in humans through its inhibition of ferroportin."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is a Golgi apparatus-associated protein, not an endoplasmic reticulum resident protein, involved in the processing and maturation of other proteins, including hepcidin.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the largest metabolic gene cluster in yeast is the DAL cluster. According to Document 0, the DAL cluster consists of six adjacent genes encoding proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source.",
    "llama-2-13b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the DAL cluster.\n2. The DAL cluster consists of six adjacent genes.\n3. These genes encode proteins that allow Saccharomyces cerevisiae to use allantoin as a nitrogen source.",
    "llama-2-13b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the DAL cluster.",
      "The DAL cluster consists of six adjacent genes.",
      "These genes encode proteins that allow Saccharomyces cerevisiae to use allantoin as a nitrogen source."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The DAL cluster consists of seven adjacent genes.\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the role of LIMT lncRNA is not explicitly mentioned. However, we can infer some information about the role of LIMT lncRNA based on the context of the provided documents.\nDocument 0 mentions that TERC, a lncRNA, is required for telomere maintenance, which is a vital cellular function. This suggests that LIMT lncRNA, as a member of the same class of molecules as TERC, may also play a role in telomere maintenance.\nDocument 1 provides a general overview of lncRNAs, stating that they are transcripts longer than 200 nucleotides that lack protein-coding potential. This suggests that LIMT lncRNA, like other lncRNAs, may not have a direct role in protein synthesis but may instead regulate gene expression or other cellular processes.\nIn light of these documents, it is possible that the role of LIMT lncRNA is related to telomere maintenance or regulation of gene expression, but further research is needed to confirm this hypothesis.",
    "llama-2-13b-chat-hf_fact_raw": "1. TERC, a lncRNA, is required for telomere maintenance.\n2. LIMT lncRNA is a member of the same class of molecules as TERC.\n3. LncRNAs are transcripts longer than 200 nucleotides.\n4. LncRNAs lack protein-coding potential.\n5. LIMT lncRNA may regulate gene expression or other cellular processes.",
    "llama-2-13b-chat-hf_fact": [
      "TERC, a lncRNA, is required for telomere maintenance.",
      "LIMT lncRNA is a member of the same class of molecules as TERC.",
      "LncRNAs are transcripts longer than 200 nucleotides.",
      "LncRNAs lack protein-coding potential.",
      "LIMT lncRNA may regulate gene expression or other cellular processes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the R/Bioconductor package used for performing SNP enrichment analysis is traseR.",
    "llama-2-13b-chat-hf_fact_raw": "1. The R/Bioconductor package traseR is used for performing SNP enrichment analysis.",
    "llama-2-13b-chat-hf_fact": [
      "The R/Bioconductor package traseR is used for performing SNP enrichment analysis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The R/Bioconductor package traseR is used for trajectory inference in single-cell RNA-seq data analysis, not for SNP enrichment analysis.",
    "llama-2-13b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the key players in radial glial specification to ependymal cells are:\n1. Mcidas\n2. GemC1/Lynkeas\nThese two proteins were initially described as cell cycle regulators, but recent findings suggest that they also play a crucial role in radial glial specification to ependymal cells.",
    "llama-2-13b-chat-hf_fact_raw": "1. Mcidas is a key player in radial glial specification to ependymal cells.\n2. GemC1/Lynkeas is a key player in radial glial specification to ependymal cells.\n3. Mcidas and GemC1/Lynkeas were initially described as cell cycle regulators.\n4. Recent findings suggest that Mcidas and GemC1/Lynkeas play a crucial role in radial glial specification to ependymal cells.",
    "llama-2-13b-chat-hf_fact": [
      "Mcidas is a key player in radial glial specification to ependymal cells.",
      "GemC1/Lynkeas is a key player in radial glial specification to ependymal cells.",
      "Mcidas and GemC1/Lynkeas were initially described as cell cycle regulators.",
      "Recent findings suggest that Mcidas and GemC1/Lynkeas play a crucial role in radial glial specification to ependymal cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n\nThe statements pertain to specific roles of proteins or genes in cellular biology, which are likely to be based on scientific research findings. Without the specific context or reference to the relevant scientific literature, it is difficult to verify the accuracy of the first two statements. However, the third statement is generally consistent with the roles that many genes and proteins are initially characterized by their functions in cell cycle regulation before other roles are discovered. The fourth statement seems to be a summary of the findings related to the first two statements, and if those are based on recent scientific findings, it would be true. However, without specific sources or more detailed context, the veracity of the first two statements remains unknown.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Documents 0 and 1, triple negative gliomas are characterized by the absence of all three major alterations, specifically:\n1. Lack of IDH1/2 mutations\n2. Lack of TP53 mutations\n3. Lack of 1p/19q codeletion\nThese alterations are commonly found in other types of gliomas, such as glioblastoma, but are absent in triple negative gliomas. This absence of major alterations makes triple negative gliomas an \"enigmatic\" group of tumors, as described in Document 1.",
    "llama-2-13b-chat-hf_fact_raw": "1. Triple negative gliomas lack IDH1/2 mutations.\n2. Triple negative gliomas lack TP53 mutations.\n3. Triple negative gliomas lack 1p/19q codeletion.\n4. The absence of these three major alterations makes triple negative gliomas distinct from other types of gliomas.\n5. Triple negative gliomas are considered an \"enigmatic\" group of tumors.",
    "llama-2-13b-chat-hf_fact": [
      "Triple negative gliomas lack IDH1/2 mutations.",
      "Triple negative gliomas lack TP53 mutations.",
      "Triple negative gliomas lack 1p/19q codeletion.",
      "The absence of these three major alterations makes triple negative gliomas distinct from other types of gliomas.",
      "Triple negative gliomas are considered an \"enigmatic\" group of tumors."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Triple negative gliomas often have TP53 mutations.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, TOPAZ1 is a clinical trial that evaluated the use of durvalumab plus chemotherapy for patients with advanced biliary tract cancer. The trial was conducted in 17 countries across the globe, including the United States, Europe, South America, South Korea, Thailand, Japan, Taiwan, and China. The primary endpoint of the study was overall survival (OS), while secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. The trial enrolled 685 patients who were randomly assigned to receive either durvalumab plus gemcitabine or placebo plus gemcitabine. The results of the study were presented at the 2022 ASCO GI conference.",
    "llama-2-13b-chat-hf_fact_raw": "1. TOPAZ1 is a clinical trial that evaluated the use of durvalumab plus chemotherapy in patients with advanced biliary tract cancer.\n2. The TOPAZ1 trial was conducted in 17 countries, including the United States, Europe, South America, South Korea, Thailand, Japan, Taiwan, and China.\n3. The primary endpoint of the TOPAZ1 study was overall survival (OS).\n4. Secondary endpoints of the TOPAZ1 study included progression-free survival (PFS), objective response rate (ORR), and safety.\n5. A total of 685 patients were enrolled in the TOPAZ1 trial and were randomly assigned to receive either durvalumab plus gemcitabine or placebo plus gemcitabine.",
    "llama-2-13b-chat-hf_fact": [
      "TOPAZ1 is a clinical trial that evaluated the use of durvalumab plus chemotherapy in patients with advanced biliary tract cancer.",
      "The TOPAZ1 trial was conducted in 17 countries, including the United States, Europe, South America, South Korea, Thailand, Japan, Taiwan, and China.",
      "The primary endpoint of the TOPAZ1 study was overall survival (OS).",
      "Secondary endpoints of the TOPAZ1 study included progression-free survival (PFS), objective response rate (ORR), and safety.",
      "A total of 685 patients were enrolled in the TOPAZ1 trial and were randomly assigned to receive either durvalumab plus gemcitabine or placebo plus gemcitabine."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: A total of 685 patients were enrolled in the TOPAZ1 trial and were randomly assigned to receive either durvalumab plus gemcitabine and cisplatin or placebo plus gemcitabine and cisplatin.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the gene that controls the expression of GATA-1 isoforms is GATA1 itself. Document 1 states that K562 cells expressing GATA1s or GATA1FL transgenes were used to model the effects of the two isoforms on in vitro haematopoietic differentiation, indicating that GATA1 is the gene that controls the expression of GATA-1 isoforms.",
    "llama-2-13b-chat-hf_fact_raw": "1. The gene that controls the expression of GATA-1 isoforms is GATA1.\n2. K562 cells were used to model the effects of GATA-1 isoforms on in vitro hematopoietic differentiation.\n3. GATA1s and GATA1FL are transgenes representing two isoforms of GATA-1.",
    "llama-2-13b-chat-hf_fact": [
      "The gene that controls the expression of GATA-1 isoforms is GATA1.",
      "K562 cells were used to model the effects of GATA-1 isoforms on in vitro hematopoietic differentiation.",
      "GATA1s and GATA1FL are transgenes representing two isoforms of GATA-1."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, MIRA-seq is a DNA methylation analysis platform that uses the high affinity of methylated-CpG-binding protein complexes (MBD2B and MBD3L1) to enrich regions with methylated CpG dinucleotides. This approach can be applied to both array-based DNA analysis and next-generation sequencing (NGS) sequencing, and is particularly useful for scoring DNA methylation differences at CpG-rich genomic regions. MIRA-seq is a reliable and cost-effective method that is not limited by primer or probe design.",
    "llama-2-13b-chat-hf_fact_raw": "1. MIRA-seq is a DNA methylation analysis platform.\n2. MIRA-seq uses the high affinity of methylated-CpG-binding protein complexes (MBD2B and MBD3L1) to enrich regions with methylated CpG dinucleotides.\n3. MIRA-seq can be applied to both array-based DNA analysis and next-generation sequencing (NGS).\n4. MIRA-seq is particularly useful for scoring DNA methylation differences at CpG-rich genomic regions.\n5. MIRA-seq is not limited by primer or probe design.",
    "llama-2-13b-chat-hf_fact": [
      "MIRA-seq is a DNA methylation analysis platform.",
      "MIRA-seq uses the high affinity of methylated-CpG-binding protein complexes (MBD2B and MBD3L1) to enrich regions with methylated CpG dinucleotides.",
      "MIRA-seq can be applied to both array-based DNA analysis and next-generation sequencing (NGS).",
      "MIRA-seq is particularly useful for scoring DNA methylation differences at CpG-rich genomic regions.",
      "MIRA-seq is not limited by primer or probe design."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nMIRA-seq, which stands for Methylated CpG Island Recovery Assay followed by sequencing, is indeed a platform used for DNA methylation analysis. It utilizes the high affinity of methyl-CpG-binding domain proteins, such as MBD2B and MBD3L1, to enrich for regions of DNA that contain methylated CpG dinucleotides. This technique can be applied to various DNA analysis methods, including both array-based platforms and next-generation sequencing. MIRA-seq is particularly useful for analyzing DNA methylation differences in CpG-rich regions of the genome. Since it is based on the affinity capture of methylated DNA, it is not constrained by the limitations that affect methods requiring specific primers or probes for amplification or hybridization.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the indication of ARCALYST is to treat Recurrent Pericarditis (RP) and reduce the risk of recurrence in adults and pediatric patients 12 years and older.",
    "llama-2-13b-chat-hf_fact_raw": "1. ARCALYST is indicated for the treatment of Recurrent Pericarditis (RP).\n2. ARCALYST is used to reduce the risk of recurrence of RP in adults.\n3. ARCALYST is also indicated for pediatric patients 12 years and older.",
    "llama-2-13b-chat-hf_fact": [
      "ARCALYST is indicated for the treatment of Recurrent Pericarditis (RP).",
      "ARCALYST is used to reduce the risk of recurrence of RP in adults.",
      "ARCALYST is also indicated for pediatric patients 12 years and older."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the human acrocentric chromosomes involved in Robertsonian translocation are:\n1. Chromosome 13\n2. Chromosome 14\n3. Chromosome 15\n4. Chromosome 21\n5. Chromosome 22\nThese chromosomes are all associated with Robertsonian translocations, and the short arms of all of the acrocentric chromosomes contain numerous copies of the genes coding for ribosomal RNA.",
    "llama-2-13b-chat-hf_fact_raw": "1. Chromosome 13 is involved in Robertsonian translocation.\n2. Chromosome 14 is involved in Robertsonian translocation.\n3. Chromosome 15 is involved in Robertsonian translocation.\n4. Chromosome 21 is involved in Robertsonian translocation.\n5. Chromosome 22 is involved in Robertsonian translocation.",
    "llama-2-13b-chat-hf_fact": [
      "Chromosome 13 is involved in Robertsonian translocation.",
      "Chromosome 14 is involved in Robertsonian translocation.",
      "Chromosome 15 is involved in Robertsonian translocation.",
      "Chromosome 21 is involved in Robertsonian translocation.",
      "Chromosome 22 is involved in Robertsonian translocation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nRobertsonian translocations are a type of chromosomal rearrangement that involves the fusion of two acrocentric chromosomes. Acrocentric chromosomes in humans include chromosomes 13, 14, 15, 21, and 22. Therefore, any of these chromosomes can be involved in a Robertsonian translocation.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the R package that could be used for the identification of pediatric brain tumors is MethPed. Documents 0 and 1 mention that MethPed is a classifier (classification tool) that efficiently classifies pediatric brain tumors using DNA methylation profiles. The package is available via Bioconductor, and it can be used to analyze data from the 450K platform.\nMethPed is specifically designed to identify and classify pediatric brain tumors, including Glioblastoma, Medulloblastoma, Ependymoma, and Astrocytoma. The package uses a random forest algorithm to classify tumors based on their DNA methylation profiles.\nTherefore, if you are looking for an R package to identify pediatric brain tumors, MethPed is a good choice. It is specifically designed for this task and has been shown to be efficient in classifying pediatric brain tumors using DNA methylation profiles.",
    "llama-2-13b-chat-hf_fact_raw": "1. MethPed is an R package used for the identification of pediatric brain tumors.\n2. MethPed classifies pediatric brain tumors using DNA methylation profiles.\n3. The MethPed package is available via Bioconductor.\n4. MethPed can analyze data from the 450K platform.\n5. MethPed uses a random forest algorithm for tumor classification.",
    "llama-2-13b-chat-hf_fact": [
      "MethPed is an R package used for the identification of pediatric brain tumors.",
      "MethPed classifies pediatric brain tumors using DNA methylation profiles.",
      "The MethPed package is available via Bioconductor.",
      "MethPed can analyze data from the 450K platform.",
      "MethPed uses a random forest algorithm for tumor classification."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The MethPed package is available via GitHub, not Bioconductor.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, NEMO (Inhibitor of κB kinase gamma) is a zinc finger protein. The article from ScienceDirect states that the zinc finger of NEMO is a functional ubiquitin-binding domain.",
    "llama-2-13b-chat-hf_fact_raw": "1. NEMO stands for Inhibitor of κB kinase gamma.\n2. NEMO is a zinc finger protein.\n3. The zinc finger of NEMO is a functional ubiquitin-binding domain according to an article from ScienceDirect.",
    "llama-2-13b-chat-hf_fact": [
      "NEMO stands for Inhibitor of κB kinase gamma.",
      "NEMO is a zinc finger protein.",
      "The zinc finger of NEMO is a functional ubiquitin-binding domain according to an article from ScienceDirect."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: NEMO stands for NF-kappaB essential modulator.\n2. FALSE [correction]: NEMO is not classified as a zinc finger protein; it is an essential regulatory component of the IκB kinase (IKK) complex, which is involved in NF-kappaB activation.\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, it appears that TFIIS does affect nucleosome positioning. Document 0 states that the lack of TFIIS influences nucleosome occupancy across the genome, particularly in genes with a canonical TATA box, and Document 1 suggests that TFIIS contributes to nucleosome positioning in both gene promoters and bodies. These findings suggest that TFIIS plays a role in regulating the positioning of nucleosomes during transcription elongation, and that this regulation may be particularly important in genes with a specific sequence context.",
    "llama-2-13b-chat-hf_fact_raw": "1. TFIIS influences nucleosome occupancy across the genome.\n2. The lack of TFIIS has an effect particularly in genes with a canonical TATA box.\n3. TFIIS contributes to nucleosome positioning in gene promoters and bodies.\n4. TFIIS plays a role in regulating the positioning of nucleosomes during transcription elongation.\n5. The regulation of nucleosome positioning by TFIIS may be particularly important in genes with a specific sequence context.",
    "llama-2-13b-chat-hf_fact": [
      "TFIIS influences nucleosome occupancy across the genome.",
      "The lack of TFIIS has an effect particularly in genes with a canonical TATA box.",
      "TFIIS contributes to nucleosome positioning in gene promoters and bodies.",
      "TFIIS plays a role in regulating the positioning of nucleosomes during transcription elongation.",
      "The regulation of nucleosome positioning by TFIIS may be particularly important in genes with a specific sequence context."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe statements about TFIIS (Transcription Factor II S) are specific to molecular biology and would require specific scientific evidence to confirm or refute. Statements 1, 3, and 4 are generally consistent with the known functions of TFIIS in transcription, but without specific context or references, it's not possible to definitively confirm statements 2 and 5.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the origins of replication close to yeast centromeres fire late. According to Document 1, the early replication of baker's yeast centromeres is one frequently cited example of temporal regulation, but the biological significance of early centromere replication remains speculative. This suggests that the origins of replication close to yeast centromeres do not fire early, but rather late in the replication process.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, the properties of mammalian GA-sequences are:\n1. Length: GA-sequences are longer than 50 bases.\n2. Composition: Exclusively consist of G's and A's (pure GA-sequences).\n3. Frequency of incidence: The frequency of incidence of GA-sequences in mammalian genomes is 10^-16 or smaller.\n4. Ubiquitous location: GA-sequences are ubiquitously located along the chromosomes of human, chimpanzee, dog, cat, rat, and mouse.\n5. Species-dependent distribution: The distribution of GA-sequences varies among different species, with a species-dependent distribution.\nThese properties of GA-sequences are based on the information provided in Document 0 and Document 1, and are relevant to understanding the structure and evolution of mammalian genomes.",
    "llama-2-13b-chat-hf_fact_raw": "1. Mammalian GA-sequences are longer than 50 bases.\n2. GA-sequences consist exclusively of G's and A's.\n3. The frequency of incidence of GA-sequences in mammalian genomes is 10^-16 or smaller.\n4. GA-sequences are located along the chromosomes of humans, chimpanzees, dogs, cats, rats, and mice.\n5. The distribution of GA-sequences varies among different species.",
    "llama-2-13b-chat-hf_fact": [
      "Mammalian GA-sequences are longer than 50 bases.",
      "GA-sequences consist exclusively of G's and A's.",
      "The frequency of incidence of GA-sequences in mammalian genomes is 10^-16 or smaller.",
      "GA-sequences are located along the chromosomes of humans, chimpanzees, dogs, cats, rats, and mice.",
      "The distribution of GA-sequences varies among different species."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: GA-sequences do not consist exclusively of G's and A's; they are often characterized by a high frequency of these nucleotides but can contain other nucleotides as well.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there are at least 17 Groucho-related genes (GRG) contained in the mouse genome. This is according to Document 0, which mentions \"Groucho related gene 5 (GRG5)\" and Document 1, which discusses the Groucho-related gene family and their regulation of the gonadotropin-releasing hormone gene.",
    "llama-2-13b-chat-hf_fact_raw": "1. There are at least 17 Groucho-related genes (GRG) in the mouse genome.\n2. Document 0 mentions \"Groucho related gene 5 (GRG5)\".\n3. Document 1 discusses the Groucho-related gene family and their regulation of the gonadotropin-releasing hormone gene.",
    "llama-2-13b-chat-hf_fact": [
      "There are at least 17 Groucho-related genes (GRG) in the mouse genome.",
      "Document 0 mentions \"Groucho related gene 5 (GRG5)\".",
      "Document 1 discusses the Groucho-related gene family and their regulation of the gonadotropin-releasing hormone gene."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout the actual documents or a specific passage that provides the necessary information to verify these statements, it is not possible to determine the truthfulness of the statements regarding the Groucho-related genes (GRG) in the mouse genome, the mention of \"Groucho related gene 5 (GRG5)\" in Document 0, or the discussion of the Groucho-related gene family in Document 1.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0, the RNA polymerase II subunit that carries RNA cleavage activity is not specified. However, according to Document 1, paused RNA polymerase II (RNAPII) enhances the targeting and activity of BAF chromatin remodelers, suggesting that RNAPII may play a role in RNA cleavage. Therefore, I cannot provide a definitive answer to the user's question based on the given information.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the genetic basis of Ohdo syndrome is likely to be a genetic mutation or variation in a specific gene or set of genes. The Say-Barber-Biesecker-Young-Simpson (SBBYS) variant of Ohdo syndrome is a rare condition that is characterized by genital abnormalities in males, missing or underdeveloped kneecaps (patellae), intellectual disability, distinctive facial features, and abnormalities affecting other parts of the body. The Maat-Kievit-Brunner type of Ohdo syndrome is another rare form of the condition that is characterized by intellectual disability and distinctive facial features. Both forms of Ohdo syndrome have only been reported in males.\nIt is likely that the genetic basis of Ohdo syndrome is related to mutations or variations in genes that are involved in the development and growth of the genitalia, kneecaps, and other body parts. However, the specific genetic causes of Ohdo syndrome have not been definitively identified and require further research to determine.\nIt is important to note that Ohdo syndrome is a rare condition, and there is limited information available about its genetic basis. Further research is needed to better understand the underlying genetic causes of this condition and to develop effective treatments and management strategies for individuals affected by Ohdo syndrome.",
    "llama-2-13b-chat-hf_fact_raw": "1. Ohdo syndrome is likely caused by a genetic mutation or variation in specific genes.\n2. The Say-Barber-Biesecker-Young-Simpson (SBBYS) variant of Ohdo syndrome is characterized by genital abnormalities in males, missing or underdeveloped kneecaps, intellectual disability, distinctive facial features, and other body abnormalities.\n3. The Maat-Kievit-Brunner type of Ohdo syndrome is characterized by intellectual disability and distinctive facial features.\n4. Both forms of Ohdo syndrome have only been reported in males.\n5. The specific genetic causes of Ohdo syndrome have not been definitively identified.",
    "llama-2-13b-chat-hf_fact": [
      "Ohdo syndrome is likely caused by a genetic mutation or variation in specific genes.",
      "The Say-Barber-Biesecker-Young-Simpson (SBBYS) variant of Ohdo syndrome is characterized by genital abnormalities in males, missing or underdeveloped kneecaps, intellectual disability, distinctive facial features, and other body abnormalities.",
      "The Maat-Kievit-Brunner type of Ohdo syndrome is characterized by intellectual disability and distinctive facial features.",
      "Both forms of Ohdo syndrome have only been reported in males.",
      "The specific genetic causes of Ohdo syndrome have not been definitively identified."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Both forms of Ohdo syndrome have been reported in both males and females.\n5. FALSE [correction]: The specific genetic causes of some forms of Ohdo syndrome have been identified, such as mutations in the KAT6B gene for the Say-Barber-Biesecker-Young-Simpson variant.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the R/Bioconductor package that has been developed for the analysis of psychiatric disease genes is Psygenet2r. According to the information provided in Document 0, Psygenet2r is especially suited for network medicine analysis of psychiatric disorders and is available under MIT license from Bioconductor. Therefore, I recommend using Psygenet2r for the analysis of psychiatric disease genes. Additionally, Document 1 provides information on GeneTonic, an R/Bioconductor package for streamlining the interpretation of RNA-seq data, which may also be relevant for the analysis of psychiatric disease genes.",
    "llama-2-13b-chat-hf_fact_raw": "1. The R/Bioconductor package developed for the analysis of psychiatric disease genes is called Psygenet2r.\n2. Psygenet2r is particularly designed for network medicine analysis of psychiatric disorders.\n3. Psygenet2r is available under the MIT license from Bioconductor.\n4. GeneTonic is an R/Bioconductor package that can be used for interpreting RNA-seq data.",
    "llama-2-13b-chat-hf_fact": [
      "The R/Bioconductor package developed for the analysis of psychiatric disease genes is called Psygenet2r.",
      "Psygenet2r is particularly designed for network medicine analysis of psychiatric disorders.",
      "Psygenet2r is available under the MIT license from Bioconductor.",
      "GeneTonic is an R/Bioconductor package that can be used for interpreting RNA-seq data."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Psygenet2r is available under the Artistic-2.0 license from Bioconductor.\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, the swirl sign in intracerebral hemorrhage (ICH) is a non-contrast CT appearance of acute extravasation of blood into a hematoma. It represents unclotted fresh blood, which has a lower attenuation than the clotted blood that surrounds it.\nThe swirl sign is characterized by areas of low attenuation, radiolucency, or irregular density within the hematoma. The sign is thought to be a useful indicator of the age of the hemorrhage, with the swirling pattern indicating more recent bleeding.\nStudies have shown that the swirl sign is present in a significant proportion of patients with ICH, with a reported prevalence ranging from 30% to 70%. However, the reliability of the subjective evaluation of the swirl sign on CT scans can be challenging, as the sign can be difficult to identify and may be present in different forms.\nDespite these limitations, the swirl sign has been found to have prognostic value in patients with ICH. Studies have shown that the presence of the swirl sign is associated with a higher risk of poor outcome, including death and severe disability.\nIn summary, the swirl sign in ICH is a non-contrast CT appearance of acute extravasation of blood into a hematoma, representing unclotted fresh blood with a lower attenuation than surrounding clotted blood. The sign is present in a significant proportion of patients with ICH, but its subjective evaluation can be challenging. However, the swirl sign has been found to have prognostic value in patients with ICH.",
    "llama-2-13b-chat-hf_fact_raw": "1. The swirl sign in intracerebral hemorrhage is a non-contrast CT appearance of acute extravasation of blood into a hematoma.\n2. The swirl sign represents unclotted fresh blood, which has a lower attenuation than the clotted blood that surrounds it.\n3. The swirl sign is an indicator of the age of the hemorrhage, with the swirling pattern indicating more recent bleeding.\n4. The reported prevalence of the swirl sign in patients with intracerebral hemorrhage ranges from 30% to 70%.\n5. The presence of the swirl sign is associated with a higher risk of poor outcome, including death and severe disability, in patients with intracerebral hemorrhage.",
    "llama-2-13b-chat-hf_fact": [
      "The swirl sign in intracerebral hemorrhage is a non-contrast CT appearance of acute extravasation of blood into a hematoma.",
      "The swirl sign represents unclotted fresh blood, which has a lower attenuation than the clotted blood that surrounds it.",
      "The swirl sign is an indicator of the age of the hemorrhage, with the swirling pattern indicating more recent bleeding.",
      "The reported prevalence of the swirl sign in patients with intracerebral hemorrhage ranges from 30% to 70%.",
      "The presence of the swirl sign is associated with a higher risk of poor outcome, including death and severe disability, in patients with intracerebral hemorrhage."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, it can be concluded that Arabidopsis ROF1 expression is induced by heat stress and developmentally regulated. Additionally, ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain and localizes in the cytoplasm under normal conditions.\nTherefore, the answer to the user's question \"What induces Arabidopsis ROF1 expression?\" is:\nHeat stress and developmental regulation.",
    "llama-2-13b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by heat stress.\n2. Arabidopsis ROF1 expression is developmentally regulated.\n3. ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.\n4. ROF1 localizes in the cytoplasm under normal conditions.",
    "llama-2-13b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by heat stress.",
      "Arabidopsis ROF1 expression is developmentally regulated.",
      "ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.",
      "ROF1 localizes in the cytoplasm under normal conditions."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nNote: The statements provided are consistent with the general knowledge about Arabidopsis ROF1 (AtFKBP62) and its role in heat stress response and interaction with heat shock proteins. However, without specific experimental data or a reference to a particular study, the responses are based on typical characteristics of the ROF1 protein in Arabidopsis thaliana.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the most common cause of hereditary renal amyloidosis is LECT2 amyloidosis.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, yes, the proteome of mice hippocampus has been analyzed. Document 0 states that the hippocampal proteome was analyzed at two ages (5 and 10 months) to study the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus. Additionally, Document 1 presents an in-depth characterization of the acute stress response in the mouse hippocampus, which also involves the analysis of the hippocampal proteome.",
    "llama-2-13b-chat-hf_fact_raw": "1. The proteome of mice hippocampus has been analyzed.\n2. The hippocampal proteome was analyzed at two different ages: 5 and 10 months.\n3. The analysis was conducted to study the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus.\n4. An in-depth characterization of the acute stress response in the mouse hippocampus was performed, involving the analysis of the hippocampal proteome.",
    "llama-2-13b-chat-hf_fact": [
      "The proteome of mice hippocampus has been analyzed.",
      "The hippocampal proteome was analyzed at two different ages: 5 and 10 months.",
      "The analysis was conducted to study the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus.",
      "An in-depth characterization of the acute stress response in the mouse hippocampus was performed, involving the analysis of the hippocampal proteome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nNote: While the statements seem plausible and consistent with the types of studies that might be conducted on the hippocampus, particularly in relation to neurodegenerative diseases like Alzheimer's (which is associated with amyloid plaque deposition), without specific reference to the actual study or publication, the responses are based on the assumption that the statements accurately reflect the content of the passage provided. If the passage contains these exact statements, then the responses are correct. If the passage differs, the responses may need to be adjusted accordingly.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the answer to the user's question is:\nYes, mouse chromosomes are acrocentric.\nAccording to Document 0, all chromosomes in mice are acrocentric, while other mammalian species have a mixture of acrocentric and metacentric chromosomes. Additionally, Document 1 states that all mouse chromosomes are acrocentric, further supporting the answer.",
    "llama-2-13b-chat-hf_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. Other mammalian species have a mixture of acrocentric and metacentric chromosomes.",
    "llama-2-13b-chat-hf_fact": [
      "Mouse chromosomes are acrocentric.",
      "Other mammalian species have a mixture of acrocentric and metacentric chromosomes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is no specific siRNA based drug that is in clinical trials for the treatment of pancreatic cancer. However, there are several siRNA-loaded nanotherapeutics that have shown partial response and tumor stabilization in clinical trials for various types of cancer, including pancreatic cancer. These include:\n1. ALN-VSP02: This is an siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.\n2. Au027: This is another siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.\n3. TKM-PLK1: This is a siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.\n4. siG12D LODER: This is a siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.\nIt is important to note that these are just a few examples of siRNA-loaded nanotherapeutics that have shown promise in clinical trials for the treatment of pancreatic cancer, and there may be other drugs in development that have not been mentioned here. Additionally, it is important to note that these drugs are still in the experimental stage and have not yet been approved by the FDA for the treatment of pancreatic cancer.",
    "llama-2-13b-chat-hf_fact_raw": "1. ALN-VSP02 is an siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.\n2. Au027 is an siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.\n3. TKM-PLK1 is an siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.\n4. siG12D LODER is an siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.\n5. The mentioned siRNA-loaded nanotherapeutics are still in the experimental stage and have not yet been approved by the FDA for the treatment of pancreatic cancer.",
    "llama-2-13b-chat-hf_fact": [
      "ALN-VSP02 is an siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.",
      "Au027 is an siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.",
      "TKM-PLK1 is an siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.",
      "siG12D LODER is an siRNA-loaded nanoparticle that has shown partial response and tumor stabilization in patients with advanced solid tumors, including pancreatic cancer.",
      "The mentioned siRNA-loaded nanotherapeutics are still in the experimental stage and have not yet been approved by the FDA for the treatment of pancreatic cancer."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nExplanation:\n1. ALN-VSP02 is indeed an siRNA-loaded nanoparticle that has been investigated for its potential to induce partial responses and stabilize tumors in patients with advanced solid tumors, including pancreatic cancer.\n2. Without specific information on Au027, it is not possible to confirm its effects or its existence as an siRNA-loaded nanoparticle for cancer treatment. Therefore, the statement is UNKNOWN.\n3. The statement about TKM-PLK1 is also UNKNOWN without additional context or data to support the claim.\n4. Similarly, the statement about siG12D LODER is UNKNOWN without further information to verify the claim.\n5. As of my knowledge cutoff date in 2023, many siRNA-loaded nanoparticles, including those mentioned, are typically still in the experimental or clinical trial stages and have not received FDA approval for the treatment of pancreatic cancer. This is a common status for many emerging cancer therapies, as they must undergo rigorous testing to ensure safety and efficacy before receiving approval.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the HPG Pore is a toolkit for exploring and analyzing nanopore sequencing data. It can run on both individual computers and in the Hadoop distributed computing framework, allowing for easy scaling to manage large amounts of data expected to result from the extensive use of nanopore technologies in the future.",
    "llama-2-13b-chat-hf_fact_raw": "1. The HPG Pore is a toolkit designed for exploring and analyzing nanopore sequencing data.\n2. The HPG Pore can be operated on individual computers.\n3. The HPG Pore is compatible with the Hadoop distributed computing framework.\n4. The HPG Pore is intended to scale for managing large amounts of data from nanopore technologies.",
    "llama-2-13b-chat-hf_fact": [
      "The HPG Pore is a toolkit designed for exploring and analyzing nanopore sequencing data.",
      "The HPG Pore can be operated on individual computers.",
      "The HPG Pore is compatible with the Hadoop distributed computing framework.",
      "The HPG Pore is intended to scale for managing large amounts of data from nanopore technologies."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe statements provided suggest that the HPG Pore is a toolkit for handling nanopore sequencing data, which is typically large in volume, thus the compatibility with distributed computing frameworks like Hadoop and the ability to scale for large data management is consistent with such a tool. It is also reasonable that it can be operated on individual computers for smaller scale analysis. Without contradictory information, these statements are assumed to be true.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the 959 Nematode Genomes initiative is a community-curated semantic wiki that aims to coordinate the sequencing efforts of individual labs to collectively sequence 959 genomes spanning the phylum Nematoda. The main goal of the initiative is to track sequencing projects that have been proposed, are in progress, or have been completed. This initiative is inspired by the success of the C. elegans genome sequencing project and aims to provide a comprehensive understanding of the biology of the phylum Nematoda.",
    "llama-2-13b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative is a community-curated semantic wiki.\n2. The initiative's aim is to coordinate the sequencing of 959 genomes across the phylum Nematoda.\n3. It tracks sequencing projects that are proposed, in progress, or completed.\n4. The initiative was inspired by the success of the C. elegans genome sequencing project.\n5. The goal of the initiative is to provide a comprehensive understanding of the biology of the phylum Nematoda.",
    "llama-2-13b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative is a community-curated semantic wiki.",
      "The initiative's aim is to coordinate the sequencing of 959 genomes across the phylum Nematoda.",
      "It tracks sequencing projects that are proposed, in progress, or completed.",
      "The initiative was inspired by the success of the C. elegans genome sequencing project.",
      "The goal of the initiative is to provide a comprehensive understanding of the biology of the phylum Nematoda."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The 959 Nematode Genomes initiative is not a community-curated semantic wiki; it is a scientific project aimed at sequencing the genomes of 959 nematode species.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the R package developed for analyzing Non-invasive prenatal testing (NIPT) data is \"NIPTeR\".",
    "llama-2-13b-chat-hf_fact_raw": "1. The R package \"NIPTeR\" has been developed for analyzing Non-invasive prenatal testing (NIPT) data.",
    "llama-2-13b-chat-hf_fact": [
      "The R package \"NIPTeR\" has been developed for analyzing Non-invasive prenatal testing (NIPT) data."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, Achenbach's syndrome is a condition characterized by recurring painful bruising of the fingers or palm, without any underlying serious conditions. It is more common in middle-aged females, with a median age of onset of 48-50 years. The condition is also known as paroxysmal finger hematoma. The symptoms include blue-purple discoloration of the volar aspect of one or more digits, accompanied by pain and paresthesia. It is an underdiagnosed condition, and patients may experience apprehension due to the alarming appearance of the bruising.",
    "llama-2-13b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by recurring painful bruising of the fingers or palm.\n2. Achenbach's syndrome is more common in middle-aged females.\n3. The median age of onset for Achenbach's syndrome is between 48-50 years.\n4. The condition is also known as paroxysmal finger hematoma.\n5. Symptoms of Achenbach's syndrome include blue-purple discoloration of the volar aspect of one or more digits, accompanied by pain and paresthesia.",
    "llama-2-13b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by recurring painful bruising of the fingers or palm.",
      "Achenbach's syndrome is more common in middle-aged females.",
      "The median age of onset for Achenbach's syndrome is between 48-50 years.",
      "The condition is also known as paroxysmal finger hematoma.",
      "Symptoms of Achenbach's syndrome include blue-purple discoloration of the volar aspect of one or more digits, accompanied by pain and paresthesia."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the algorithm used for detection of long repeat expansions is ExpansionHunter. This is mentioned in Document 1, where it is stated that ExpansionHunter can be used to accurately detect known pathogenic repeat expansions and provides researchers with a tool to identify new pathogenic repeat expansions.",
    "llama-2-13b-chat-hf_fact_raw": "1. ExpansionHunter is an algorithm used for the detection of long repeat expansions.\n2. ExpansionHunter can accurately detect known pathogenic repeat expansions.\n3. ExpansionHunter is also used by researchers to identify new pathogenic repeat expansions.",
    "llama-2-13b-chat-hf_fact": [
      "ExpansionHunter is an algorithm used for the detection of long repeat expansions.",
      "ExpansionHunter can accurately detect known pathogenic repeat expansions.",
      "ExpansionHunter is also used by researchers to identify new pathogenic repeat expansions."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, neuroligin-3 (NLGN3) promotes high-grade glioma (HGG) cell proliferation.",
    "llama-2-13b-chat-hf_fact_raw": "1. Neuroligin-3 promotes high-grade glioma cell proliferation.",
    "llama-2-13b-chat-hf_fact": [
      "Neuroligin-3 promotes high-grade glioma cell proliferation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0, the approximate size of gas vesicles is 0.045-0.2 μm wide and 0.1-2 μm long.",
    "llama-2-13b-chat-hf_fact_raw": "1. Gas vesicles are approximately 0.045-0.2 μm wide.\n2. Gas vesicles are approximately 0.1-2 μm long.",
    "llama-2-13b-chat-hf_fact": [
      "Gas vesicles are approximately 0.045-0.2 μm wide.",
      "Gas vesicles are approximately 0.1-2 μm long."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, here is a list of BET proteins:\n1. BRD2 (Bromodomain-Containing Protein 2)\n2. BRD3 (Bromodomain-Containing Protein 3)\n3. BRD4 (Bromodomain-Containing Protein 4)\n4. BRDT (Bromodomain and Extraterminal Domain-Containing Protein T)\nThese proteins are known as BET proteins and play a crucial role in regulating cellular processing, including cell cycle progression, neurogenesis, differentiation, and maturation of erythroids and spermatogenesis. Additionally, research has linked BET proteins to various pathological conditions, such as cancer, inflammation, infections, and renal disease.",
    "llama-2-13b-chat-hf_fact_raw": "1. BRD2 is known as Bromodomain-Containing Protein 2.\n2. BRD3 is known as Bromodomain-Containing Protein 3.\n3. BRD4 is known as Bromodomain-Containing Protein 4.\n4. BRDT is known as Bromodomain and Extraterminal Domain-Containing Protein T.\n5. BET proteins are linked to various pathological conditions, such as cancer, inflammation, infections, and renal disease.",
    "llama-2-13b-chat-hf_fact": [
      "BRD2 is known as Bromodomain-Containing Protein 2.",
      "BRD3 is known as Bromodomain-Containing Protein 3.",
      "BRD4 is known as Bromodomain-Containing Protein 4.",
      "BRDT is known as Bromodomain and Extraterminal Domain-Containing Protein T.",
      "BET proteins are linked to various pathological conditions, such as cancer, inflammation, infections, and renal disease."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: BRDT is known as Bromodomain Testis-Specific Protein.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the algorithm that has been developed for prediction of protein subcellular localization using deep learning is DeepPSL (Deep Learning for Protein Subcellular Localization) proposed in Document 1.",
    "llama-2-13b-chat-hf_fact_raw": "1. An algorithm called DeepPSL has been developed for prediction of protein subcellular localization using deep learning.\n2. DeepPSL is proposed in a document referred to as Document 1.",
    "llama-2-13b-chat-hf_fact": [
      "An algorithm called DeepPSL has been developed for prediction of protein subcellular localization using deep learning.",
      "DeepPSL is proposed in a document referred to as Document 1."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, MULTOVL is an application suite for detecting and statistically analyzing multiple overlaps of genomic regions. It is designed to be fast and efficient, and can identify intersections, unions, and solitary regions in genomic data. The significance of observed overlaps can also be determined using MULTOVL.",
    "llama-2-13b-chat-hf_fact_raw": "1. MULTOVL is an application suite used for detecting and statistically analyzing multiple overlaps of genomic regions.\n2. MULTOVL can identify intersections, unions, and solitary regions in genomic data.\n3. The application suite is designed to be fast and efficient.\n4. MULTOVL can determine the significance of observed overlaps.",
    "llama-2-13b-chat-hf_fact": [
      "MULTOVL is an application suite used for detecting and statistically analyzing multiple overlaps of genomic regions.",
      "MULTOVL can identify intersections, unions, and solitary regions in genomic data.",
      "The application suite is designed to be fast and efficient.",
      "MULTOVL can determine the significance of observed overlaps."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is evidence to suggest that GDF15 could be a biomarker for metformin treatment. Document 0 states that GDF15 is increased by cellular stressors, including metformin, and Document 1 suggests that the weight-lowering effects of metformin might involve GDF15. This suggests that GDF15 may be a useful biomarker for assessing the effectiveness of metformin treatment, or for monitoring the response to treatment. However, further research is needed to confirm this and to determine the specific role of GDF15 in metformin treatment.",
    "llama-2-13b-chat-hf_fact_raw": "1. GDF15 is increased by cellular stressors, including metformin.\n2. The weight-lowering effects of metformin might involve GDF15.\n3. GDF15 may be a useful biomarker for assessing the effectiveness of metformin treatment.\n4. GDF15 could be used for monitoring the response to metformin treatment.\n5. Further research is needed to confirm the role of GDF15 in metformin treatment.",
    "llama-2-13b-chat-hf_fact": [
      "GDF15 is increased by cellular stressors, including metformin.",
      "The weight-lowering effects of metformin might involve GDF15.",
      "GDF15 may be a useful biomarker for assessing the effectiveness of metformin treatment.",
      "GDF15 could be used for monitoring the response to metformin treatment.",
      "Further research is needed to confirm the role of GDF15 in metformin treatment."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, it appears that recursive splicing is more common in short introns.\nDocument 0 mentions that recursive splicing involves non-canonical splicing elements positioned deep within introns, and different mechanisms for its deployment have been proposed. This suggests that recursive splicing is a more complex process that occurs in introns of varying lengths.\nDocument 1 notes that eukaryotic genomes have evolved to host genes carrying multiple exons separated by increasingly larger intronic sequences, most of which are non-protein-coding. This suggests that introns have evolved to play a more significant role in the regulation of gene expression, and that recursive splicing may be a common mechanism for regulating gene expression in these introns.\nGiven that short introns are more common in eukaryotic genomes, it is likely that recursive splicing is more common in short introns as well. However, further research is needed to confirm this hypothesis.",
    "llama-2-13b-chat-hf_fact_raw": "1. Recursive splicing involves non-canonical splicing elements positioned deep within introns.\n2. Different mechanisms for the deployment of recursive splicing have been proposed.\n3. Eukaryotic genomes have evolved to host genes with multiple exons separated by increasingly larger intronic sequences.\n4. Most intronic sequences in eukaryotic genomes are non-protein-coding.\n5. Short introns are more common in eukaryotic genomes.",
    "llama-2-13b-chat-hf_fact": [
      "Recursive splicing involves non-canonical splicing elements positioned deep within introns.",
      "Different mechanisms for the deployment of recursive splicing have been proposed.",
      "Eukaryotic genomes have evolved to host genes with multiple exons separated by increasingly larger intronic sequences.",
      "Most intronic sequences in eukaryotic genomes are non-protein-coding.",
      "Short introns are more common in eukaryotic genomes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Long introns are more common in eukaryotic genomes, especially in more complex organisms. Short introns are less common in comparison.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the TALE-iD method is used for genome editing. Specifically, it is a technology that uses a type of protein called a zinc finger protein to target specific DNA sequences and make edits to the genome. The TALE-iD method is an evolution of the original TALEN technology, which was the first easy-to-use genome editing technology and sparked the genome editing revolution. The TALE-iD method is designed to be more specific and efficient than previous genome editing technologies, and it has a wide range of potential applications in both agriculture and medicine.",
    "llama-2-13b-chat-hf_fact_raw": "1. The TALE-iD method is used for genome editing.\n2. It uses a type of protein called a zinc finger protein to target specific DNA sequences.\n3. The TALE-iD method is an evolution of the original TALEN technology.\n4. The TALE-iD method aims to be more specific and efficient than previous genome editing technologies.\n5. The TALE-iD method has potential applications in agriculture and medicine.",
    "llama-2-13b-chat-hf_fact": [
      "The TALE-iD method is used for genome editing.",
      "It uses a type of protein called a zinc finger protein to target specific DNA sequences.",
      "The TALE-iD method is an evolution of the original TALEN technology.",
      "The TALE-iD method aims to be more specific and efficient than previous genome editing technologies.",
      "The TALE-iD method has potential applications in agriculture and medicine."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The TALE-iD method uses transcription activator-like effector (TALE) proteins to target specific DNA sequences, not zinc finger proteins.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the answer to the user's question is:\nFunImageJ is a Lisp framework for scientific image processing built upon the ImageJ software ecosystem.",
    "llama-2-13b-chat-hf_fact_raw": "1. FunImageJ is a Lisp framework for scientific image processing.\n2. FunImageJ is built upon the ImageJ software ecosystem.",
    "llama-2-13b-chat-hf_fact": [
      "FunImageJ is a Lisp framework for scientific image processing.",
      "FunImageJ is built upon the ImageJ software ecosystem."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, it is known that Saccharomyces cerevisiae has many duplicate genes that are phenotypically redundant. Document 1 provides information on the number of high-quality reference-based SNPs detected across 1,011 genomes, but it does not directly answer the question about ancient whole genome duplication.\nHowever, based on the information in Document 0, it is possible to infer that a significant number of genes in S. cerevisiae are the result of an ancient whole genome duplication. The document states that many duplicate genes have been found in S. cerevisiae, and these often seem to be phenotypically redundant. This suggests that these duplicate genes may have arisen as a result of an ancient whole genome duplication event, which is a common mechanism for genome expansion in eukaryotes.\nTherefore, based on the information provided, it is likely that a significant proportion of the genes in S. cerevisiae are the result of an ancient whole genome duplication. However, without more specific information on the timing and extent of this event, it is not possible to provide a more precise estimate of the number of genes involved.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the complex bound by estrogen-related receptor β (Esrrb) is the mesendoderm and extra-embryonic markers.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the role of ZCCHC17 is to negatively regulate rDNA transcription. It does this by interacting with the upstream binding factor (UBF) and reducing its binding to the rDNA promoter. Additionally, ZCCHC17 is involved in alternative splicing and trans-splicing, suggesting it may have a broader role in regulating gene expression.",
    "llama-2-13b-chat-hf_fact_raw": "1. ZCCHC17 negatively regulates rDNA transcription.\n2. ZCCHC17 interacts with the upstream binding factor (UBF).\n3. ZCCHC17 reduces the binding of UBF to the rDNA promoter.\n4. ZCCHC17 is involved in alternative splicing.\n5. ZCCHC17 is involved in trans-splicing.",
    "llama-2-13b-chat-hf_fact": [
      "ZCCHC17 negatively regulates rDNA transcription.",
      "ZCCHC17 interacts with the upstream binding factor (UBF).",
      "ZCCHC17 reduces the binding of UBF to the rDNA promoter.",
      "ZCCHC17 is involved in alternative splicing.",
      "ZCCHC17 is involved in trans-splicing."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific to the function of the protein ZCCHC17, and without the appropriate scientific context or research data, it is not possible to accurately determine the truthfulness of these statements. They would require specific knowledge or access to scientific studies that detail the function and interactions of ZCCHC17.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the proteins that form the nuclear pore basket in human cells are not well understood due to the complexity of the nuclear pore complex (NPC) and the lack of structural studies at the atomic level. However, proteome analysis has indicated that proteins related to nuclear division and tRNA ligases are preferentially cargoes of TNPO1, while proteins related to DNA repair and HMG proteins are also present in the nuclear pore basket. These proteins play important roles in regulating the transport of molecules through the NPC and maintaining the integrity of the nucleus.",
    "llama-2-13b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) is complex and not well understood at the atomic level.\n2. Proteome analysis has indicated that proteins related to nuclear division and tRNA ligases are cargoes of TNPO1.\n3. Proteins related to DNA repair and HMG proteins are present in the nuclear pore basket.\n4. These proteins regulate the transport of molecules through the NPC.\n5. These proteins help maintain the integrity of the nucleus.",
    "llama-2-13b-chat-hf_fact": [
      "The nuclear pore complex (NPC) is complex and not well understood at the atomic level.",
      "Proteome analysis has indicated that proteins related to nuclear division and tRNA ligases are cargoes of TNPO1.",
      "Proteins related to DNA repair and HMG proteins are present in the nuclear pore basket.",
      "These proteins regulate the transport of molecules through the NPC.",
      "These proteins help maintain the integrity of the nucleus."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with current scientific understanding, although the level of detail and specificity in the statements is limited. The nuclear pore complex (NPC) is indeed complex and not fully understood at the atomic level. Proteome analysis has identified various proteins, including those related to nuclear division and tRNA ligases, as cargoes for transport proteins like TNPO1. Proteins related to DNA repair and high mobility group (HMG) proteins are known to be associated with the nuclear pore complex, particularly in the nuclear basket. These proteins are involved in regulating the transport of molecules through the NPC and also play a role in maintaining the structural integrity of the nucleus. However, without specific references to the source material, it is difficult to provide a more detailed assessment of the accuracy of these statements.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, gepotidacin is a type of topoisomerase inhibitor that belongs to the class of Novel Bacterial Topoisomerase Inhibitors (NBTIs).",
    "llama-2-13b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase inhibitor.\n2. Gepotidacin belongs to the class of Novel Bacterial Topoisomerase Inhibitors (NBTIs).",
    "llama-2-13b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase inhibitor.",
      "Gepotidacin belongs to the class of Novel Bacterial Topoisomerase Inhibitors (NBTIs)."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-13b-chat-hf_response": "Based on the information provided, Canvas SPW is a tool for identifying de novo variants in genomic sequencing data. It supports a variety of family structures and offers a range of scoring and filtering options to automate and streamline the identification process. Canvas SPW is available for download from the GitHub repository of Illumina, and users can contact sivakhno@illumina.com for more information. Additionally, Canvas is a tool for identifying copy number changes in diverse sequencing experiments, including whole-genome matched tumor-normal, small pedigree, and single-sample normal resequencing, as well as whole-exome matched and unmatched tumor-normal studies.",
    "llama-2-13b-chat-hf_fact_raw": "1. Canvas SPW is a tool for identifying de novo variants in genomic sequencing data.\n2. Canvas SPW supports a variety of family structures.\n3. Canvas SPW offers scoring and filtering options to automate the identification process.\n4. Canvas SPW can be downloaded from the GitHub repository of Illumina.\n5. Canvas is also used for identifying copy number changes in various sequencing experiments.",
    "llama-2-13b-chat-hf_fact": [
      "Canvas SPW is a tool for identifying de novo variants in genomic sequencing data.",
      "Canvas SPW supports a variety of family structures.",
      "Canvas SPW offers scoring and filtering options to automate the identification process.",
      "Canvas SPW can be downloaded from the GitHub repository of Illumina.",
      "Canvas is also used for identifying copy number changes in various sequencing experiments."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE: Canvas, including its various workflows such as Canvas SPW (Small Pedigree Workflow), is an open-source software tool developed by Illumina, and it can be downloaded from the GitHub repository of Illumina.\n5. TRUE: Canvas is indeed used for identifying copy number variations (CNVs) in genomic sequencing data, which includes various sequencing experiments.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-13b-chat-hf_response": "Based on the information provided, here are some STING agonists that have been identified in the literature:\n1. SHR1032: This is a novel STING agonist that has been shown to stimulate anti-tumor immunity and directly induce apoptosis in acute myeloid leukemia (AML) cells (Source: Document 1).\n2. Resiquimod (R848): This is an imidazoquinoline compound that has been shown to activate STING and induce the production of type I interferons, leading to the activation of antiviral and immune-stimulatory pathways (Source: Document 2).\n3. Cyclo(adenosine-3',5'-monophosphate) (cAMP): This is a second messenger molecule that has been shown to activate STING and induce the production of type I interferons (Source: Document 3).\n4. 2',3'-cGAMP: This is a synthetic nucleic acid that has been shown to activate STING and induce the production of type I interferons (Source: Document 4).\n5. STING-activating peptides: These are short peptides that have been engineered to bind to STING and activate its signaling pathways, leading to the production of type I interferons and the activation of immune cells (Source: Document 5).\nIt is important to note that the list of STING agonists is not exhaustive and there may be other compounds that have not been identified or characterized yet. Additionally, the specific activity of each STING agonist may vary depending on the cellular context and the specific disease being targeted.",
    "llama-2-13b-chat-hf_fact_raw": "1. SHR1032 is a STING agonist that stimulates anti-tumor immunity and induces apoptosis in acute myeloid leukemia cells.\n2. Resiquimod (R848) is an imidazoquinoline compound that activates STING and induces the production of type I interferons.\n3. Cyclo(adenosine-3',5'-monophosphate) (cAMP) activates STING and induces the production of type I interferons.\n4. 2',3'-cGAMP is a synthetic nucleic acid that activates STING and induces the production of type I interferons.\n5. STING-activating peptides are engineered to bind to STING and activate its signaling pathways, leading to the production of type I interferons and the activation of immune cells.",
    "llama-2-13b-chat-hf_fact": [
      "SHR1032 is a STING agonist that stimulates anti-tumor immunity and induces apoptosis in acute myeloid leukemia cells.",
      "Resiquimod (R848) is an imidazoquinoline compound that activates STING and induces the production of type I interferons.",
      "Cyclo(adenosine-3',5'-monophosphate) (cAMP) activates STING and induces the production of type I interferons.",
      "2',3'-cGAMP is a synthetic nucleic acid that activates STING and induces the production of type I interferons.",
      "STING-activating peptides are engineered to bind to STING and activate its signaling pathways, leading to the production of type I interferons and the activation of immune cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Resiquimod (R848) is an imidazoquinoline compound that activates Toll-like receptors (TLRs), not STING, and induces the production of type I interferons.\n3. FALSE [correction]: Cyclo(adenosine-3',5'-monophosphate) (cAMP) is a second messenger important in many biological processes, but it does not activate STING. STING is activated by cyclic dinucleotides like cGAMP, not cAMP.\n4. TRUE\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, SLIC-CAGE is a method for generating a complex, high-quality library from mouse embryonic day 11.5 primordial germ cells with 1000-fold less material than required by existing CAGE methods. This is according to Document 0, which was published in 2018 by Cvetesic et al. and is available from Cold Spring Harbor Laboratory Press.\nThe document describes the ability of SLIC-CAGE to generate data for genome-wide promoterome analysis with less material, which is a significant advantage over existing CAGE methods. Additionally, the document mentions that a wide array of RNA-seq protocols have been developed to profile different aspects of the transcriptome, including strand-specific coverage of gene bodies and selective amplification of RNA 5′ ends.\nOverall, SLIC-CAGE is a powerful tool for transcriptome analysis that offers several advantages over existing methods, including the ability to generate high-quality data with less material.",
    "llama-2-13b-chat-hf_fact_raw": "1. SLIC-CAGE is a method for generating a library from mouse embryonic day 11.5 primordial germ cells.\n2. SLIC-CAGE requires 1000-fold less material than existing CAGE methods.\n3. The information about SLIC-CAGE was published in 2018 by Cvetesic et al.\n4. The publication is available from Cold Spring Harbor Laboratory Press.\n5. SLIC-CAGE allows for genome-wide promoterome analysis with less material than previous methods.",
    "llama-2-13b-chat-hf_fact": [
      "SLIC-CAGE is a method for generating a library from mouse embryonic day 11.5 primordial germ cells.",
      "SLIC-CAGE requires 1000-fold less material than existing CAGE methods.",
      "The information about SLIC-CAGE was published in 2018 by Cvetesic et al.",
      "The publication is available from Cold Spring Harbor Laboratory Press.",
      "SLIC-CAGE allows for genome-wide promoterome analysis with less material than previous methods."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nWithout specific information on SLIC-CAGE, the publication by Cvetesic et al., or the details of the publication's availability from Cold Spring Harbor Laboratory Press, I cannot verify the accuracy of statements 1, 2, 3, and 4. However, statement 5 is generally consistent with the purpose of CAGE (Cap Analysis Gene Expression) methods, which are designed to enable genome-wide promoterome analysis, and it is reasonable to assume that a new method like SLIC-CAGE would aim to improve upon previous methods by requiring less material.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, the roles of LEM-3 are:\n1. Processing of chromatin bridges: LEM-3 locally processes chromatin bridges that arise from incomplete DNA replication, unresolved recombination intermediates, or the perturbance of chromosome structure.\n2. Regulation of meiotic recombination repair: The conserved LEM-3/Ankle1 nuclease is involved in the combinatorial regulation of meiotic recombination repair and chromosome segregation in Caenorhabditis elegans.\nIn summary, LEM-3 plays a role in the processing of chromatin bridges and the regulation of meiotic recombination repair in Caenorhabditis elegans.",
    "llama-2-13b-chat-hf_fact_raw": "1. LEM-3 is involved in processing chromatin bridges that can result from incomplete DNA replication or unresolved recombination intermediates.\n2. LEM-3 plays a role in the regulation of meiotic recombination repair in Caenorhabditis elegans.\n3. LEM-3 is associated with the perturbance of chromosome structure.\n4. The LEM-3/Ankle1 nuclease is conserved and involved in chromosome segregation in Caenorhabditis elegans.",
    "llama-2-13b-chat-hf_fact": [
      "LEM-3 is involved in processing chromatin bridges that can result from incomplete DNA replication or unresolved recombination intermediates.",
      "LEM-3 plays a role in the regulation of meiotic recombination repair in Caenorhabditis elegans.",
      "LEM-3 is associated with the perturbance of chromosome structure.",
      "The LEM-3/Ankle1 nuclease is conserved and involved in chromosome segregation in Caenorhabditis elegans."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nLEM-3 is indeed involved in processing chromatin bridges, which can be a result of issues such as incomplete DNA replication or unresolved recombination intermediates. It plays a role in the regulation of meiotic recombination repair in the organism Caenorhabditis elegans. LEM-3 is associated with the maintenance of chromosome structure, and disturbances in its function can lead to perturbances in chromosome structure. The LEM-3/Ankle1 nuclease is a conserved enzyme that is involved in chromosome segregation in Caenorhabditis elegans.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, here are the releases of tmVar:\n1. tmVar 2.0\n2. tmVar 3.0\nThe Java code for tmVar 2.0 is publicly available, and it is also a part of PubTator Central, a web-based system that provides automatic annotation of biomedical concepts in PubMed and PMC articles. The results for these articles are available at the tool's website or through its RESTful API.\nAdditionally, tmVar 3.0 provides advanced variant normalization options, such as allele-specific identifiers from the ClinGen Allele Registry, and it exhibits state-of-the-art performance with over 90% in F-measure for variant recognition and normalization, when evaluated on three independent benchmarking datasets.",
    "llama-2-13b-chat-hf_fact_raw": "1. tmVar 2.0 is a release of tmVar.\n2. tmVar 3.0 is a release of tmVar.\n3. The Java code for tmVar 2.0 is publicly available.\n4. tmVar 2.0 is part of PubTator Central.\n5. tmVar 3.0 includes advanced variant normalization options like allele-specific identifiers from the ClinGen Allele Registry.",
    "llama-2-13b-chat-hf_fact": [
      "tmVar 2.0 is a release of tmVar.",
      "tmVar 3.0 is a release of tmVar.",
      "The Java code for tmVar 2.0 is publicly available.",
      "tmVar 2.0 is part of PubTator Central.",
      "tmVar 3.0 includes advanced variant normalization options like allele-specific identifiers from the ClinGen Allele Registry."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWithout specific information about the features of tmVar 3.0, it is not possible to confirm the details about advanced variant normalization options like allele-specific identifiers from the ClinGen Allele Registry.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the database of somatic mutations in normal cells is the \"Database of Somatic Mutations in Normal Cells\" (DSMNC).",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-13b-chat-hf_response": "Yes, there are several graph kernel libraries available implemented in Java. Here are a few options:\n1. GraphKernels: This is a Java library for graph kernel methods, which provides a set of kernel functions for various graph types, including dense, sparse, and weighted graphs. The library includes a range of algorithms for computing graph kernels, including the popular Laplacian and degree kernels. The library also provides a simple API for computing kernel matrices and performing kernel-based machine learning tasks. You can find more information and download the library here: <https://github.com/graphkernels/graphkernels>.\n2. JGraphKernels: This is another Java library for graph kernel methods, which provides a range of kernel functions and algorithms for computing graph kernels. The library includes a simple API for computing kernel matrices and performing kernel-based machine learning tasks, and it also provides a number of pre-defined kernel functions for common graph types. You can find more information and download the library here: <https://github.com/jgraphkernels/jgraphkernels>.\n3. Weka Graph Kernels: This is a Java implementation of graph kernels for the Weka machine learning software. The library provides a range of kernel functions for various graph types, including dense, sparse, and weighted graphs, and it also includes a number of pre-defined kernel functions for common graph types. You can find more information and download the library here: <https://www.cs.waikato.ac.nz/software/weka/graph-kernels/>.\nAll of these libraries provide a way to include the header file \"graphKernels.h\" in your program, and they also require the Eigen and igraph libraries to be installed. Additionally, the GraphKernels and JGraphKernels libraries provide a short tutorial for the basic usage of their package, and they also provide an example script for computing graph kernels on a benchmark dataset.\nPlease note that the citation for the graphkernels package is:\n@inproceedings{grover2016graphkernels,\ntitle={GraphKernels: A Library for Graph Kernel Methods},\nauthor={Grover, R and Leskovec, J and Rajaraman, A and Ustun, E and Vishnoi, S},\nbooktitle",
    "llama-2-13b-chat-hf_fact_raw": "1. GraphKernels is a Java library for graph kernel methods that includes kernel functions for various graph types.\n2. JGraphKernels is a Java library that provides a range of kernel functions and algorithms for computing graph kernels.\n3. Weka Graph Kernels is a Java implementation of graph kernels for the Weka machine learning software.\n4. The GraphKernels and JGraphKernels libraries require the Eigen and igraph libraries to be installed.\n5. The GraphKernels library was cited in a publication with the title \"GraphKernels: A Library for Graph Kernel Methods\".",
    "llama-2-13b-chat-hf_fact": [
      "GraphKernels is a Java library for graph kernel methods that includes kernel functions for various graph types.",
      "JGraphKernels is a Java library that provides a range of kernel functions and algorithms for computing graph kernels.",
      "Weka Graph Kernels is a Java implementation of graph kernels for the Weka machine learning software.",
      "The GraphKernels and JGraphKernels libraries require the Eigen and igraph libraries to be installed.",
      "The GraphKernels library was cited in a publication with the title \"GraphKernels: A Library for Graph Kernel Methods\"."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: GraphKernels is not a Java library; it is a Python library for graph kernel methods that includes kernel functions for various graph types.\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The GraphKernels library is a Python library and does not require the Eigen and igraph libraries to be installed. These libraries are associated with C++ and C, respectively, not Python.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided in Document 1, the four advances integrated into the SHERLOCKv2 platform are:\n1. 4-channel single reaction multiplexing using orthogonal CRISPR enzymes\n2. Quantitative measurement of input down to 2 aM (nanomolar)\n3. 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR enzyme\n4. Integration of the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection.",
    "llama-2-13b-chat-hf_fact_raw": "1. The SHERLOCKv2 platform integrates 4-channel single reaction multiplexing using orthogonal CRISPR enzymes.\n2. The SHERLOCKv2 platform is capable of quantitative measurement of input down to 2 aM (attomolar).\n3. The SHERLOCKv2 platform achieves a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6.\n4. The SHERLOCKv2 platform includes the integration of the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection.",
    "llama-2-13b-chat-hf_fact": [
      "The SHERLOCKv2 platform integrates 4-channel single reaction multiplexing using orthogonal CRISPR enzymes.",
      "The SHERLOCKv2 platform is capable of quantitative measurement of input down to 2 aM (attomolar).",
      "The SHERLOCKv2 platform achieves a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6.",
      "The SHERLOCKv2 platform includes the integration of the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe statements provided are consistent with the capabilities and features of the SHERLOCKv2 platform, which is an advanced version of the SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) technology. It integrates CRISPR enzymes for nucleic acid detection and has been reported to have improved sensitivity and multiplexing capabilities.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided in Documents 0 and 1, here is a description of the Bartender algorithm:\nBartender is a clustering algorithm specifically designed for counting high-complexity deeply sequenced barcode reads. It is considered the most accurate algorithm for this task, with a comparable speed to other existing algorithms. The accuracy of Bartender stems from a new statistical test schema that utilizes both nucleotide sequence and cluster size information to prevent over-clustering and ensure accurate counting.\nThe algorithm works by first aligning the barcode reads to a reference sequence, and then grouping the reads into clusters based on their similarity. The key innovation of Bartender is the use of a new statistical test to determine the optimal cluster size, which takes into account both the nucleotide sequence and the size of the clusters. This test is designed to prevent over-clustering, which can lead to inaccurate counting of the barcode reads.\nBartender has been shown to be highly accurate and efficient in counting barcode reads, with a comparable speed to other existing algorithms. It has a wide range of applications in fields such as biology, medicine, and environmental science, where the accurate counting of barcode reads is critical for downstream analyses.\nOverall, Bartender is a powerful and accurate clustering algorithm that is specifically designed for counting high-complexity deeply sequenced barcode reads. Its unique statistical test schema ensures accurate counting while preventing over-clustering, making it a valuable tool for researchers in a variety of fields.",
    "llama-2-13b-chat-hf_fact_raw": "1. Bartender is a clustering algorithm used for counting high-complexity deeply sequenced barcode reads.\n2. The Bartender algorithm is considered the most accurate algorithm for counting barcode reads, with a speed comparable to other existing algorithms.\n3. Bartender uses a new statistical test schema that incorporates nucleotide sequence and cluster size information to prevent over-clustering.\n4. The algorithm aligns barcode reads to a reference sequence and groups them into clusters based on similarity.\n5. Bartender has applications in biology, medicine, and environmental science for accurate counting of barcode reads.",
    "llama-2-13b-chat-hf_fact": [
      "Bartender is a clustering algorithm used for counting high-complexity deeply sequenced barcode reads.",
      "The Bartender algorithm is considered the most accurate algorithm for counting barcode reads, with a speed comparable to other existing algorithms.",
      "Bartender uses a new statistical test schema that incorporates nucleotide sequence and cluster size information to prevent over-clustering.",
      "The algorithm aligns barcode reads to a reference sequence and groups them into clusters based on similarity.",
      "Bartender has applications in biology, medicine, and environmental science for accurate counting of barcode reads."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While Bartender is known for its accuracy, it is not necessarily considered the most accurate algorithm for counting barcode reads in all cases, as this can depend on the specific dataset and conditions. Additionally, its speed compared to other algorithms can vary based on the implementation and the complexity of the data.\n3. TRUE\n4. FALSE [correction]: Bartender does not align barcode reads to a reference sequence; instead, it groups them into clusters based on the similarity of the sequences themselves without the need for a reference.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, one web-based pedigree editor that is available and can be easily configured and incorporated into web applications is Pedigreejs. It is an open-source Javascript library that provides a hierarchical layout and produces images in scalable vector graphics (SVG) format, which can be viewed and edited in web browsers.",
    "llama-2-13b-chat-hf_fact_raw": "1. Pedigreejs is a web-based pedigree editor.\n2. Pedigreejs can be configured and incorporated into web applications.\n3. Pedigreejs is an open-source Javascript library.\n4. Pedigreejs provides a hierarchical layout.\n5. Pedigreejs produces images in scalable vector graphics (SVG) format.",
    "llama-2-13b-chat-hf_fact": [
      "Pedigreejs is a web-based pedigree editor.",
      "Pedigreejs can be configured and incorporated into web applications.",
      "Pedigreejs is an open-source Javascript library.",
      "Pedigreejs provides a hierarchical layout.",
      "Pedigreejs produces images in scalable vector graphics (SVG) format."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is one curated database that exists for spider-venom toxins, and that is ArachnoServer (www.arachnoserver.org). ArachnoServer is a manually curated database that provides information on the sequence, structure, and biological activity of protein toxins from spider venoms. It is a valuable resource for researchers interested in the diverse applications of spider venom toxins in medicine, neuroscience, pharmacology, drug discovery, and agriculture.",
    "llama-2-13b-chat-hf_fact_raw": "1. ArachnoServer is a curated database for spider-venom toxins.\n2. ArachnoServer provides information on the sequence, structure, and biological activity of protein toxins from spider venoms.\n3. ArachnoServer is a resource used in medicine, neuroscience, pharmacology, drug discovery, and agriculture.",
    "llama-2-13b-chat-hf_fact": [
      "ArachnoServer is a curated database for spider-venom toxins.",
      "ArachnoServer provides information on the sequence, structure, and biological activity of protein toxins from spider venoms.",
      "ArachnoServer is a resource used in medicine, neuroscience, pharmacology, drug discovery, and agriculture."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is no direct answer to whether Axitinib prolongs survival for pancreatic cancer patients. However, I can provide some context and insights based on the given information.\nFirstly, it is noted that surgical resection of the primary tumor and systemic chemotherapy are the best treatments for patients with localized pancreatic ductal adenocarcinoma (PDAC). However, most patients eventually relapse, and the 5-year survival rate is only 2%-9%.\nSecondly, Axitinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGF) and is used to treat renal cell carcinoma and non-small cell lung cancer. There is limited information available on the use of Axitinib for pancreatic cancer.\nLastly, the risk factors for pancreatic cancer include family history, pancreatitis, and diabetes.\nIn conclusion, while there is no direct answer to the question, it is clear that pancreatic cancer is a complex and aggressive disease with limited treatment options and poor survival rates. Further research and clinical trials are needed to determine the efficacy of Axitinib or other potential treatments for pancreatic cancer.",
    "llama-2-13b-chat-hf_fact_raw": "1. Surgical resection of the primary tumor and systemic chemotherapy are considered the best treatments for patients with localized pancreatic ductal adenocarcinoma (PDAC).\n2. The 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) is only 2%-9%.\n3. Axitinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGF).\n4. Axitinib is used to treat renal cell carcinoma and non-small cell lung cancer.\n5. Risk factors for pancreatic cancer include family history, pancreatitis, and diabetes.",
    "llama-2-13b-chat-hf_fact": [
      "Surgical resection of the primary tumor and systemic chemotherapy are considered the best treatments for patients with localized pancreatic ductal adenocarcinoma (PDAC).",
      "The 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) is only 2%-9%.",
      "Axitinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGF).",
      "Axitinib is used to treat renal cell carcinoma and non-small cell lung cancer.",
      "Risk factors for pancreatic cancer include family history, pancreatitis, and diabetes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: Surgical resection of the primary tumor and systemic chemotherapy are indeed considered the standard treatments for patients with localized pancreatic ductal adenocarcinoma (PDAC), aiming to remove the tumor and address any potential spread of the disease.\n\n2. TRUE: The 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) is indeed very low, with most sources citing a range between 2% and 9%, reflecting the aggressive nature of this type of cancer.\n\n3. TRUE: Axitinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR), which are involved in the pathway for angiogenesis, the formation of new blood vessels that can feed tumors.\n\n4. FALSE [correction]: Axitinib is approved for the treatment of advanced renal cell carcinoma (RCC). It is not typically used to treat non-small cell lung cancer (NSCLC); treatments for NSCLC often include other tyrosine kinase inhibitors that target different molecular pathways.\n\n5. TRUE: Risk factors for pancreatic cancer do include a family history of the disease, chronic pancreatitis, and long-standing diabetes, among others such as smoking and obesity.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, MLP (mRNA-like protein) regulates F-actin dynamics through its interaction with the actin-regulatory machinery. This interaction is mediated by the binding of MLP to the actin-binding protein, cofilin. Cofilin is a key regulator of F-actin dynamics and is involved in the disassembly of F-actin filaments. By binding to cofilin, MLP can modulate the activity of cofilin and influence the dynamics of F-actin filaments. This regulation of F-actin dynamics by MLP is important for maintaining proper cellular functions, such as cell migration and adhesion.",
    "llama-2-13b-chat-hf_fact_raw": "1. MLP (mRNA-like protein) regulates F-actin dynamics.\n2. MLP interacts with the actin-regulatory machinery.\n3. MLP binds to the actin-binding protein, cofilin.\n4. Cofilin is involved in the disassembly of F-actin filaments.\n5. The regulation of F-actin dynamics by MLP is important for cellular functions like cell migration and adhesion.",
    "llama-2-13b-chat-hf_fact": [
      "MLP (mRNA-like protein) regulates F-actin dynamics.",
      "MLP interacts with the actin-regulatory machinery.",
      "MLP binds to the actin-binding protein, cofilin.",
      "Cofilin is involved in the disassembly of F-actin filaments.",
      "The regulation of F-actin dynamics by MLP is important for cellular functions like cell migration and adhesion."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: MLP stands for Muscle LIM Protein, not mRNA-like protein, and it is involved in the cytoarchitecture of the muscle cells.\n2. TRUE: MLP has been shown to interact with the actin-regulatory machinery.\n3. UNKNOWN: Without specific context or reference, it is unclear whether MLP directly binds to cofilin. MLP is known to interact with various proteins in the regulation of actin dynamics, but a direct interaction with cofilin would need to be confirmed by a specific study or source.\n4. TRUE: Cofilin is indeed involved in the disassembly and severing of F-actin filaments, which is a critical process in actin dynamics.\n5. TRUE: The regulation of F-actin dynamics is important for cellular functions such as cell migration and adhesion, and proteins like MLP are known to play a role in these processes.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there are approximately 518 protein kinases in the human kinome, according to Document 0. Of these, 478 contain a eukaryotic protein kinase (ePK) domain, while 40 lack sequence similarity to the ePK domain. Therefore, there are approximately 40 pseudokinases in the human kinome.",
    "llama-2-13b-chat-hf_fact_raw": "1. There are approximately 518 protein kinases in the human kinome.\n2. Of the protein kinases in the human kinome, 478 contain a eukaryotic protein kinase (ePK) domain.\n3. There are approximately 40 pseudokinases in the human kinome.\n4. The 40 pseudokinases lack sequence similarity to the ePK domain.",
    "llama-2-13b-chat-hf_fact": [
      "There are approximately 518 protein kinases in the human kinome.",
      "Of the protein kinases in the human kinome, 478 contain a eukaryotic protein kinase (ePK) domain.",
      "There are approximately 40 pseudokinases in the human kinome.",
      "The 40 pseudokinases lack sequence similarity to the ePK domain."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The 40 pseudokinases do not possess catalytic activity but still retain sequence similarity to the ePK domain.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, here are three apoE mimetics:\n1. ApoA-I mimetics: ApoA-I is a major protein component of high-density lipoproteins (HDL) and plays a crucial role in cholesterol transport and reverse cholesterol transport. ApoA-I mimetics have been developed to mimic the structure and function of HDL and have been shown to improve lipid profiles and reduce cardiovascular risk.\n2. ApoE mimetics: ApoE is a key player in lipid metabolism and is involved in the transport of lipids and cholesterol in the bloodstream. ApoE mimetics have been developed to mimic the structure and function of ApoE and have been shown to improve lipid profiles and reduce cardiovascular risk.\n3. ApoC-II mimetics: ApoC-II is a protein component of very-low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL) and plays a role in lipid metabolism. ApoC-II mimetics have been developed to mimic the structure and function of ApoC-II and have been shown to improve lipid profiles and reduce cardiovascular risk.\nI hope this information is helpful! Let me know if you have any further questions.",
    "llama-2-13b-chat-hf_fact_raw": "1. ApoA-I mimetics are designed to mimic the structure and function of the protein component of high-density lipoproteins (HDL).\n2. ApoE mimetics are developed to mimic the structure and function of ApoE, which is involved in lipid and cholesterol transport.\n3. ApoC-II mimetics are created to mimic the structure and function of ApoC-II, a protein component of very-low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL).\n4. ApoA-I mimetics have been shown to improve lipid profiles and reduce cardiovascular risk.\n5. ApoC-II mimetics have been shown to improve lipid profiles and reduce cardiovascular risk.",
    "llama-2-13b-chat-hf_fact": [
      "ApoA-I mimetics are designed to mimic the structure and function of the protein component of high-density lipoproteins (HDL).",
      "ApoE mimetics are developed to mimic the structure and function of ApoE, which is involved in lipid and cholesterol transport.",
      "ApoC-II mimetics are created to mimic the structure and function of ApoC-II, a protein component of very-low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL).",
      "ApoA-I mimetics have been shown to improve lipid profiles and reduce cardiovascular risk.",
      "ApoC-II mimetics have been shown to improve lipid profiles and reduce cardiovascular risk."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements are accurate based on the known functions of the apolipoprotein mimetics mentioned. ApoA-I mimetics are indeed designed to mimic the structure and function of the protein component of HDL, which is involved in reverse cholesterol transport. ApoE mimetics are developed to mimic ApoE, which plays a crucial role in lipid and cholesterol transport. ApoC-II mimetics are created to mimic ApoC-II, which is a component of VLDL and IDL and is important for the activation of lipoprotein lipase, an enzyme necessary for the hydrolysis of triglycerides.\n\nThe fifth statement is more complex. While it is true that ApoC-II mimetics are designed to mimic the structure and function of ApoC-II, the specific effects on lipid profiles and cardiovascular risk reduction would depend on the outcomes of clinical trials and research studies. Without specific data or references to such studies, it is not possible to confirm the statement's accuracy, hence the response \"UNKNOWN\".",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there are sex differences in SAMHD1 activity. Specifically, SAMHD1 activity is higher in macrophages from female donors than in macrophages from male donors, which correlates with the lower infectivity of HIV-1 in female-derived macrophages. These findings suggest that SAMHD1 plays a critical role in regulating the infectivity of HIV-1 in a sex-dependent manner in macrophages, and that it may be a novel component of sex differences in innate immune control of HIV-1.",
    "llama-2-13b-chat-hf_fact_raw": "1. SAMHD1 activity is higher in macrophages from female donors compared to those from male donors.\n2. There is a correlation between higher SAMHD1 activity in female-derived macrophages and lower infectivity of HIV-1.\n3. SAMHD1 is implicated in regulating the infectivity of HIV-1 in a sex-dependent manner in macrophages.\n4. SAMHD1 may be a component of sex differences in innate immune control of HIV-1.",
    "llama-2-13b-chat-hf_fact": [
      "SAMHD1 activity is higher in macrophages from female donors compared to those from male donors.",
      "There is a correlation between higher SAMHD1 activity in female-derived macrophages and lower infectivity of HIV-1.",
      "SAMHD1 is implicated in regulating the infectivity of HIV-1 in a sex-dependent manner in macrophages.",
      "SAMHD1 may be a component of sex differences in innate immune control of HIV-1."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe statements provided are specific scientific claims that require access to the relevant research data or literature for verification. Without the specific context or references to the studies that have investigated the role of SAMHD1 in macrophages and its relationship to HIV-1 infectivity, it is not possible to determine the truthfulness of these statements.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, it appears that RUNX2 does not inhibit astrocyte differentiation, but rather promotes astrocyte maturation. This is indicated in Document 0, which states that NFIA and ATF3 are drivers of astrocyte differentiation from neural precursor cells, while RUNX2 promotes astrocyte maturation. This suggests that RUNX2 plays a role in the maturation of astrocytes, but does not inhibit their differentiation.",
    "llama-2-13b-chat-hf_fact_raw": "1. RUNX2 promotes astrocyte maturation.\n2. NFIA and ATF3 are drivers of astrocyte differentiation from neural precursor cells.",
    "llama-2-13b-chat-hf_fact": [
      "RUNX2 promotes astrocyte maturation.",
      "NFIA and ATF3 are drivers of astrocyte differentiation from neural precursor cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: RUNX2 is not typically associated with astrocyte maturation. It is more commonly known for its role in bone development and osteoblast differentiation.\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the Cobb-Stainsby excision arthroplasty would be performed on the metatarsophalangeal joint.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is performed on the metatarsophalangeal joint.",
    "llama-2-13b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is performed on the metatarsophalangeal joint."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, it appears that GRHL2 over-expression does not directly lead to EMT (epithelial-to-mesenchymal transition). Instead, the information suggests that GRHL2 suppresses EMT, which is a process that is required for the migration and invasion of carcinoma cells. This implies that over-expression of GRHL2 may actually inhibit or prevent EMT from occurring.",
    "llama-2-13b-chat-hf_fact_raw": "1. GRHL2 over-expression does not directly lead to EMT (epithelial-to-mesenchymal transition).\n2. GRHL2 is suggested to suppress EMT.\n3. EMT is required for the migration and invasion of carcinoma cells.\n4. Over-expression of GRHL2 may inhibit or prevent EMT from occurring.",
    "llama-2-13b-chat-hf_fact": [
      "GRHL2 over-expression does not directly lead to EMT (epithelial-to-mesenchymal transition).",
      "GRHL2 is suggested to suppress EMT.",
      "EMT is required for the migration and invasion of carcinoma cells.",
      "Over-expression of GRHL2 may inhibit or prevent EMT from occurring."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: GRHL2 over-expression is suggested to suppress EMT (epithelial-to-mesenchymal transition), which implies that it does have a direct effect on EMT.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is one T-UCR that has been implicated in lung cancer, specifically uc.339. This was identified as an oncogene in lung cancer in Document 0.",
    "llama-2-13b-chat-hf_fact_raw": "1. T-UCR uc.339 has been implicated in lung cancer.\n2. T-UCR uc.339 was identified as an oncogene in lung cancer.",
    "llama-2-13b-chat-hf_fact": [
      "T-UCR uc.339 has been implicated in lung cancer.",
      "T-UCR uc.339 was identified as an oncogene in lung cancer."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: T-UCR uc.339 has been implicated in lung cancer, but being implicated does not necessarily mean it has been identified as an oncogene. T-UCRs (transcribed ultraconserved regions) can be involved in cancer in various ways, not just as oncogenes but also as tumor suppressors or regulators of other genes. Without specific evidence stating that uc.339 functions as an oncogene, this statement cannot be confirmed as true.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Documents 0 and 1, here is what is known about the orphan receptor GPR151:\nGPR151 is an inhibitory G protein-coupled receptor that is enriched in the habenula, a small brain region involved in aversion and emotion regulation. It is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function.\nRecently, a rare, putative loss-of-function mutation in the GPR151 gene was found to be associated with lower odds ratio for type 2 diabetes. This suggests that GPR151 may play a role in the regulation of glucose metabolism, although the exact mechanisms are not yet fully understood.\nOverall, GPR151 is a poorly understood receptor that is thought to be involved in the regulation of emotion and metabolism, but further research is needed to fully elucidate its functions and physiological roles.",
    "llama-2-13b-chat-hf_fact_raw": "1. GPR151 is an inhibitory G protein-coupled receptor.\n2. GPR151 is enriched in the habenula, a brain region involved in aversion and emotion regulation.\n3. GPR151 is classified as an orphan receptor, which means it does not have a well-defined endogenous ligand or a clear physiological function.\n4. A rare mutation in the GPR151 gene has been associated with lower odds ratio for type 2 diabetes.\n5. GPR151 is thought to be involved in the regulation of emotion and metabolism.",
    "llama-2-13b-chat-hf_fact": [
      "GPR151 is an inhibitory G protein-coupled receptor.",
      "GPR151 is enriched in the habenula, a brain region involved in aversion and emotion regulation.",
      "GPR151 is classified as an orphan receptor, which means it does not have a well-defined endogenous ligand or a clear physiological function.",
      "A rare mutation in the GPR151 gene has been associated with lower odds ratio for type 2 diabetes.",
      "GPR151 is thought to be involved in the regulation of emotion and metabolism."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine are:\n1. Influenza A subtype H1N1\n2. Influenza A subtype H3N2\n3. Influenza B virus Yamagata strain\n4. Influenza B virus Victoria strain\nThese viruses are attenuated, meaning they have been weakened so they can no longer cause severe illness, but they still retain enough of their original characteristics to trigger an immune response in the body. The vaccine is administered intradermally, meaning it is injected into the skin, rather than muscle, to stimulate an immune response.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains an attenuated version of the Influenza A subtype H1N1 virus.\n2. The Fluzone intradermal quadrivalent vaccine contains an attenuated version of the Influenza A subtype H3N2 virus.\n3. The Fluzone intradermal quadrivalent vaccine contains an attenuated version of the Influenza B virus Yamagata strain.\n4. The Fluzone intradermal quadrivalent vaccine contains an attenuated version of the Influenza B virus Victoria strain.\n5. The Fluzone intradermal quadrivalent vaccine is administered intradermally.",
    "llama-2-13b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated version of the Influenza A subtype H1N1 virus.",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated version of the Influenza A subtype H3N2 virus.",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated version of the Influenza B virus Yamagata strain.",
      "The Fluzone intradermal quadrivalent vaccine contains an attenuated version of the Influenza B virus Victoria strain.",
      "The Fluzone intradermal quadrivalent vaccine is administered intradermally."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains an inactivated version of the Influenza A subtype H1N1 virus, not an attenuated version.\n2. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains an inactivated version of the Influenza A subtype H3N2 virus, not an attenuated version.\n3. TRUE: The Fluzone intradermal quadrivalent vaccine contains an inactivated version of the Influenza B virus Yamagata strain.\n4. TRUE: The Fluzone intradermal quadrivalent vaccine contains an inactivated version of the Influenza B virus Victoria strain.\n5. TRUE: The Fluzone intradermal quadrivalent vaccine is administered intradermally.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the part of the TNFR2 gene that is genetically associated with Systemic Lupus Erythematosus (SLE) is the rs1061624 polymorphism. This polymorphism has been linked to HBV-related chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in Chinese populations, particularly in males. However, it is important to note that the association between the TNFR2 gene and SLE is not as well-established as the association with HBV-related liver diseases. Further research is needed to confirm this association and to understand the underlying mechanisms.",
    "llama-2-13b-chat-hf_fact_raw": "1. The rs1061624 polymorphism of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE).\n2. The rs1061624 polymorphism has been linked to HBV-related chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in Chinese populations.\n3. The association between the TNFR2 gene and SLE is not as well-established as the association with HBV-related liver diseases.\n4. The rs1061624 polymorphism has been particularly linked to the mentioned diseases in males within Chinese populations.",
    "llama-2-13b-chat-hf_fact": [
      "The rs1061624 polymorphism of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE).",
      "The rs1061624 polymorphism has been linked to HBV-related chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in Chinese populations.",
      "The association between the TNFR2 gene and SLE is not as well-established as the association with HBV-related liver diseases.",
      "The rs1061624 polymorphism has been particularly linked to the mentioned diseases in males within Chinese populations."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: The rs1061624 polymorphism of the TNFR2 gene has been reported in scientific literature to be associated with Systemic Lupus Erythematosus (SLE).\n2. TRUE: The rs1061624 polymorphism has indeed been linked to HBV-related chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in Chinese populations according to various studies.\n3. UNKNOWN: Without specific data or studies to compare the level of establishment between the associations of the TNFR2 gene with SLE and HBV-related liver diseases, it is difficult to determine the accuracy of this statement.\n4. UNKNOWN: The statement is specific, and without access to the particular studies or data that confirm the link of the rs1061624 polymorphism to the mentioned diseases specifically in males within Chinese populations, it is not possible to determine the truthfulness of this statement.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is currently no vaccine available for peanut allergy. However, there is a promising antibody treatment that has shown early evidence of being safe, effective, and rapid in treating severe peanut allergies. This treatment involves a single injection of an antibody, which allows individuals to consume a nut's worth of peanut protein two weeks later. This study was conducted by Stanford and is a small pilot study, but it provides hope for those suffering from peanut allergies. Additionally, allergen immunotherapy, a form of therapeutic vaccination, is available for other common allergen sources such as pollens, house dust mites, and stinging insect venom.",
    "llama-2-13b-chat-hf_fact_raw": "1. There is currently no vaccine available for peanut allergy.\n2. An antibody treatment for severe peanut allergies has shown early evidence of being safe and effective.\n3. The antibody treatment for peanut allergies involves a single injection.\n4. After receiving the antibody treatment, individuals could consume a nut's worth of peanut protein two weeks later.\n5. The study on the antibody treatment for peanut allergies was conducted by Stanford.",
    "llama-2-13b-chat-hf_fact": [
      "There is currently no vaccine available for peanut allergy.",
      "An antibody treatment for severe peanut allergies has shown early evidence of being safe and effective.",
      "The antibody treatment for peanut allergies involves a single injection.",
      "After receiving the antibody treatment, individuals could consume a nut's worth of peanut protein two weeks later.",
      "The study on the antibody treatment for peanut allergies was conducted by Stanford."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: As of my knowledge cutoff in 2023, a vaccine for peanut allergy is not available for widespread use, but there are treatments such as oral immunotherapy that have been approved by the FDA.\n2. TRUE\n3. UNKNOWN: Without specific information about the antibody treatment being referenced, it is not possible to confirm whether it involves a single injection or a series of injections.\n4. UNKNOWN: The specifics of the outcome, such as the ability to consume a nut's worth of peanut protein two weeks after treatment, would depend on the details of the study and treatment protocol, which are not provided.\n5. UNKNOWN: Without additional information, it is not possible to confirm whether Stanford conducted the study on the antibody treatment for peanut allergies.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0, the Fxy gene in C57BL/6 mice has a unique chromosomal position, as the 5' end of the gene is X-specific but the 3' end is present on both the X and Y chromosomes. This means that the gene is located on the X chromosome, but a portion of it is also present on the Y chromosome.\nDocument 1 provides additional information that the Fxy gene was translocated into the pseudoautosomal region, which is a highly recombining region, resulting in a rapid increase in GC content. This suggests that the gene has undergone a recent evolutionary event that has affected its chromosomal position and composition.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Fxy gene in C57BL/6 mice has a unique chromosomal position.\n2. The 5' end of the Fxy gene is X-specific.\n3. The 3' end of the Fxy gene is present on both the X and Y chromosomes.\n4. The Fxy gene was translocated into the pseudoautosomal region.\n5. The translocation of the Fxy gene into the pseudoautosomal region resulted in a rapid increase in GC content.",
    "llama-2-13b-chat-hf_fact": [
      "The Fxy gene in C57BL/6 mice has a unique chromosomal position.",
      "The 5' end of the Fxy gene is X-specific.",
      "The 3' end of the Fxy gene is present on both the X and Y chromosomes.",
      "The Fxy gene was translocated into the pseudoautosomal region.",
      "The translocation of the Fxy gene into the pseudoautosomal region resulted in a rapid increase in GC content."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific to the genetics of C57BL/6 mice and the characteristics of the Fxy gene. Without access to the specific scientific literature or genetic studies that detail the Fxy gene's characteristics, it is not possible to accurately determine the truthfulness of these statements. Therefore, all responses are marked as UNKNOWN.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method is the use of methidiumpropyl-EDTA (MPE) and ferrous iron to digest nuclei and isolate nucleosomes, which are then subjected to massively parallel sequencing. The MPE-Fe (II) complex preferentially cleaves the linker DNA between nucleosomes, allowing for the genome-wide characterization of chromatin.",
    "llama-2-13b-chat-hf_fact_raw": "1. Methidiumpropyl-EDTA sequencing (MPE-seq) uses methidiumpropyl-EDTA (MPE) and ferrous iron to digest nuclei.\n2. MPE-seq isolates nucleosomes for massively parallel sequencing.\n3. The MPE-Fe (II) complex preferentially cleaves the linker DNA between nucleosomes.\n4. MPE-seq allows for the genome-wide characterization of chromatin.",
    "llama-2-13b-chat-hf_fact": [
      "Methidiumpropyl-EDTA sequencing (MPE-seq) uses methidiumpropyl-EDTA (MPE) and ferrous iron to digest nuclei.",
      "MPE-seq isolates nucleosomes for massively parallel sequencing.",
      "The MPE-Fe (II) complex preferentially cleaves the linker DNA between nucleosomes.",
      "MPE-seq allows for the genome-wide characterization of chromatin."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: MPE-seq does not isolate nucleosomes for sequencing. Instead, it digests the linker DNA between nucleosomes, allowing for the mapping of nucleosome positions.\n3. TRUE\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the programming language used for implementing GWAR is Python. This is mentioned in Document 1, which states that Python is an object-oriented, high-level programming language launched in 1992, and it's a very popular language right now, meaning there are plenty of Python jobs available. Additionally, the fact that the tool will be implemented in a standalone version (e.g. in Perl programming language) suggests that Python is not the only language being considered for the implementation.",
    "llama-2-13b-chat-hf_fact_raw": "1. The programming language used for implementing GWAR is Python.\n2. Python is an object-oriented, high-level programming language.\n3. Python was launched in 1992.\n4. Python is currently a very popular programming language.\n5. There are plenty of Python jobs available.",
    "llama-2-13b-chat-hf_fact": [
      "The programming language used for implementing GWAR is Python.",
      "Python is an object-oriented, high-level programming language.",
      "Python was launched in 1992.",
      "Python is currently a very popular programming language.",
      "There are plenty of Python jobs available."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: Python was officially launched in 1991.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is no direct answer to whether xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS). However, the information does suggest that improved prognosis, such as that achieved with the survival model from the European Network for the Cure of ALS, could inform the patient and their family about disease course and improve end-of-life planning. Additionally, novel staging and scoring systems can help monitor disease progression and might potentially serve as clinical trial outcomes.\nIt is important to note that ALS is a fatal motor neurone disease, and there is currently no cure. However, there are various treatments available that can help manage the symptoms and slow down the progression of the disease. Xaliproden is one such treatment that has been shown to improve functional abilities and slow down the progression of ALS. However, more research is needed to confirm its effectiveness and to determine its place in the treatment of ALS.\nIn summary, while there is no direct answer to whether xaliproden improves the prognosis of ALS, the information provided suggests that it may be a useful treatment option for managing the symptoms and slowing down the progression of the disease. It is important for patients and their families to discuss their treatment options with their healthcare provider and to carefully consider the potential benefits and risks of any treatment.",
    "llama-2-13b-chat-hf_fact_raw": "1. Amyotrophic lateral sclerosis (ALS) is a fatal motor neurone disease.\n2. There is currently no cure for ALS.\n3. Xaliproden is a treatment that has been shown to improve functional abilities in ALS patients.\n4. Xaliproden has been shown to slow down the progression of ALS.\n5. More research is needed to confirm the effectiveness of xaliproden in the treatment of ALS.",
    "llama-2-13b-chat-hf_fact": [
      "Amyotrophic lateral sclerosis (ALS) is a fatal motor neurone disease.",
      "There is currently no cure for ALS.",
      "Xaliproden is a treatment that has been shown to improve functional abilities in ALS patients.",
      "Xaliproden has been shown to slow down the progression of ALS.",
      "More research is needed to confirm the effectiveness of xaliproden in the treatment of ALS."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: As of my knowledge cutoff date in 2023, xaliproden has not been conclusively shown to improve functional abilities in ALS patients. Clinical trials have been conducted, but results have been mixed and not definitive.\n4. FALSE [correction]: There is no consensus that xaliproden has been shown to slow down the progression of ALS. While some studies may suggest potential benefits, they are not conclusive, and xaliproden is not widely recognized as a standard treatment for ALS.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the transgenes are inserted in chromosome 15. Specifically, the LiPS-A3S site is located within the 3' UTR region of the gene on chromosome 15.",
    "llama-2-13b-chat-hf_fact_raw": "1. Transgenes are inserted in chromosome 15 in the case of the LiPS-A3S line.\n2. The LiPS-A3S site is located within the 3' UTR region of a gene on chromosome 15.",
    "llama-2-13b-chat-hf_fact": [
      "Transgenes are inserted in chromosome 15 in the case of the LiPS-A3S line.",
      "The LiPS-A3S site is located within the 3' UTR region of a gene on chromosome 15."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nWithout specific context or additional information about the LiPS-A3S line and the procedures used to create it, it is not possible to determine the accuracy of these statements. The insertion of transgenes can vary depending on the techniques used and the goals of the genetic modification. Similarly, the location of the insertion within a specific region of the genome, such as the 3' UTR region of a gene, would require specific genetic mapping or sequencing data to confirm.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, one tool that exists for predicting drug synergy with deep learning is DeepSynergy, which is available via the website www.bioinf.jku.at/software/DeepSynergy. The tool was mentioned in Document 0 as a valuable tool for selecting novel synergistic drug combinations. The contact for inquiries and implementation is given as klambauer@bioinf.jku.at.",
    "llama-2-13b-chat-hf_fact_raw": "1. DeepSynergy is a tool for predicting drug synergy with deep learning.\n2. DeepSynergy is available through the website www.bioinf.jku.at/software/DeepSynergy.\n3. DeepSynergy was mentioned as a valuable tool for selecting novel synergistic drug combinations.\n4. The contact email for DeepSynergy inquiries and implementation is klambauer@bioinf.jku.at.",
    "llama-2-13b-chat-hf_fact": [
      "DeepSynergy is a tool for predicting drug synergy with deep learning.",
      "DeepSynergy is available through the website www.bioinf.jku.at/software/DeepSynergy.",
      "DeepSynergy was mentioned as a valuable tool for selecting novel synergistic drug combinations.",
      "The contact email for DeepSynergy inquiries and implementation is klambauer@bioinf.jku.at."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the cloud-based platform that has been developed for comparing GWAS (Genome-Wide Association Studies) is easyGWAS. According to Document 1, easyGWAS is a cloud-based platform that allows for the comparison of the results of Genome-Wide Association Studies across different experiments and data sets in an interactive and user-friendly interface. It supports multiple species, the uploading of private genotype data, and summary statistics of existing GWAS.",
    "llama-2-13b-chat-hf_fact_raw": "1. easyGWAS is a cloud-based platform developed for comparing Genome-Wide Association Studies (GWAS).\n2. easyGWAS allows for the comparison of results across different experiments and data sets.\n3. The interface of easyGWAS is interactive and user-friendly.\n4. easyGWAS supports multiple species.\n5. easyGWAS allows users to upload private genotype data and summary statistics of existing GWAS.",
    "llama-2-13b-chat-hf_fact": [
      "easyGWAS is a cloud-based platform developed for comparing Genome-Wide Association Studies (GWAS).",
      "easyGWAS allows for the comparison of results across different experiments and data sets.",
      "The interface of easyGWAS is interactive and user-friendly.",
      "easyGWAS supports multiple species.",
      "easyGWAS allows users to upload private genotype data and summary statistics of existing GWAS."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, CMB305 has been shown to be effective in treating NY-ESO-1-expressing synovial or myxoid round cell liposarcoma, but there is no direct evidence to suggest that it is effective against sarcomas in general.\nDocument 0 mentions that CMB305 is a heterologous prime-boost vaccination regimen created to prime NY-ESO-1-specific CD8 T-cell populations and then activate the immune response with a potent TLR-4 agonist. This suggests that CMB305 is designed to target NY-ESO-1-expressing cells, but it does not provide information on its effectiveness against other types of cancer, such as sarcomas.\nDocument 1 reports the results of a trial assessing the efficacy of CMB305 plus atezolizumab or atezolizumab alone in patients with NY-ESO-1-expressing synovial or myxoid round cell liposarcoma. The study found that the combination of CMB305 and atezolizumab was effective in improving overall survival and progression-free survival in these patients. However, the study did not include patients with sarcomas, so there is no information on the effectiveness of CMB305 against sarcomas.\nIn conclusion, while CMB305 has shown promise in treating NY-ESO-1-expressing synovial or myxoid round cell liposarcoma, there is no direct evidence to suggest that it is effective against sarcomas in general. Further research is needed to determine the efficacy of CMB305 against other types of cancer, including sarcomas.",
    "llama-2-13b-chat-hf_fact_raw": "1. CMB305 has been shown to be effective in treating NY-ESO-1-expressing synovial or myxoid round cell liposarcoma.\n2. CMB305 is a heterologous prime-boost vaccination regimen designed to prime NY-ESO-1-specific CD8 T-cell populations.\n3. CMB305 activates the immune response with a potent TLR-4 agonist.\n4. A study found that the combination of CMB305 and atezolizumab improved overall survival and progression-free survival in patients with NY-ESO-1-expressing synovial or myxoid round cell liposarcoma.\n5. There is no direct evidence to suggest that CMB305 is effective against sarcomas in general.",
    "llama-2-13b-chat-hf_fact": [
      "CMB305 has been shown to be effective in treating NY-ESO-1-expressing synovial or myxoid round cell liposarcoma.",
      "CMB305 is a heterologous prime-boost vaccination regimen designed to prime NY-ESO-1-specific CD8 T-cell populations.",
      "CMB305 activates the immune response with a potent TLR-4 agonist.",
      "A study found that the combination of CMB305 and atezolizumab improved overall survival and progression-free survival in patients with NY-ESO-1-expressing synovial or myxoid round cell liposarcoma.",
      "There is no direct evidence to suggest that CMB305 is effective against sarcomas in general."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe responses to statements 1, 4, and 5 are marked as UNKNOWN because, without specific data or references from clinical trials or scientific studies, it is not possible to confirm the effectiveness of CMB305 in treating specific cancers or its impact on overall survival and progression-free survival. The effectiveness of a treatment can only be confirmed through rigorous clinical trials and peer-reviewed studies, which are not provided in the context of these statements.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the manifestations of the Saint's Triad are:\n1. Hiatal hernia\n2. Gallbladder disease\n3. Diverticulosis\nThese conditions are often found together in patients with atypical abdominal symptoms, as described by Professor Charles Frederick Morris Saint.",
    "llama-2-13b-chat-hf_fact_raw": "1. Hiatal hernia is a manifestation of the Saint's Triad.\n2. Gallbladder disease is a manifestation of the Saint's Triad.\n3. Diverticulosis is a manifestation of the Saint's Triad.\n4. The Saint's Triad is associated with atypical abdominal symptoms.\n5. Professor Charles Frederick Morris Saint described the Saint's Triad.",
    "llama-2-13b-chat-hf_fact": [
      "Hiatal hernia is a manifestation of the Saint's Triad.",
      "Gallbladder disease is a manifestation of the Saint's Triad.",
      "Diverticulosis is a manifestation of the Saint's Triad.",
      "The Saint's Triad is associated with atypical abdominal symptoms.",
      "Professor Charles Frederick Morris Saint described the Saint's Triad."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Saint's Triad is associated with typical abdominal symptoms, not atypical.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is no evidence to suggest that overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients. In fact, the first document states that LY6K is negatively correlated with poor prognosis in patients, suggesting that high levels of LY6K expression may be associated with a worse prognosis.\nHowever, the second document does suggest that overexpression of PSMB8 and PSMB9, which are components of the immunoproteasome, is predictive of better survival and improved response to immune-checkpoint inhibitors in NSCLC patients. This suggests that high levels of immunoproteasome expression may be associated with a better prognosis in NSCLC patients, but does not provide any information about LY6K expression.\nTherefore, based on the information provided, there is no clear answer to the question of whether overexpression of LY6K is associated with better prognosis for NSCLC patients. Further research and analysis would be needed to determine the relationship between LY6K expression and prognosis in NSCLC patients.",
    "llama-2-13b-chat-hf_fact_raw": "1. Overexpression of LY6K is negatively correlated with prognosis in non-small cell lung cancer (NSCLC) patients, suggesting a worse prognosis with high levels of LY6K expression.\n2. Overexpression of PSMB8 and PSMB9 is predictive of better survival and improved response to immune-checkpoint inhibitors in NSCLC patients.\n3. High levels of immunoproteasome expression may be associated with a better prognosis in NSCLC patients.\n4. There is no evidence to suggest that overexpression of LY6K is associated with better prognosis for NSCLC patients.\n5. Further research is needed to determine the relationship between LY6K expression and prognosis in NSCLC patients.",
    "llama-2-13b-chat-hf_fact": [
      "Overexpression of LY6K is negatively correlated with prognosis in non-small cell lung cancer (NSCLC) patients, suggesting a worse prognosis with high levels of LY6K expression.",
      "Overexpression of PSMB8 and PSMB9 is predictive of better survival and improved response to immune-checkpoint inhibitors in NSCLC patients.",
      "High levels of immunoproteasome expression may be associated with a better prognosis in NSCLC patients.",
      "There is no evidence to suggest that overexpression of LY6K is associated with better prognosis for NSCLC patients.",
      "Further research is needed to determine the relationship between LY6K expression and prognosis in NSCLC patients."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, here are some Cdk targets that are dephosphorylated during cytokinesis:\n1. Cdc14: As mentioned in Document 0, Cdc14 is a phosphatase that counteracts Cdk activity and is upregulated during cytokinesis.\n2. Furrow ingression proteins: Document 0 states that downregulation of Cdk activity and upregulation of Cdc14 are required for furrow ingression during cytokinesis. Therefore, it is likely that Cdk targets involved in furrow ingression are also dephosphorylated during this process.\n3. Membrane resolution proteins: Document 0 mentions that Cdk activity is required for membrane resolution during cytokinesis. Therefore, it is likely that Cdk targets involved in membrane resolution are also dephosphorylated during this process.\n4. Cell separation proteins: Document 0 states that Cdk activity is required for cell separation during cytokinesis. Therefore, it is likely that Cdk targets involved in cell separation are also dephosphorylated during this process.\nAccording to Document 1, phosphoproteome analysis was used to identify Cdk targets that are dephosphorylated at the time of cytokinesis. The study found that several proteins involved in cytokinesis, including Cdc14, were dephosphorylated during this process.\nIn summary, based on the information provided, Cdk targets that are dephosphorylated during cytokinesis include Cdc14, furrow ingression proteins, membrane resolution proteins, and cell separation proteins.",
    "llama-2-13b-chat-hf_fact_raw": "1. Cdc14 is a phosphatase that counteracts Cdk activity and is upregulated during cytokinesis.\n2. Cdk targets involved in furrow ingression are dephosphorylated during cytokinesis.\n3. Cdk targets involved in membrane resolution are dephosphorylated during cytokinesis.\n4. Cdk targets involved in cell separation are dephosphorylated during cytokinesis.\n5. Phosphoproteome analysis was used to identify Cdk targets that are dephosphorylated at the time of cytokinesis.",
    "llama-2-13b-chat-hf_fact": [
      "Cdc14 is a phosphatase that counteracts Cdk activity and is upregulated during cytokinesis.",
      "Cdk targets involved in furrow ingression are dephosphorylated during cytokinesis.",
      "Cdk targets involved in membrane resolution are dephosphorylated during cytokinesis.",
      "Cdk targets involved in cell separation are dephosphorylated during cytokinesis.",
      "Phosphoproteome analysis was used to identify Cdk targets that are dephosphorylated at the time of cytokinesis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with general knowledge about cell cycle regulation and the role of Cdc14 and Cdk (cyclin-dependent kinase). Cdc14 is known to counteract Cdk activity, which is crucial for various processes during cell division, including cytokinesis. Dephosphorylation of Cdk targets is a key step in progressing through cytokinesis, and phosphoproteome analysis is a technique that could be used to identify such targets. However, without specific experimental data or a passage to reference, it is not possible to confirm the accuracy of the last statement with absolute certainty, but it is plausible based on common scientific methodologies.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, Xanamem is an investigational therapy for Alzheimer's disease that inhibits 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme in the hypothalamic-pituitary-adrenal (HPA) axis of the body's stress response. By inhibiting 11β-HSD1, Xanamem reduces the conversion of cortisol to its active form, which binds to glucocorticoid receptors. This may have a potential therapeutic effect on Alzheimer's disease.",
    "llama-2-13b-chat-hf_fact_raw": "1. Xanamem is an investigational therapy for Alzheimer's disease.\n2. Xanamem works by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).\n3. 11β-HSD1 is part of the hypothalamic-pituitary-adrenal (HPA) axis.\n4. Inhibition of 11β-HSD1 by Xanamem reduces the conversion of cortisol to its active form.\n5. The reduction of active cortisol by Xanamem is believed to have a potential therapeutic effect on Alzheimer's disease.",
    "llama-2-13b-chat-hf_fact": [
      "Xanamem is an investigational therapy for Alzheimer's disease.",
      "Xanamem works by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).",
      "11β-HSD1 is part of the hypothalamic-pituitary-adrenal (HPA) axis.",
      "Inhibition of 11β-HSD1 by Xanamem reduces the conversion of cortisol to its active form.",
      "The reduction of active cortisol by Xanamem is believed to have a potential therapeutic effect on Alzheimer's disease."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Inhibition of 11β-HSD1 by Xanamem reduces the conversion of inactive cortisone to its active form, cortisol.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the role of the Hof1-Cyk3 interaction in yeast is crucial for proper cytokinesis. The interaction mediates the cleavage-furrow ingression and primary-septum formation during yeast cytokinesis, specifically at the time of cytokinesis. The interaction is direct, binding the Hof1 SH3 domain to a proline-rich motif in Cyk3, and is independent of the (hyper)phosphorylation of both proteins. The interaction is not essential for the normal localization of both proteins. This information is supported by Document 1, which provides evidence that the Hof1-Cyk3 interaction plays a critical role in cleavage-furrow ingression and primary-septum formation during yeast cytokinesis.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction in yeast is crucial for proper cytokinesis.\n2. This interaction mediates cleavage-furrow ingression and primary-septum formation during yeast cytokinesis.\n3. The Hof1 SH3 domain binds to a proline-rich motif in Cyk3.\n4. The interaction between Hof1 and Cyk3 is independent of the (hyper)phosphorylation of both proteins.\n5. The Hof1-Cyk3 interaction is not essential for the normal localization of both proteins.",
    "llama-2-13b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction in yeast is crucial for proper cytokinesis.",
      "This interaction mediates cleavage-furrow ingression and primary-septum formation during yeast cytokinesis.",
      "The Hof1 SH3 domain binds to a proline-rich motif in Cyk3.",
      "The interaction between Hof1 and Cyk3 is independent of the (hyper)phosphorylation of both proteins.",
      "The Hof1-Cyk3 interaction is not essential for the normal localization of both proteins."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The interaction between Hof1 and Cyk3 is dependent on the (hyper)phosphorylation of both proteins.\n5. FALSE [correction]: The Hof1-Cyk3 interaction is essential for the normal localization of both proteins.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, there is currently limited information available on which T-UCRs have been implicated in gastric cancer. However, we can infer that T-UCRs are involved in three different regulatory mechanisms in tumors: CpG island methylation, interaction with miRNAs, and direct binding to target mRNAs.\nDocument 0 mentions that the regulatory mechanism of T-UCRs in tumorigenesis and cancer development is largely unclear, but current studies have found that T-UCRs are involved in these three mechanisms. Therefore, it is possible that some T-UCRs may be implicated in gastric cancer, but further research is needed to confirm this.\nDocument 1 provides an overview of T-UCRs as a novel class of non-coding RNAs that are absolutely conserved between the orthologous regions of the human, rat, and mouse genomes. However, it does not provide specific information on the involvement of T-UCRs in gastric cancer.\nIn summary, based on the information provided, there is currently limited information available on which T-UCRs have been implicated in gastric cancer. Further research is needed to determine the specific T-UCRs that may be involved in gastric cancer and their underlying mechanisms.",
    "llama-2-13b-chat-hf_fact_raw": "1. T-UCRs are involved in three different regulatory mechanisms in tumors: CpG island methylation, interaction with miRNAs, and direct binding to target mRNAs.\n2. The regulatory mechanism of T-UCRs in tumorigenesis and cancer development is largely unclear.\n3. Current studies have found that T-UCRs are involved in CpG island methylation, interaction with miRNAs, and direct binding to target mRNAs.\n4. There is limited information available on which T-UCRs have been implicated in gastric cancer.\n5. T-UCRs are a novel class of non-coding RNAs that are absolutely conserved between the orthologous regions of the human, rat, and mouse genomes.",
    "llama-2-13b-chat-hf_fact": [
      "T-UCRs are involved in three different regulatory mechanisms in tumors: CpG island methylation, interaction with miRNAs, and direct binding to target mRNAs.",
      "The regulatory mechanism of T-UCRs in tumorigenesis and cancer development is largely unclear.",
      "Current studies have found that T-UCRs are involved in CpG island methylation, interaction with miRNAs, and direct binding to target mRNAs.",
      "There is limited information available on which T-UCRs have been implicated in gastric cancer.",
      "T-UCRs are a novel class of non-coding RNAs that are absolutely conserved between the orthologous regions of the human, rat, and mouse genomes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: T-UCRs are a novel class of non-coding RNAs that are highly conserved between the orthologous regions of the human, rat, and mouse genomes, not absolutely conserved.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the Lupus Severity Index (LSI) is a predictive tool used to assess the severity of Systemic Lupus Erythematosus (SLE) and its potential impact on patient outcomes. The LSI was derived from the American College of Rheumatology (ACR) classification criteria and was found to have high predictive accuracy for immunosuppressive use and early mortality in patients with SLE. The index is also strongly correlated with a previously existing severity score for lupus.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of Systemic Lupus Erythematosus (SLE).\n2. The LSI is a predictive tool for assessing the potential impact on patient outcomes.\n3. The LSI was derived from the American College of Rheumatology (ACR) classification criteria.\n4. The LSI has high predictive accuracy for immunosuppressive use in patients with SLE.\n5. The LSI has high predictive accuracy for early mortality in patients with SLE.",
    "llama-2-13b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of Systemic Lupus Erythematosus (SLE).",
      "The LSI is a predictive tool for assessing the potential impact on patient outcomes.",
      "The LSI was derived from the American College of Rheumatology (ACR) classification criteria.",
      "The LSI has high predictive accuracy for immunosuppressive use in patients with SLE.",
      "The LSI has high predictive accuracy for early mortality in patients with SLE."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to a specific medical tool, the Lupus Severity Index (LSI), and its applications and derivations. Without access to the specific medical literature or guidelines that discuss the LSI, its predictive accuracy, and its relationship to the ACR classification criteria, it is not possible to accurately determine the truthfulness of these statements. Medical tools and their validation are subject to research and peer-reviewed studies, which would need to be consulted to verify these claims.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, de novo mutations in the ZSWIM6 gene have been associated with the following disorders:\n1. Acromelic frontonasal dysostosis (AFND): A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 has been reported to cause AFND, an autosomal-dominant severe frontonasal and limb malformation syndrome, associated with neurocognitive and motor delay.\n2. Other rare disorders: In 2014, a de novo variant in the ZSWIM6 gene was commonly identified in four patients with acromelic frontonasal dysostosis (MIM #603671), a rare genetic disorder characterized by frontonasal and limb malformations.\nIt is important to note that these disorders are caused by de novo mutations in the ZSWIM6 gene, meaning that the mutations are not inherited from the parents and are present for the first time in the affected individual.",
    "llama-2-13b-chat-hf_fact_raw": "1. De novo mutations in the ZSWIM6 gene have been associated with Acromelic frontonasal dysostosis (AFND).\n2. A recurrent de novo missense variant in the ZSWIM6 gene's C-terminal Sin3-like domain causes AFND.\n3. AFND is an autosomal-dominant severe frontonasal and limb malformation syndrome.\n4. AFND is associated with neurocognitive and motor delay.\n5. In 2014, a de novo variant in the ZSWIM6 gene was identified in four patients with acromelic frontonasal dysostosis.",
    "llama-2-13b-chat-hf_fact": [
      "De novo mutations in the ZSWIM6 gene have been associated with Acromelic frontonasal dysostosis (AFND).",
      "A recurrent de novo missense variant in the ZSWIM6 gene's C-terminal Sin3-like domain causes AFND.",
      "AFND is an autosomal-dominant severe frontonasal and limb malformation syndrome.",
      "AFND is associated with neurocognitive and motor delay.",
      "In 2014, a de novo variant in the ZSWIM6 gene was identified in four patients with acromelic frontonasal dysostosis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Acromelic frontonasal dysostosis (AFND) is typically caused by de novo mutations, meaning it is not usually inherited in an autosomal-dominant manner, but rather occurs spontaneously.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the disease that can be classified using the Koos Classification is vestibular schwannoma (VS). The Koos grading scale is a commonly used classification system for VS that takes into account the extrameatal tumor dimension and compression of the brain stem.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Koos Classification is used to classify vestibular schwannoma (VS).\n2. The Koos grading scale considers the extrameatal tumor dimension.\n3. The Koos grading scale also considers the compression of the brain stem.",
    "llama-2-13b-chat-hf_fact": [
      "The Koos Classification is used to classify vestibular schwannoma (VS).",
      "The Koos grading scale considers the extrameatal tumor dimension.",
      "The Koos grading scale also considers the compression of the brain stem."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the in vivo effects of AZD8601 are:\n1. Improved vascularization: Sequential dosing of AZD8601 has been shown to improve vascularization and tissue oxygenation of the wound bed, as measured by a boron nanoparticle-based tissue oxygen sensor.\n2. Accelerated healing: The improved vascularization and tissue oxygenation led to accelerated healing of the wound.\nIt is important to note that AZD8601 is an investigational mRNA-based therapy, and its effects on the body are still being studied. Further research is needed to fully understand the in vivo effects of AZD8601 and its potential as a treatment for various conditions.",
    "llama-2-13b-chat-hf_fact_raw": "1. AZD8601 is an investigational mRNA-based therapy.\n2. Sequential dosing of AZD8601 has been shown to improve vascularization and tissue oxygenation of the wound bed.\n3. Improved vascularization and tissue oxygenation from AZD8601 led to accelerated healing of the wound.\n4. The effects of AZD8601 on the body are still being studied.\n5. Further research is needed to fully understand the in vivo effects of AZD8601.",
    "llama-2-13b-chat-hf_fact": [
      "AZD8601 is an investigational mRNA-based therapy.",
      "Sequential dosing of AZD8601 has been shown to improve vascularization and tissue oxygenation of the wound bed.",
      "Improved vascularization and tissue oxygenation from AZD8601 led to accelerated healing of the wound.",
      "The effects of AZD8601 on the body are still being studied.",
      "Further research is needed to fully understand the in vivo effects of AZD8601."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: While the statements about AZD8601 are consistent with the general understanding of investigational mRNA-based therapies aimed at improving vascularization and tissue oxygenation, which could lead to accelerated healing, the specific outcomes and the need for further research are typical of investigational treatments. However, without access to the latest and specific research data on AZD8601, it is not possible to verify the accuracy of statements 2 and 3 with absolute certainty. Therefore, these responses are based on the assumption that the statements are presented in a context that is accurate as of the knowledge cutoff date.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, SAHFS (Senescence Associated Heterochromatic Foci) are created as a result of cellular senescence, which is a stress response that occurs in response to DNA damage, telomere erosion, and activation of oncogenic signaling. This process is a permanent cell cycle exit, and it can be triggered by various factors, including prolonged passaging and replicative exhaustion of cells in culture. The accumulation of senescent cells in tissues is a hallmark of aging, and it is thought to contribute to the development of age-related diseases.",
    "llama-2-13b-chat-hf_fact_raw": "1. SAHFS (Senescence Associated Heterochromatic Foci) are created as a result of cellular senescence.\n2. Cellular senescence is a stress response that can occur due to DNA damage.\n3. Telomere erosion can trigger cellular senescence.\n4. Activation of oncogenic signaling can lead to the formation of SAHFS.\n5. The accumulation of senescent cells in tissues is considered a hallmark of aging.",
    "llama-2-13b-chat-hf_fact": [
      "SAHFS (Senescence Associated Heterochromatic Foci) are created as a result of cellular senescence.",
      "Cellular senescence is a stress response that can occur due to DNA damage.",
      "Telomere erosion can trigger cellular senescence.",
      "Activation of oncogenic signaling can lead to the formation of SAHFS.",
      "The accumulation of senescent cells in tissues is considered a hallmark of aging."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the function of the PDZ domain in SATB1 is to mediate interactions with chromatin proteins.",
    "llama-2-13b-chat-hf_fact_raw": "1. The PDZ domain in SATB1 mediates interactions with chromatin proteins.",
    "llama-2-13b-chat-hf_fact": [
      "The PDZ domain in SATB1 mediates interactions with chromatin proteins."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n\nThe statement about the PDZ domain in SATB1 mediating interactions with chromatin proteins is very specific and would require access to scientific literature or specific knowledge about the SATB1 protein and its domains to verify. Without additional context or information, it is not possible to determine the truthfulness of this statement.",
    "llama-2-13b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the basis of the BLISS technique is to relieve and dissolve pain, improve healing, and create the basis for stronger immunity by incorporating specific practices and mantras into one's meditation routine. According to Deepak Chopra's book \"Quantum Healing,\" the technique is designed to enhance bliss in the mind-body system and promote overall well-being.",
    "llama-2-13b-chat-hf_fact_raw": "1. The BLISS technique is designed to relieve and dissolve pain.\n2. The BLISS technique aims to improve healing.\n3. The BLISS technique is intended to create the basis for stronger immunity.\n4. The BLISS technique incorporates specific practices and mantras into one's meditation routine.\n5. Deepak Chopra's book \"Quantum Healing\" discusses the BLISS technique as a way to enhance bliss in the mind-body system and promote overall well-being.",
    "llama-2-13b-chat-hf_fact": [
      "The BLISS technique is designed to relieve and dissolve pain.",
      "The BLISS technique aims to improve healing.",
      "The BLISS technique is intended to create the basis for stronger immunity.",
      "The BLISS technique incorporates specific practices and mantras into one's meditation routine.",
      "Deepak Chopra's book \"Quantum Healing\" discusses the BLISS technique as a way to enhance bliss in the mind-body system and promote overall well-being."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Deepak Chopra's book \"Quantum Healing\" does not discuss the BLISS technique; it explores the connection between the mind and body and how consciousness can lead to healing. The BLISS technique is not mentioned in this context.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-13b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, here are three NK3R antagonists that have been identified in clinical trials for the treatment of menopausal vasomotor symptoms:\n1. UMB-130: This is a selective oral NK3R antagonist that has been studied in four clinical trials for the treatment of menopausal flushes. The trials have consistently shown that UMB-130 is effective in reducing the frequency and severity of hot flashes and night sweats in postmenopausal women.\n2. LY-308235: This is another oral NK3R antagonist that has been studied in clinical trials for the treatment of menopausal vasomotor symptoms. LY-308235 has been shown to be effective in reducing hot flashes and improving quality of life in postmenopausal women.\n3. MK-869: This is a selective oral NK3R antagonist that has also been studied in clinical trials for the treatment of menopausal vasomotor symptoms. MK-869 has been shown to be effective in reducing hot flashes and improving quality of life in postmenopausal women.\nIt's important to note that these are just a few examples of NK3R antagonists that have been studied for the treatment of menopausal vasomotor symptoms, and there may be other agents in development that have also shown promise in clinical trials.",
    "llama-2-13b-chat-hf_fact_raw": "1. UMB-130 is a selective oral NK3R antagonist that has been studied in four clinical trials for the treatment of menopausal flushes.\n2. LY-308235 is an oral NK3R antagonist that has been studied in clinical trials for the treatment of menopausal vasomotor symptoms.\n3. MK-869 is a selective oral NK3R antagonist that has been studied in clinical trials for the treatment of menopausal vasomotor symptoms.",
    "llama-2-13b-chat-hf_fact": [
      "UMB-130 is a selective oral NK3R antagonist that has been studied in four clinical trials for the treatment of menopausal flushes.",
      "LY-308235 is an oral NK3R antagonist that has been studied in clinical trials for the treatment of menopausal vasomotor symptoms.",
      "MK-869 is a selective oral NK3R antagonist that has been studied in clinical trials for the treatment of menopausal vasomotor symptoms."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: MK-869 is not an NK3R antagonist; it is a substance P antagonist that was studied as an antiemetic and for the treatment of depression.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the answer to the user's question is:\nPF-05190457 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
    "llama-2-13b-chat-hf_fact_raw": "1. PF-05190457 is an oral ghrelin receptor inverse agonist.\n2. PF-05190457 was profiled in healthy subjects.",
    "llama-2-13b-chat-hf_fact": [
      "PF-05190457 is an oral ghrelin receptor inverse agonist.",
      "PF-05190457 was profiled in healthy subjects."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, I can answer the user's question as follows:\nThe protective efficacy of Vaxchora against moderate to severe cholera has been demonstrated in clinical trials. According to Document 1, Vaxchora is a live, attenuated oral cholera vaccine that contains a recombinant cholera toxin subunit (CT) and is formulated as a freeze-dried powder. The vaccine is administered orally and has been shown to be highly effective in preventing moderate to severe cholera in individuals 1 year of age and older.\nIn a clinical trial conducted in Bangladesh, Vaxchora was found to be 80-90% effective in preventing moderate to severe cholera in individuals 1 year of age and older. Additionally, the vaccine was found to be safe and well-tolerated, with the most common adverse reactions being mild and temporary, such as headache, fatigue, and muscle pain.\nIt is important to note that while Vaxchora is highly effective in preventing moderate to severe cholera, it is not 100% effective and may not provide complete protection against all strains of the disease. Therefore, it is still important to take precautions to prevent the spread of cholera, such as practicing good hygiene and sanitation, and seeking medical attention immediately if symptoms of cholera develop.\nI hope this information is helpful. If you have any further questions, please do not hesitate to ask.",
    "llama-2-13b-chat-hf_fact_raw": "1. Vaxchora is a live, attenuated oral cholera vaccine.\n2. Vaxchora contains a recombinant cholera toxin subunit and is formulated as a freeze-dried powder.\n3. The vaccine is administered orally and is intended for individuals 1 year of age and older.\n4. In a clinical trial in Bangladesh, Vaxchora was found to be 80-90% effective in preventing moderate to severe cholera in individuals 1 year of age and older.\n5. The most common adverse reactions to Vaxchora were mild and temporary, including headache, fatigue, and muscle pain.",
    "llama-2-13b-chat-hf_fact": [
      "Vaxchora is a live, attenuated oral cholera vaccine.",
      "Vaxchora contains a recombinant cholera toxin subunit and is formulated as a freeze-dried powder.",
      "The vaccine is administered orally and is intended for individuals 1 year of age and older.",
      "In a clinical trial in Bangladesh, Vaxchora was found to be 80-90% effective in preventing moderate to severe cholera in individuals 1 year of age and older.",
      "The most common adverse reactions to Vaxchora were mild and temporary, including headache, fatigue, and muscle pain."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Vaxchora does not contain a recombinant cholera toxin subunit; it is a live, attenuated vaccine that contains the cholera bacterium Vibrio cholerae CVD 103-HgR.\n3. TRUE\n4. UNKNOWN (The effectiveness percentage and the specific clinical trial in Bangladesh would need to be verified with the actual clinical trial data or official sources.)\n5. TRUE (While the specific adverse reactions listed are common for many vaccines, the exact reactions and their prevalence for Vaxchora would need to be verified with the vaccine's prescribing information or clinical trial data.)",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the first cholera vaccine approved in the US is Vaxchora, which was approved by the Food and Drug Administration (FDA) for the prophylaxis of cholera infection caused by serogroup 01.",
    "llama-2-13b-chat-hf_fact_raw": "1. Vaxchora was the first cholera vaccine approved in the US.\n2. The Food and Drug Administration (FDA) approved Vaxchora.\n3. Vaxchora is used for the prophylaxis of cholera infection caused by serogroup 01.",
    "llama-2-13b-chat-hf_fact": [
      "Vaxchora was the first cholera vaccine approved in the US.",
      "The Food and Drug Administration (FDA) approved Vaxchora.",
      "Vaxchora is used for the prophylaxis of cholera infection caused by serogroup 01."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 1, the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous loss-of-function variants in the NFKB1 gene.",
    "llama-2-13b-chat-hf_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous loss-of-function variants in the NFKB1 gene.",
    "llama-2-13b-chat-hf_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous loss-of-function variants in the NFKB1 gene."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE) is as an interferon-stimulated gene (ISG) that is upregulated in response to excessive production of interferon (IFN) in the body. The overproduction of IFN and the subsequent upregulation of ISGs, including IFIT1, contribute to the complex pathogenesis of SLE. Specifically, IFIT1 is involved in the regulation of inflammation and immune responses, and its dysregulation can impact the severity and heterogeneity of SLE symptoms. Additionally, the upregulation of IFIT1 and other ISGs can contribute to the development of autoantibodies and the progression of SLE.",
    "llama-2-13b-chat-hf_fact_raw": "1. The IFIT1 gene is an interferon-stimulated gene (ISG).\n2. IFIT1 is upregulated in response to excessive production of interferon (IFN) in the body.\n3. The upregulation of IFIT1 contributes to the pathogenesis of Systemic Lupus Erythematosus (SLE).\n4. IFIT1 is involved in the regulation of inflammation and immune responses.\n5. Dysregulation of IFIT1 can impact the severity and heterogeneity of SLE symptoms.",
    "llama-2-13b-chat-hf_fact": [
      "The IFIT1 gene is an interferon-stimulated gene (ISG).",
      "IFIT1 is upregulated in response to excessive production of interferon (IFN) in the body.",
      "The upregulation of IFIT1 contributes to the pathogenesis of Systemic Lupus Erythematosus (SLE).",
      "IFIT1 is involved in the regulation of inflammation and immune responses.",
      "Dysregulation of IFIT1 can impact the severity and heterogeneity of SLE symptoms."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - While the exact mechanisms are complex and research is ongoing, IFIT1 has been implicated in the pathogenesis of SLE due to its role in the immune response and interferon signaling.\n4. TRUE - IFIT1 is involved in the immune response, particularly in response to viral infections, and thus plays a role in the regulation of inflammation and immune responses.\n5. TRUE - Given that IFIT1 is involved in immune response regulation, dysregulation of this gene could potentially impact the severity and heterogeneity of symptoms in diseases like SLE, where the immune system is involved.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the Liverpool Elbow Score (LES) is a valid and reliable scoring system used to evaluate joint function in patients with elbow stiffness. It assesses both subjective and objective parameters and contains 15 items with a scale ranging from 0 to 10 points, where higher scores indicate better function.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to evaluate joint function in patients with elbow stiffness.\n2. The LES assesses both subjective and objective parameters.\n3. The LES contains 15 items.\n4. The scoring scale for the LES ranges from 0 to 10 points.\n5. Higher scores on the LES indicate better elbow function.",
    "llama-2-13b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to evaluate joint function in patients with elbow stiffness.",
      "The LES assesses both subjective and objective parameters.",
      "The LES contains 15 items.",
      "The scoring scale for the LES ranges from 0 to 10 points.",
      "Higher scores on the LES indicate better elbow function."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Liverpool Elbow Score (LES) contains 10 items.\n4. FALSE [correction]: The scoring scale for the LES ranges from 0 to 100 points.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-13b-chat-hf_response": "Based on the information provided, here is an answer to the user's question:\nThe 100,000 Genomes Project, launched in the UK in 2015, was the largest whole genome sequencing (WGS) endeavor for cancer and rare diseases. Despite sarcoma's rarity, it ranked third among the number of patients' samples sent for sequencing. The Project aimed to achieve five main objectives:\n1. Establish a genomic medicine service for the NHS, providing clinical diagnosis with new personalized treatment options.\n2. Enable scientific discovery and improve understanding of the genetic basis of cancer and rare diseases.\n3. Develop and implement new technologies and methods for WGS and data analysis.\n4. Create a comprehensive database of genomic information for future research and clinical use.\n5. Engage with patients and the public to ensure the Project's benefits are accessible and beneficial to all.\nThe Project's efforts on sarcoma focused on identifying genetic mutations and variations that contribute to the development and progression of the disease. By analyzing the genomes of sarcoma patients, researchers aimed to discover new therapeutic targets and develop personalized treatment strategies. The Project's findings have the potential to improve the diagnosis and treatment of sarcoma, as well as other rare and complex diseases.",
    "llama-2-13b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in the UK in 2015.\n2. It was the largest whole genome sequencing endeavor for cancer and rare diseases at the time of its launch.\n3. Sarcoma ranked third among the number of patients' samples sent for sequencing in the Project.\n4. One of the Project's objectives was to establish a genomic medicine service for the NHS.\n5. The Project aimed to identify genetic mutations and variations that contribute to the development and progression of sarcoma.",
    "llama-2-13b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in the UK in 2015.",
      "It was the largest whole genome sequencing endeavor for cancer and rare diseases at the time of its launch.",
      "Sarcoma ranked third among the number of patients' samples sent for sequencing in the Project.",
      "One of the Project's objectives was to establish a genomic medicine service for the NHS.",
      "The Project aimed to identify genetic mutations and variations that contribute to the development and progression of sarcoma."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE (assuming the context of the project includes understanding genetic contributions to various diseases, including sarcoma, which is a type of cancer)",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, it appears that protein ALEX1 does not contain armadillo repeats. The information in Document 0 and Document 1 mentions armadillo repeat-containing proteins, such as ARMCX1, and their involvement in development, maintenance of tissue integrity, and tumorigenesis. However, there is no mention of ALEX1 or any other protein containing armadillo repeats. Therefore, the answer to the user's question is \"no.\"",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-13b-chat-hf_response": "Based on the information provided, here are some enzymes that remove histone modifications:\n1. HDACs (deacetylases): These enzymes remove acetyl groups from histone proteins, specifically from lysine residues on histones H3 and H4.\n2. KDMs (lysine demethylases): These enzymes remove methyl groups from histone proteins, which can affect chromatin structure and gene expression.\n3. HMTs (histone methyltransferases): These enzymes add methyl groups to histone proteins, which can also affect chromatin structure and gene expression.\n4. Chromatin remodelers: These enzymes use energy to move nucleosomes along DNA strands, which can alter chromatin structure and accessibility to transcription factors.\n5. MicroRNA-induced silencing complex (miRISC): This complex uses small RNAs to bind to target messenger RNAs (mRNAs) and prevent their translation into proteins, leading to gene silencing.\nIt's worth noting that histone modifications are dynamic and can be added and removed by various enzymes in a coordinated manner to regulate gene expression. Additionally, other epigenetic marks such as DNA methylation and non-coding RNAs also play important roles in regulating gene expression.",
    "llama-2-13b-chat-hf_fact_raw": "1. HDACs are enzymes that remove acetyl groups from lysine residues on histones H3 and H4.\n2. KDMs are enzymes that remove methyl groups from histone proteins.\n3. HMTs are enzymes that add methyl groups to histone proteins.\n4. Chromatin remodelers are enzymes that move nucleosomes along DNA strands.\n5. The MicroRNA-induced silencing complex (miRISC) uses small RNAs to bind to target mRNAs and prevent their translation.",
    "llama-2-13b-chat-hf_fact": [
      "HDACs are enzymes that remove acetyl groups from lysine residues on histones H3 and H4.",
      "KDMs are enzymes that remove methyl groups from histone proteins.",
      "HMTs are enzymes that add methyl groups to histone proteins.",
      "Chromatin remodelers are enzymes that move nucleosomes along DNA strands.",
      "The MicroRNA-induced silencing complex (miRISC) uses small RNAs to bind to target mRNAs and prevent their translation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is evidence to suggest that head CT scans may increase the risk of brain tumors in pediatric patients. According to Document 0, low dose radiation from head CT scans may pose a low but non-zero risk of tumor induction in pediatric patients. Additionally, Document 1 suggests that CT scans may increase the risk of brain tumors. However, it is important to note that the risk is still considered low, and the benefits of head CT scans in managing medical conditions often outweigh the potential risks. It is recommended that parents and caregivers discuss the risks and benefits of head CT scans with their child's healthcare provider before undergoing the procedure.",
    "llama-2-13b-chat-hf_fact_raw": "1. Head CT scans may increase the risk of brain tumors in pediatric patients.\n2. Low dose radiation from head CT scans may pose a low but non-zero risk of tumor induction in pediatric patients.\n3. The risk of brain tumors from CT scans is considered low.\n4. The benefits of head CT scans often outweigh the potential risks.\n5. It is recommended that parents and caregivers discuss the risks and benefits of head CT scans with their child's healthcare provider.",
    "llama-2-13b-chat-hf_fact": [
      "Head CT scans may increase the risk of brain tumors in pediatric patients.",
      "Low dose radiation from head CT scans may pose a low but non-zero risk of tumor induction in pediatric patients.",
      "The risk of brain tumors from CT scans is considered low.",
      "The benefits of head CT scans often outweigh the potential risks.",
      "It is recommended that parents and caregivers discuss the risks and benefits of head CT scans with their child's healthcare provider."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: Head CT scans involve ionizing radiation, which can increase the risk of brain tumors, especially in pediatric patients whose tissues are more sensitive to radiation.\n2. TRUE: Low dose radiation from head CT scans is associated with a low but non-zero risk of tumor induction, particularly in children.\n3. TRUE: The risk of brain tumors from CT scans is generally considered low, but it is not negligible, especially in pediatric patients.\n4. TRUE: In many clinical situations, the benefits of obtaining a head CT scan for diagnostic purposes often outweigh the potential risks associated with radiation exposure.\n5. TRUE: It is recommended practice for parents and caregivers to discuss the risks and benefits of medical imaging procedures, including head CT scans, with their child's healthcare provider to make informed decisions.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, Otx2 is associated with pluripotency. Document 1 states that Otx2 drives enhancer activation and affects chromatin marks, which is a characteristic of pluripotency. Additionally, Document 0 mentions that Otx2 is present during early differentiation of embryonic stem cells, which suggests that it plays a role in maintaining pluripotency. Therefore, the answer to the user's question is that Otx2 is associated with pluripotency.",
    "llama-2-13b-chat-hf_fact_raw": "1. Otx2 is associated with pluripotency.\n2. Otx2 drives enhancer activation and affects chromatin marks, characteristics of pluripotency.\n3. Otx2 is present during early differentiation of embryonic stem cells.",
    "llama-2-13b-chat-hf_fact": [
      "Otx2 is associated with pluripotency.",
      "Otx2 drives enhancer activation and affects chromatin marks, characteristics of pluripotency.",
      "Otx2 is present during early differentiation of embryonic stem cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there are 11 DNaseI hypersensitive sites (DHSs) marking the murine beta globin locus region. This information can be found in Document 1, which states that DHSs are markers of regulatory DNA and have underpinned the discovery of all classes of cis-regulatory elements, including enhancers, promoters, insulators, and other elements. The document also mentions that high-resolution maps of DHSs have been created, which likely includes the murine beta globin locus region. Therefore, based on the information provided, there are 11 DHSs marking the murine beta globin locus region.",
    "llama-2-13b-chat-hf_fact_raw": "1. There are 11 DNaseI hypersensitive sites (DHSs) marking the murine beta globin locus region.\n2. DNaseI hypersensitive sites are markers of regulatory DNA.\n3. DHSs have underpinned the discovery of all classes of cis-regulatory elements, including enhancers, promoters, insulators, and other elements.\n4. High-resolution maps of DHSs have been created.\n5. The murine beta globin locus region is included in these high-resolution maps of DHSs.",
    "llama-2-13b-chat-hf_fact": [
      "There are 11 DNaseI hypersensitive sites (DHSs) marking the murine beta globin locus region.",
      "DNaseI hypersensitive sites are markers of regulatory DNA.",
      "DHSs have underpinned the discovery of all classes of cis-regulatory elements, including enhancers, promoters, insulators, and other elements.",
      "High-resolution maps of DHSs have been created.",
      "The murine beta globin locus region is included in these high-resolution maps of DHSs."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe number of DNaseI hypersensitive sites (DHSs) in a specific locus, such as the murine beta globin locus region, is a detail that requires specific scientific knowledge or data to confirm, hence the \"UNKNOWN\" status for statement 1. Similarly, statement 5 is \"UNKNOWN\" because it requires specific data to confirm whether the murine beta globin locus region is included in the high-resolution maps of DHSs. Statements 2, 3, and 4 are general knowledge about DHSs and are therefore marked as \"TRUE\".",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-13b-chat-hf_response": "Sure, here are some European influenza vaccines:\n1. Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals)\n2. Pandemic Influenza Vaccine H5N1 Baxter AG\n3. Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune)\n4. Seasonal influenza vaccines (e.g. Fluarix, FluMist, Fluviral)\n5. A–Z disease list Seasonal influenza Prevention and control\n6. Protect yourself against flu: Learn more about preventive measures\n7. Seasonal influenza vaccination strategies\n8. Risk groups for severe influenza (e.g. elderly, young children, people with certain underlying health conditions)\n9. Types of seasonal influenza vaccine (e.g. trivalent, quadrivalent)\nNote that this list may not be exhaustive, and there may be other European influenza vaccines available as well. Additionally, the availability and specifications of these vaccines may vary depending on the country and region.",
    "llama-2-13b-chat-hf_fact_raw": "1. Adjupanrix is a European influenza vaccine previously known as Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) by GlaxoSmithKline Biologicals.\n2. Pandemic Influenza Vaccine H5N1 Baxter AG is a European influenza vaccine.\n3. Pandemic influenza vaccine H5N1 AstraZeneca, previously known as Pandemic influenza vaccine H5N1 Medimmune, is a European influenza vaccine.\n4. Fluarix, FluMist, and Fluviral are examples of seasonal influenza vaccines available in Europe.\n5. There are different types of seasonal influenza vaccines, such as trivalent and quadrivalent.",
    "llama-2-13b-chat-hf_fact": [
      "Adjupanrix is a European influenza vaccine previously known as Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) by GlaxoSmithKline Biologicals.",
      "Pandemic Influenza Vaccine H5N1 Baxter AG is a European influenza vaccine.",
      "Pandemic influenza vaccine H5N1 AstraZeneca, previously known as Pandemic influenza vaccine H5N1 Medimmune, is a European influenza vaccine.",
      "Fluarix, FluMist, and Fluviral are examples of seasonal influenza vaccines available in Europe.",
      "There are different types of seasonal influenza vaccines, such as trivalent and quadrivalent."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: FluMist is not typically available in Europe; it is a seasonal influenza vaccine primarily used in the United States.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Document 0 and Document 1, the answer to the user's question is:\nYes, the Paramyxovirus genome is segmented, negative-sense RNA.\nAccording to Document 0, the paramyxovirus family has a genome consisting of a single strand of negative-sense RNA, which acts as a template for two distinct processes: transcription to generate subgenomic, capped and polyadenylated mRNAs, and genome replication. This indicates that the paramyxovirus genome is segmented, as it is composed of multiple regions that are transcribed and replicated separately.\nAdditionally, Document 1 states that the viral RNA is single-stranded and generally negative-sense, which further supports the idea that the paramyxovirus genome is segmented. The presence of multiple proteins, including the L protein, which is necessary for transcription of viral RNA, also suggests that the genome is segmented and undergoes complex transcriptional regulation.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Paramyxovirus genome consists of a single strand of negative-sense RNA.\n2. The Paramyxovirus genome acts as a template for transcription to generate subgenomic, capped, and polyadenylated mRNAs.\n3. The Paramyxovirus genome also acts as a template for genome replication.\n4. The Paramyxovirus genome is composed of multiple regions that are transcribed and replicated separately, indicating it is segmented.\n5. The L protein is necessary for transcription of Paramyxovirus viral RNA.",
    "llama-2-13b-chat-hf_fact": [
      "The Paramyxovirus genome consists of a single strand of negative-sense RNA.",
      "The Paramyxovirus genome acts as a template for transcription to generate subgenomic, capped, and polyadenylated mRNAs.",
      "The Paramyxovirus genome also acts as a template for genome replication.",
      "The Paramyxovirus genome is composed of multiple regions that are transcribed and replicated separately, indicating it is segmented.",
      "The L protein is necessary for transcription of Paramyxovirus viral RNA."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Paramyxovirus genome is non-segmented; it is not composed of multiple regions that are transcribed and replicated separately.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, Roflumilast Cream is effective for the treatment of plaque psoriasis. Document 1 states that roflumilast cream was safe and highly effective at doses of 0.5% and 0.15% and represents a potential novel once-daily topical therapy for the treatment of chronic plaque psoriasis.",
    "llama-2-13b-chat-hf_fact_raw": "1. Roflumilast Cream is used for the treatment of plaque psoriasis.\n2. Roflumilast Cream has been found to be safe and highly effective at doses of 0.5% and 0.15%.\n3. Roflumilast Cream is a potential novel once-daily topical therapy for chronic plaque psoriasis.",
    "llama-2-13b-chat-hf_fact": [
      "Roflumilast Cream is used for the treatment of plaque psoriasis.",
      "Roflumilast Cream has been found to be safe and highly effective at doses of 0.5% and 0.15%.",
      "Roflumilast Cream is a potential novel once-daily topical therapy for chronic plaque psoriasis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there are several tools that have been developed for identifying and visualizing ncRNA promoters. One such tool is ncPro-ML, which was proposed in Document 0 and is specifically designed to identify the promoters of ncRNA in Homo sapiens and Mus musculus. This method uses different kinds of sequence encoding schemes to identify ncRNA promoters.\nAnother tool that can be used for identifying and visualizing ncRNA promoters is R2DT, which is a framework for predicting and visualizing RNA secondary structure using templates, as mentioned in Document 1. R2DT can be used to predict the secondary structure of ncRNAs and identify potential promoter regions.\nOther tools that can be used for identifying ncRNA promoters include:\n1. CRNAC: This is a web server for identifying conserved non-coding RNA elements in genomes. It can be used to identify potential ncRNA promoters and other elements.\n2. RNA-Pro: This is a tool for predicting the secondary structure of RNA molecules, including ncRNAs. It can be used to identify potential promoter regions and predict the stability of ncRNAs.\n3. Infernal: This is a tool for predicting RNA secondary structure and identifying potential binding sites. It can be used to identify potential ncRNA promoters and predict the stability of ncRNAs.\n4. RNAfold: This is a tool for predicting the secondary structure of RNA molecules, including ncRNAs. It can be used to identify potential promoter regions and predict the stability of ncRNAs.\nThese tools can be used in combination to identify and visualize ncRNA promoters, and to predict the stability and function of ncRNAs.",
    "llama-2-13b-chat-hf_fact_raw": "1. ncPro-ML is a tool designed to identify the promoters of ncRNA in Homo sapiens and Mus musculus.\n2. R2DT is a framework for predicting and visualizing RNA secondary structure using templates.\n3. CRNAC is a web server for identifying conserved non-coding RNA elements in genomes.\n4. RNA-Pro is a tool for predicting the secondary structure of RNA molecules, including ncRNAs.\n5. Infernal is a tool for predicting RNA secondary structure and identifying potential binding sites.",
    "llama-2-13b-chat-hf_fact": [
      "ncPro-ML is a tool designed to identify the promoters of ncRNA in Homo sapiens and Mus musculus.",
      "R2DT is a framework for predicting and visualizing RNA secondary structure using templates.",
      "CRNAC is a web server for identifying conserved non-coding RNA elements in genomes.",
      "RNA-Pro is a tool for predicting the secondary structure of RNA molecules, including ncRNAs.",
      "Infernal is a tool for predicting RNA secondary structure and identifying potential binding sites."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: CRNAC is not a known standard tool or acronym for identifying conserved non-coding RNA elements in genomes. The correct tool might be \"RNAcode\" which is used to predict conserved protein-coding regions in multiple alignments of nucleotide sequences, or \"CMfinder\" which is a tool for identifying conserved RNA secondary structures in multiple sequence alignments.\n4. UNKNOWN\n5. FALSE [correction]: Infernal is a tool for searching DNA sequence databases for RNA structure and sequence similarities. It is primarily used for identifying members of RNA families represented by covariance models (CMs), not for predicting RNA secondary structure or identifying potential binding sites.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-13b-chat-hf_response": "Based on the information provided, here are some examples of genes that have been identified by the SWIM tool as being down-regulated in glioblastoma stem-like cells:\n1. CAV1 (caveolin-1)\n2. COL5A1 (collagen type V alpha 1)\n3. COL6A3 (collagen type VI alpha 3)\n4. FLNB (four-and-a-half LIM domain protein 2)\n5. HMMR (hermansky-pudlak syndrome protein 3)\n6. ITGA3 (integrin alpha 3)\n7. ITGA5 (integrin alpha 5)\n8. MET (hepatocyte growth factor receptor)\n9. SDC1 (syndecan 1)\n10. THBS1 (thrombospondin 1)\n11. VEGFC (vascular endothelial growth factor C)\nThese genes are involved in various cellular pathways, including \"ECM-receptor interaction\" and \"focal adhesion\". The down-regulation of these genes in glioblastoma stem-like cells may play a role in the development and progression of glioblastoma.",
    "llama-2-13b-chat-hf_fact_raw": "1. CAV1 (caveolin-1) has been identified by the SWIM tool as being down-regulated in glioblastoma stem-like cells.\n2. COL5A1 (collagen type V alpha 1) is among the genes identified by the SWIM tool as down-regulated in glioblastoma stem-like cells.\n3. ITGA3 (integrin alpha 3) is listed as a gene down-regulated in glioblastoma stem-like cells according to the SWIM tool.\n4. MET (hepatocyte growth factor receptor) is reported to be down-regulated in glioblastoma stem-like cells by the SWIM tool.\n5. VEGFC (vascular endothelial growth factor C) is identified by the SWIM tool as down-regulated in glioblastoma stem-like cells.",
    "llama-2-13b-chat-hf_fact": [
      "CAV1 (caveolin-1) has been identified by the SWIM tool as being down-regulated in glioblastoma stem-like cells.",
      "COL5A1 (collagen type V alpha 1) is among the genes identified by the SWIM tool as down-regulated in glioblastoma stem-like cells.",
      "ITGA3 (integrin alpha 3) is listed as a gene down-regulated in glioblastoma stem-like cells according to the SWIM tool.",
      "MET (hepatocyte growth factor receptor) is reported to be down-regulated in glioblastoma stem-like cells by the SWIM tool.",
      "VEGFC (vascular endothelial growth factor C) is identified by the SWIM tool as down-regulated in glioblastoma stem-like cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific to the results of a scientific analysis using the SWIM tool, which is presumably a tool for analyzing gene expression. Without access to the specific study or dataset that these statements are derived from, it is not possible to verify the accuracy of these statements. Therefore, the truthfulness of these statements regarding the regulation of CAV1, COL5A1, ITGA3, MET, and VEGFC in glioblastoma stem-like cells as identified by the SWIM tool remains unknown.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there are at least two R packages that have been developed for studying Topologically Associated Domains (TADs):\n1. TADsplimer: This package was developed by Lili Zhang, John P. Cooke, Qi Cao, and Kaifu Chen, and was published in the journal Genome Biology in 2020. TADsplimer is the first computational tool to systematically detect TAD splits and mergers across the genome between Hi-C samples.\n2. SpectralTAD: This package was developed by Kellen G. Cresswell, John C. Stansfield, and Mikhail G. Dozmorov, and was published in the journal Bioinformatics in 2018. SpectralTAD is an R package for defining a hierarchy of TADs using spectral clustering.\nBoth of these packages are available on GitHub and can be installed and used in R to study TADs in genomic data.",
    "llama-2-13b-chat-hf_fact_raw": "1. TADsplimer is an R package developed for studying Topologically Associated Domains (TADs).\n2. TADsplimer was developed by Lili Zhang, John P. Cooke, Qi Cao, and Kaifu Chen.\n3. TADsplimer was published in the journal Genome Biology in 2020.\n4. SpectralTAD is an R package developed by Kellen G. Cresswell, John C. Stansfield, and Mikhail G. Dozmorov.\n5. SpectralTAD was published in the journal Bioinformatics in 2018.",
    "llama-2-13b-chat-hf_fact": [
      "TADsplimer is an R package developed for studying Topologically Associated Domains (TADs).",
      "TADsplimer was developed by Lili Zhang, John P. Cooke, Qi Cao, and Kaifu Chen.",
      "TADsplimer was published in the journal Genome Biology in 2020.",
      "SpectralTAD is an R package developed by Kellen G. Cresswell, John C. Stansfield, and Mikhail G. Dozmorov.",
      "SpectralTAD was published in the journal Bioinformatics in 2018."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: SpectralTAD was published in the journal Bioinformatics in 2020.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the bioconductor tool that has been developed for accessing bacterial regulatory networks is RegulonDB. According to Document 0, RegulonDB has collected, harmonized, and centralized data from hundreds of experiments for nearly two decades and is considered a point of reference for transcriptional regulation in Escherichia coli. Additionally, Document 1 mentions that genome-scale transfer of transcriptional regulatory networks (TRNs) has been applied to provide insights into the regulatory mechanisms of bacterial organisms, suggesting that RegulonDB is a useful tool for accessing and analyzing bacterial regulatory networks.",
    "llama-2-13b-chat-hf_fact_raw": "1. RegulonDB is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. RegulonDB has been collecting, harmonizing, and centralizing data from experiments for nearly two decades.\n3. RegulonDB is considered a point of reference for transcriptional regulation in Escherichia coli.\n4. Genome-scale transfer of transcriptional regulatory networks (TRNs) has been applied to provide insights into regulatory mechanisms of bacterial organisms.\n5. RegulonDB is used for accessing and analyzing bacterial regulatory networks.",
    "llama-2-13b-chat-hf_fact": [
      "RegulonDB is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "RegulonDB has been collecting, harmonizing, and centralizing data from experiments for nearly two decades.",
      "RegulonDB is considered a point of reference for transcriptional regulation in Escherichia coli.",
      "Genome-scale transfer of transcriptional regulatory networks (TRNs) has been applied to provide insights into regulatory mechanisms of bacterial organisms.",
      "RegulonDB is used for accessing and analyzing bacterial regulatory networks."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: RegulonDB is a database developed for accessing bacterial regulatory networks, not specifically a bioconductor tool.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the end products of the shikimate pathway are:\n1. Chorismate, which is the precursor of aromatic amino acids and many aromatic secondary metabolites.",
    "llama-2-13b-chat-hf_fact_raw": "1. Chorismate is the precursor of aromatic amino acids.\n2. Chorismate is the precursor of many aromatic secondary metabolites.",
    "llama-2-13b-chat-hf_fact": [
      "Chorismate is the precursor of aromatic amino acids.",
      "Chorismate is the precursor of many aromatic secondary metabolites."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, cabergoline is not used for the treatment of Nelson's syndrome. Nelson's syndrome is a condition that can develop in patients with Cushing's disease who have undergone bilateral adrenalectomy, and it is characterized by an enlarging adrenocorticotropic hormone (ACTH)-secreting pituitary tumor.\nAccording to the information provided in Document 1, the management of Nelson's syndrome can be challenging, and the treatment options may include medical and/or radiation therapy to the adenoma, as well as bilateral adrenalectomy. However, cabergoline is not mentioned as a treatment option for Nelson's syndrome.\nTherefore, based on the information provided, the answer to the user's question is \"no,\" cabergoline is not used for the treatment of Nelson's syndrome.",
    "llama-2-13b-chat-hf_fact_raw": "1. Cabergoline is not used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome can develop in patients with Cushing's disease who have undergone bilateral adrenalectomy.\n3. Nelson's syndrome is characterized by an enlarging adrenocorticotropic hormone (ACTH)-secreting pituitary tumor.\n4. Treatment options for Nelson's syndrome may include medical and/or radiation therapy to the adenoma.\n5. Treatment options for Nelson's syndrome may also include bilateral adrenalectomy.",
    "llama-2-13b-chat-hf_fact": [
      "Cabergoline is not used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome can develop in patients with Cushing's disease who have undergone bilateral adrenalectomy.",
      "Nelson's syndrome is characterized by an enlarging adrenocorticotropic hormone (ACTH)-secreting pituitary tumor.",
      "Treatment options for Nelson's syndrome may include medical and/or radiation therapy to the adenoma.",
      "Treatment options for Nelson's syndrome may also include bilateral adrenalectomy."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Treatment options for Nelson's syndrome do not include bilateral adrenalectomy, as Nelson's syndrome typically develops after bilateral adrenalectomy has already been performed for Cushing's disease. Treatment options may include medical therapy, radiation therapy, or surgical resection of the pituitary tumor.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the main manifestation of Liebenberg syndrome is characteristic arm malformations that can vary in severity. These malformations can include abnormal development of the bones and other tissues in the elbows, forearms, wrists, and hands, which can resemble the structures of the lower limbs.",
    "llama-2-13b-chat-hf_fact_raw": "1. Liebenberg syndrome is characterized by arm malformations.\n2. The severity of arm malformations in Liebenberg syndrome can vary.\n3. Malformations in Liebenberg syndrome can affect the elbows, forearms, wrists, and hands.\n4. The arm malformations in Liebenberg syndrome can resemble the structures of the lower limbs.",
    "llama-2-13b-chat-hf_fact": [
      "Liebenberg syndrome is characterized by arm malformations.",
      "The severity of arm malformations in Liebenberg syndrome can vary.",
      "Malformations in Liebenberg syndrome can affect the elbows, forearms, wrists, and hands.",
      "The arm malformations in Liebenberg syndrome can resemble the structures of the lower limbs."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-13b-chat-hf_response": "Based on the information provided in the two documents, here are some orally bioavailable MPS1 kinase inhibitors:\n1. MPI-0479605: This compound has potent activity against Mps1 (IC50 = 0.004 μM) and good cytotoxicity (HCT-116; IC50 = 0.1 μM) as shown in Document 0.\n2. Optimized compounds in the 1H-pyrrolo[3,2-c]pyridine scaffold: These compounds have been designed and optimized based on structure-based design and cellular characterization of MPS1 inhibition, as described in Document 1. They display potent and selective inhibition of MPS1 in vitro and in cellular assays.\nNote that the specific compounds and their structures are not provided in the information given, but these are some examples of orally bioavailable MPS1 kinase inhibitors that have been identified based on the provided information.",
    "llama-2-13b-chat-hf_fact_raw": "1. MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor with an IC50 value of 0.004 μM against Mps1.\n2. MPI-0479605 has demonstrated cytotoxicity with an IC50 value of 0.1 μM in HCT-116 cells.\n3. Compounds within the 1H-pyrrolo[3,2-c]pyridine scaffold have been designed for potent and selective inhibition of MPS1.\n4. The 1H-pyrrolo[3,2-c]pyridine scaffold compounds were optimized based on structure-based design and cellular characterization.\n5. These 1H-pyrrolo[3,2-c]pyridine scaffold compounds have shown efficacy in vitro and in cellular assays for MPS1 inhibition.",
    "llama-2-13b-chat-hf_fact": [
      "MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor with an IC50 value of 0.004 μM against Mps1.",
      "MPI-0479605 has demonstrated cytotoxicity with an IC50 value of 0.1 μM in HCT-116 cells.",
      "Compounds within the 1H-pyrrolo[3,2-c]pyridine scaffold have been designed for potent and selective inhibition of MPS1.",
      "The 1H-pyrrolo[3,2-c]pyridine scaffold compounds were optimized based on structure-based design and cellular characterization.",
      "These 1H-pyrrolo[3,2-c]pyridine scaffold compounds have shown efficacy in vitro and in cellular assays for MPS1 inhibition."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements about MPI-0479605 and the 1H-pyrrolo[3,2-c]pyridine scaffold compounds are specific and would require access to scientific literature or databases to verify the exact IC50 values and the results of cellular assays. Without the specific context or source, the veracity of the second statement cannot be determined. The other statements are consistent with typical drug development processes where compounds are designed for potency and selectivity, and then optimized based on structural design and cellular characterization, with efficacy being tested in vitro and in cellular assays.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, there is no mention of golimumab being tested for diabetes specifically. However, the document mentions that more specific and targeted treatments have been tested in stage 3 T1D (type 1 diabetes). As golimumab is a human monoclonal antibody specific for tumor necrosis factor α, it is possible that it may have been tested in clinical trials for other autoimmune diseases or conditions related to type 1 diabetes, but there is no direct mention of diabetes in the provided information.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, progeria is caused by an autosomal recessive gene.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, common variants at 12q14 and 12q24 are associated with hippocampal volume. The Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium and the Cohorts for Heart and Aging study found that these variants are associated with reductions in hippocampal volume, which are accelerated by Alzheimer's disease and vascular risk factors. Specifically, the study identified 46 SNPs at four loci with P values of less than 4.0 x 10(-7) that are associated with hippocampal volume.",
    "llama-2-13b-chat-hf_fact_raw": "1. Common variants at 12q14 and 12q24 are associated with hippocampal volume.\n2. The Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium and the Cohorts for Heart and Aging study found associations between these variants and reductions in hippocampal volume.\n3. Alzheimer's disease and vascular risk factors can accelerate the reductions in hippocampal volume associated with these variants.\n4. The study identified 46 SNPs at four loci that are associated with hippocampal volume.\n5. The identified SNPs have P values of less than 4.0 x 10(-7) in association with hippocampal volume.",
    "llama-2-13b-chat-hf_fact": [
      "Common variants at 12q14 and 12q24 are associated with hippocampal volume.",
      "The Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium and the Cohorts for Heart and Aging study found associations between these variants and reductions in hippocampal volume.",
      "Alzheimer's disease and vascular risk factors can accelerate the reductions in hippocampal volume associated with these variants.",
      "The study identified 46 SNPs at four loci that are associated with hippocampal volume.",
      "The identified SNPs have P values of less than 4.0 x 10(-7) in association with hippocampal volume."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: It is known that common genetic variants can be associated with brain structure, and 12q14 and 12q24 are chromosomal locations that could be associated with hippocampal volume.\n2. TRUE: The ENIGMA Consortium and the Cohorts for Heart and Aging study are large-scale research collaborations that could feasibly find such associations through meta-analysis and large cohort studies.\n3. TRUE: It is well-established that Alzheimer's disease and vascular risk factors are associated with reductions in hippocampal volume, so they could accelerate reductions associated with genetic variants.\n4. UNKNOWN: Without specific information from the study, it is not possible to confirm the exact number of SNPs and loci associated with hippocampal volume.\n5. UNKNOWN: The statement about P values is specific and would require access to the study's results to confirm its accuracy.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the ligands of the Roundabout (Robo) receptors are the SLIT proteins, specifically SLIT1, SLIT2, and SLIT3.",
    "llama-2-13b-chat-hf_fact_raw": "1. The ligands of the Roundabout (Robo) receptors are the SLIT proteins.\n2. SLIT1, SLIT2, and SLIT3 are specific ligands for the Roundabout (Robo) receptors.",
    "llama-2-13b-chat-hf_fact": [
      "The ligands of the Roundabout (Robo) receptors are the SLIT proteins.",
      "SLIT1, SLIT2, and SLIT3 are specific ligands for the Roundabout (Robo) receptors."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-13b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there is evidence to suggest that TFII-I plays a role in megakaryopoiesis. According to the documents, TFII-I acts as a repressor of β-globin gene transcription, and it is implicated in the differentiation of erythro-megakaryocytic cells. This suggests that TFII-I may play a role in the development and differentiation of megakaryocytes, which are the precursor cells of platelets.\nIn particular, the data suggest that TFII-I may be involved in the regulation of gene expression during megakaryopoiesis, and that it may play a role in the differentiation of megakaryocytes into platelets. This is consistent with the idea that TFII-I is a transcription factor that is involved in the regulation of gene expression during cell differentiation.\nOverall, the information provided in Documents 0 and 1 suggests that TFII-I is implicated in megakaryopoiesis and may play a role in the development and differentiation of platelets.",
    "llama-2-13b-chat-hf_fact_raw": "1. TFII-I acts as a repressor of β-globin gene transcription.\n2. TFII-I is implicated in the differentiation of erythro-megakaryocytic cells.\n3. TFII-I may play a role in the development and differentiation of megakaryocytes.\n4. Megakaryocytes are the precursor cells of platelets.\n5. TFII-I is a transcription factor involved in the regulation of gene expression during cell differentiation.",
    "llama-2-13b-chat-hf_fact": [
      "TFII-I acts as a repressor of β-globin gene transcription.",
      "TFII-I is implicated in the differentiation of erythro-megakaryocytic cells.",
      "TFII-I may play a role in the development and differentiation of megakaryocytes.",
      "Megakaryocytes are the precursor cells of platelets.",
      "TFII-I is a transcription factor involved in the regulation of gene expression during cell differentiation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: TFII-I acts as an activator, not a repressor, of β-globin gene transcription.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, atenolol is not metabolized by CYP2D6. According to Document 0, atenolol is metabolized primarily by CYP3A4, and the metabolism by CYP2D6 is not clinically significant.",
    "llama-2-13b-chat-hf_fact_raw": "1. Atenolol is not metabolized by CYP2D6.\n2. Atenolol is primarily metabolized by CYP3A4.",
    "llama-2-13b-chat-hf_fact": [
      "Atenolol is not metabolized by CYP2D6.",
      "Atenolol is primarily metabolized by CYP3A4."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Atenolol is not primarily metabolized by CYP3A4; it is primarily excreted unchanged in the urine.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-13b-chat-hf_response": "Based on the information provided, here is the list of versions of ExpansionHunter:\n1. ExpansionHunter-v5.0.0\nThis is the latest version of ExpansionHunter, which introduces substantial changes to accelerate analysis of large genome-wide STR catalogs, in addition to build system improvements, bug fixes, and catalog updates. The version also includes support for large catalogs, which can be accelerated across multiple threads using the new `--threads` option.",
    "llama-2-13b-chat-hf_fact_raw": "1. ExpansionHunter-v5.0.0 is the latest version of ExpansionHunter.\n2. ExpansionHunter-v5.0.0 introduces changes to accelerate analysis of large genome-wide STR catalogs.\n3. ExpansionHunter-v5.0.0 includes build system improvements, bug fixes, and catalog updates.\n4. The version supports large catalogs.\n5. ExpansionHunter-v5.0.0 can use the `--threads` option to accelerate processing across multiple threads.",
    "llama-2-13b-chat-hf_fact": [
      "ExpansionHunter-v5.0.0 is the latest version of ExpansionHunter.",
      "ExpansionHunter-v5.0.0 introduces changes to accelerate analysis of large genome-wide STR catalogs.",
      "ExpansionHunter-v5.0.0 includes build system improvements, bug fixes, and catalog updates.",
      "The version supports large catalogs.",
      "ExpansionHunter-v5.0.0 can use the `--threads` option to accelerate processing across multiple threads."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: Without current information on the software versions, it is not possible to confirm whether ExpansionHunter-v5.0.0 is the latest version.\n2. UNKNOWN: Without specific release notes or documentation, it is not possible to confirm the changes introduced in ExpansionHunter-v5.0.0.\n3. UNKNOWN: Without access to the specific release notes or documentation for ExpansionHunter-v5.0.0, it is not possible to confirm the inclusion of build system improvements, bug fixes, and catalog updates.\n4. UNKNOWN: The statement is vague and does not provide enough context to determine its truthfulness. It is unclear what is meant by \"large catalogs\" and whether ExpansionHunter-v5.0.0 specifically supports them.\n5. UNKNOWN: Without access to the user manual or release notes for ExpansionHunter-v5.0.0, it is not possible to confirm if the `--threads` option is available to accelerate processing across multiple threads.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, Adamts18 plays a role in hormone receptor signaling as a regulator of stem cell activation. The document states that Adamts18 interacts genetically with the basal membrane-specific proteoglycan, Col18a1, which suggests that Adamts18 may be involved in the regulation of cell signaling pathways. Additionally, the document mentions that Adamts18 is required for stem cell activation, which implies that it may play a role in the regulation of cellular differentiation and development.\nFurthermore, the document highlights that ADAMTS18 is a secreted protease and its dysregulation has been implicated in various diseases, including cancer and developmental disorders. This suggests that Adamts18 may also play a role in the regulation of hormone receptor signaling in these diseases.\nIn summary, based on the information provided, Adamts18 appears to play a role in hormone receptor signaling by regulating stem cell activation and cellular differentiation, and its dysregulation may be involved in various diseases.",
    "llama-2-13b-chat-hf_fact_raw": "1. Adamts18 is a regulator of stem cell activation in hormone receptor signaling.\n2. Adamts18 interacts genetically with the basal membrane-specific proteoglycan, Col18a1.\n3. Adamts18 is required for stem cell activation.\n4. ADAMTS18 is a secreted protease.\n5. Dysregulation of ADAMTS18 has been implicated in various diseases, including cancer and developmental disorders.",
    "llama-2-13b-chat-hf_fact": [
      "Adamts18 is a regulator of stem cell activation in hormone receptor signaling.",
      "Adamts18 interacts genetically with the basal membrane-specific proteoglycan, Col18a1.",
      "Adamts18 is required for stem cell activation.",
      "ADAMTS18 is a secreted protease.",
      "Dysregulation of ADAMTS18 has been implicated in various diseases, including cancer and developmental disorders."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: The statement is specific and would require access to scientific literature or specific studies on Adamts18 to confirm its role in stem cell activation in hormone receptor signaling.\n2. UNKNOWN: This statement also requires specific scientific knowledge or literature to confirm the genetic interaction between Adamts18 and Col18a1.\n3. UNKNOWN: The requirement of Adamts18 for stem cell activation is a specific claim that needs to be verified by scientific research.\n4. TRUE: ADAMTS18 is indeed a member of the ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin Motifs) family, which are known to be secreted proteases.\n5. TRUE: Dysregulation of ADAMTS18 has been implicated in various diseases, including cancer and developmental disorders, according to scientific studies.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-13b-chat-hf_response": "Based on the information provided, the mode of action of Thiazovivin is as a ROCK inhibitor. ROCK (Rho-associated protein kinase) inhibitors are a class of small molecules that inhibit the activity of ROCK proteins, which are involved in regulating cellular processes such as cell migration, differentiation, and survival. By inhibiting ROCK proteins, Thiazovivin can improve the survival and homing of cells in the body, and stimulate endogenous stem cells to enhance tissue regeneration. This information is supported by Document 1, which states that small molecules like Thiazovivin can stimulate endogenous stem cells to enhance tissue regeneration. Additionally, Document 0 mentions that Thiazovivin was selected for this protocol due to its effectiveness at lower concentrations (2 μM) and lower cost compared to other ROCK inhibitors such as Y27632 and HA-1077.",
    "llama-2-13b-chat-hf_fact_raw": "1. Thiazovivin acts as a ROCK inhibitor.\n2. ROCK inhibitors inhibit the activity of Rho-associated protein kinase proteins.\n3. Thiazovivin is used to improve the survival and homing of cells in the body.\n4. Thiazovivin can stimulate endogenous stem cells to enhance tissue regeneration.\n5. Thiazovivin is effective at lower concentrations (2 μM) compared to other ROCK inhibitors like Y27632 and HA-1077.",
    "llama-2-13b-chat-hf_fact": [
      "Thiazovivin acts as a ROCK inhibitor.",
      "ROCK inhibitors inhibit the activity of Rho-associated protein kinase proteins.",
      "Thiazovivin is used to improve the survival and homing of cells in the body.",
      "Thiazovivin can stimulate endogenous stem cells to enhance tissue regeneration.",
      "Thiazovivin is effective at lower concentrations (2 μM) compared to other ROCK inhibitors like Y27632 and HA-1077."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  }
]